XML 22 R9.htm IDEA: XBRL DOCUMENT
v3.22.2.2

CONSOLIDATED SCHEDULE OF INVESTMENTS £ in Thousands | 9 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | ---
Sep. 30, 2022 USD ($) shares | Dec. 31, 2021 USD ($) shares | Sep. 30, 2022 GBP (£) shares | Dec. 31, 2021 GBP (£) shares | Sep. 30, 2021 USD ($) | Dec. 31, 2020 USD ($)
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 2,869,469,000 |  | $ 2,390,984,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  | 2,825,738,000 |  | 2,434,522,000 |  |  |  |  |  |  |  |
Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 150,539,000 | [1] | 142,219,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 134,134,000 |  | 184,710,000 |  |  |  |  |  |  |  |
Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 31,148,000 | [1] | 27,147,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 27,159,000 |  | 38,399,000 |  |  |  |  |  |  |  |
Investments in Securities [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | 2,388,952,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | 2,432,708,000 |  |  |  |  |  |  |  |
Investment [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | 2,390,984,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | 2,434,522,000 |  |  |  |  |  |  |  |
Investment Funds & Vehicles [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 3,139,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 3,046,000 |  |  |  |  |  |  |  |  |  |
Senior Secured |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 2,607,006,000 |  | $ 2,156,709,000 |  |  |  |  |  |  |  |
Senior Secured | Blue Sprig Pediatrics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind |  |  |  | 4.45% |  |  |  | 4.45% |  |  |  |
Total Investments Before Cash And Cash Equivalent [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[3] | 2,869,469,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 2,825,738,000 |  |  |  |  |  |  |  |  |  |
Total Investments with Cash and Cash Equivalents |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[3] | 2,894,469,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [3] | 2,850,738,000 |  |  |  |  |  |  |  |  |  |
Total investments In Securities |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 2,866,330,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 2,822,692,000 |  |  |  |  |  |  |  |  |  |
Cash and Cash Equivalents | G S Financial Square Government Fund |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 25,000,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 25,000,000 |  |  |  |  |  |  |  |  |  |
Money Market Funds [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[3] | 25,000,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [3] | 25,000,000 |  |  |  |  |  |  |  |  |  |
Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 2,684,643,000 | [1] | $ 2,219,586,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 2,661,399,000 |  | 2,209,599,000 |  |  |  |  |  |  |  |
Unsecured |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 54,393,000 |  | 52,890,000 |  |  |  |  |  |  |  |
Communications & Networking |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 101,094,000 |  | 105,490,000 |  |  |  |  |  |  |  |
Communications & Networking | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | 1,230,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | 6,260,000 |  |  |  |  |  |  |  |
Communications & Networking | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 541,000 | [1] | 418,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 140,000 |  | 0 |  |  |  |  |  |  |  |
Communications & Networking | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 98,596,000 | [1] | 97,088,000 | [4] |  |  |  |  |  |  |
Investments at Fair Value |  | 100,954,000 |  | 99,230,000 |  |  |  |  |  |  |  |
Communications & Networking | Aryaka Networks, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 123,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 140,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jun. 28, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 229,611 |  |  |  | 229,611 |  |  |  |  |  |
Communications & Networking | Peerless Network Holdings, Inc. | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | 1,230,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 6,260,000 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 1,138,328 |  |  |  | 1,138,328 |  |  |  |
Communications & Networking | Peerless Network Holdings, Inc. | Equity | Preferred Series A |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 1,230,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 6,242,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Apr. 11, 2008 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 1,135,000 |  |  |  | 1,135,000 |  |  |  |
Communications & Networking | Peerless Network Holdings, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 0 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 18,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Oct. 21, 2020 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 3,328 |  |  |  | 3,328 |  |  |  |
Communications & Networking | Spring Mobile Solutions, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 418,000 | [1] | $ 418,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Apr. 19, 2013 | [5] | Apr. 19, 2013 | [6] |  |  |  |  |  |  |
Shares | shares |  | 2,834,375 |  | 2,834,375 |  | 2,834,375 |  | 2,834,375 |  |  |  |
Communications & Networking | Senior Secured | Aryaka Networks, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-07 |  |  |  | 2026-07 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 3.25% |  |  |  | 3.25% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 6.75% |  |  |  | 6.75% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 1.05% |  |  |  | 1.05% |  |  |  |  |  |
Principal Amount | [8],[9],[10] | $ 5,009,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[8],[9],[10] | 4,943,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [8],[9],[10] | $ 4,943,000 |  |  |  |  |  |  |  |  |  |
Communications & Networking | Senior Secured | Cytracom Holdings LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-02 |  | 2025-02 |  | 2025-02 |  | 2025-02 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 9.31% | [7] | 9.31% | [11] | 9.31% | [7] | 9.31% | [11] |  |  |
Investment, Interest Rate, Floor |  | 10.31% | [7] | 10.31% | [11] | 10.31% | [7] | 10.31% | [11] |  |  |
Principal Amount |  | $ 8,933,000 | [10],[12],[13] | $ 9,000,000 | [14],[15],[16] |  |  |  |  |  |  |
Investment cost |  | 8,776,000 | [1],[10],[12],[13] | 8,802,000 | [4],[14],[15],[16] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 8,728,000 | [10],[12],[13] | $ 8,725,000 | [14],[15],[16] |  |  |  |  |  |  |
Communications & Networking | Senior Secured | Rocket Lab Global Services, LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-06 |  | 2024-06 |  | 2024-06 |  | 2024-06 |  |  |  |
Investment Interest Rate | [11] |  |  | 3.25% |  |  |  | 3.25% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 4.90% | [7] | 4.90% | [11] | 4.90% | [7] | 4.90% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.15% | [7] | 8.15% | [11] | 8.15% | [7] | 8.15% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 1.25% | [7] | 1.25% | [11] | 1.25% | [7] | 1.25% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 3.25% |  |  |  | 3.25% |  |  |  |
Principal Amount |  | $ 84,314,000 | [9],[12],[17],[18],[19] | $ 88,542,000 | [20],[21] |  |  |  |  |  |  |
Investment cost |  | 84,877,000 | [1],[9],[12],[17],[18],[19] | 88,286,000 | [4],[20],[21] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 87,283,000 | [9],[12],[17],[18],[19] | 90,505,000 | [20],[21] |  |  |  |  |  |  |
Communications & Networking | Senior Secured | Exit Fee | Aryaka Networks, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.55% |  |  |  | 3.55% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.55% |  |  |  | 3.55% |  |  |  |  |  |
Communications & Networking | Senior Secured | Exit Fee | Rocket Lab Global Services, LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.20% |  |  |  | 3.20% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.20% |  |  |  | 3.20% |  |  |  |  |  |
Communications & Networking | Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 98,596,000 | [1] | 97,088,000 | [4] |  |  |  |  |  |  |
Investments at Fair Value |  | 100,954,000 |  | 99,230,000 |  |  |  |  |  |  |  |
Consumer & Business Products |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 25,497,000 |  | 28,099,000 |  |  |  |  |  |  |  |
Consumer & Business Products | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 561,000 | [1] | 128,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 185,000 |  | 447,000 |  |  |  |  |  |  |  |
Consumer & Business Products | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 1,712,000 | [1] | 2,145,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 1,122,000 |  | 4,354,000 |  |  |  |  |  |  |  |
Consumer & Business Products | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Principal Amount | [4] |  |  | 23,162,000 |  |  |  |  |  |  |  |
Investment cost | [1] | 23,774,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 24,190,000 |  | 23,298,000 |  |  |  |  |  |  |  |
Consumer & Business Products | Grove Collaborative, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5],[22] | 433,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5],[22] | $ 127,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Apr. 30, 2021 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5],[22] | 61,300 |  |  |  | 61,300 |  |  |  |  |  |
Consumer & Business Products | Grove Collaborative, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | 433,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 326,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Apr. 30, 2021 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 83,625 |  |  |  | 83,625 |  |  |  |
Consumer & Business Products | Penumbra Brands, LLC (p.k.a. Gadget Guard) | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 228,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Jun. 03, 2014 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 1,662,441 |  |  |  | 1,662,441 |  |  |  |
Consumer & Business Products | TechStyle, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 128,000 | [1] | $ 128,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 58,000 |  | $ 447,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Apr. 30, 2010 | [5] | Apr. 30, 2010 | [6] |  |  |  |  |  |  |
Shares | shares |  | 42,989 |  | 42,989 |  | 42,989 |  | 42,989 |  |  |  |
Consumer & Business Products | TechStyle, Inc. | Warrant Investment | Preferred Series B |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 1,101,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 365,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jul. 16, 2013 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 206,185 |  |  |  | 206,185 |  |  |  |  |  |
Consumer & Business Products | Gadget Guard, LLC | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 228,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jun. 03, 2014 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 1,662,441 |  |  |  | 1,662,441 |  |  |  |  |  |
Consumer & Business Products | The Neat Company | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 365,000 | [1] | $ 365,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 13, 2014 | [5] | Aug. 13, 2014 | [6] |  |  |  |  |  |  |
Shares | shares |  | 54,054 |  | 54,054 |  | 54,054 |  | 54,054 |  |  |  |
Consumer & Business Products | Whoop, Inc. | Warrant Investment | Preferred Series C |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 18,000 | [1] | $ 18,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 757,000 |  | $ 1,847,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 27, 2018 | [5] | Jun. 27, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 686,270 |  | 686,270 |  | 686,270 |  | 686,270 |  |  |  |
Consumer & Business Products | TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) | Warrant Investment | Preferred Series B |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 1,101,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 2,181,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Jul. 16, 2013 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 206,185 |  |  |  | 206,185 |  |  |  |
Consumer & Business Products | Senior Secured | Grove Collaborative, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-04 |  | 2025-04 |  | 2025-04 |  | 2025-04 |  |  |  |
Investment Interest Rate | [11] |  |  | 6.75% |  |  |  | 6.75% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.50% | [7] | 5.50% | [11] | 5.50% | [7] | 5.50% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.75% | [7] | 8.75% | [11] | 8.75% | [7] | 8.75% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 6.75% |  |  |  | 6.75% |  |  |  |
Principal Amount |  | $ 23,520,000 | [8] | $ 23,520,000 | [23] |  |  |  |  |  |  |
Investment cost |  | 23,774,000 | [1],[8] | 23,162,000 | [4],[23] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 24,190,000 | [8] | 23,298,000 | [23] |  |  |  |  |  |  |
Consumer & Business Products | Senior Secured | Exit Fee | Grove Collaborative, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 8.75% |  |  |  | 8.75% |  |  |  |  |  |
Interest Rate and Floor | [7] | 8.75% |  |  |  | 8.75% |  |  |  |  |  |
Consumer & Business Products | Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Principal Amount | [4] |  |  | 23,162,000 |  |  |  |  |  |  |  |
Investment cost | [1] | $ 23,774,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 24,190,000 |  | 23,298,000 |  |  |  |  |  |  |  |
Diversified Financial Services |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 72,061,000 |  | 65,073,000 |  |  |  |  |  |  |  |
Diversified Financial Services | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 28,444,000 | [1] | 28,041,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 38,022,000 |  | 32,608,000 |  |  |  |  |  |  |  |
Diversified Financial Services | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [4] |  |  | 403,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | 403,000 |  |  |  |  |  |  |  |
Diversified Financial Services | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 36,545,000 | [1] | 33,335,000 | [4] |  |  |  |  |  |  |
Investments at Fair Value |  | 34,039,000 |  | 32,062,000 |  |  |  |  |  |  |  |
Diversified Financial Services | Gibraltar Business Capital, LLC | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 28,006,000 | [1] | 28,006,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 15,623,000 |  | $ 20,618,000 |  |  |  |  |  |  |  |
Shares | shares |  | 11,432,752 |  | 11,432,752 |  | 11,432,752 |  | 11,432,752 |  |  |  |
Diversified Financial Services | Gibraltar Business Capital, LLC | Equity | Preferred Series A |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 26,122,000 | [1],[24] | $ 26,122,000 | [2],[25] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 14,489,000 | [24] | $ 19,393,000 | [25] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 01, 2018 | [5] | Mar. 01, 2018 | [6],[25] |  |  |  |  |  |  |
Shares | shares |  | 10,602,752 | [24] | 10,602,752 | [25] | 10,602,752 | [24] | 10,602,752 | [25] |  |  |
Diversified Financial Services | Gibraltar Business Capital, LLC | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,884,000 | [1],[24] | $ 1,884,000 | [2],[25] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,134,000 | [24] | $ 1,225,000 | [25] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 01, 2018 | [5] | Mar. 01, 2018 | [6],[25] |  |  |  |  |  |  |
Shares | shares |  | 830,000 | [24] | 830,000 | [25] | 830,000 | [24] | 830,000 | [25] |  |  |
Diversified Financial Services | Gibraltar Business Capital, LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Principal Amount |  | $ 25,000,000 |  | $ 25,000,000 |  |  |  |  |  |  |  |
Investment cost |  | 24,545,000 | [1] | 24,485,000 | [4] |  |  |  |  |  |  |
Investments at Fair Value |  | 22,039,000 |  | 23,212,000 |  |  |  |  |  |  |  |
Diversified Financial Services | Hercules Adviser LLC | Equity | Member Units |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 35,000 | [1],[24] | 35,000 | [2],[25] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 21,945,000 | [24] | $ 11,990,000 | [25] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 26, 2021 | [5] | Mar. 26, 2021 | [6],[25] |  |  |  |  |  |  |
Shares | shares |  | 1 | [24] | 1 | [25] | 1 | [24] | 1 | [25] |  |  |
Diversified Financial Services | Newfront Insurance Holdings, Inc. | Equity | Preferred Series D-2 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 403,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 454,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Sep. 30, 2021 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 210,282 |  |  |  | 210,282 |  |  |  |  |  |
Diversified Financial Services | Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 36,545,000 | [1] | $ 33,738,000 | [4] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 34,039,000 |  | $ 32,465,000 |  |  |  |  |  |  |  |
Diversified Financial Services | Unsecured | Gibraltar Business Capital, LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2026-09 |  |  |  | 2026-09 |  |  |  |
Principal Amount | [25] |  |  | $ 15,000,000 |  |  |  |  |  |  |  |
Diversified Financial Services | Unsecured | Hercules Adviser LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-06 |  |  |  | 2025-06 |  |  |  |  |  |
Investment, Interest Rate, Paid in Cash | [7] | 5.00% |  |  |  | 5.00% |  |  |  |  |  |
Principal Amount | [24] | $ 12,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[24] | 12,000,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [24] | $ 12,000,000 |  |  |  |  |  |  |  |  |  |
Diversified Financial Services | Unsecured 14.50% | Gibraltar Business Capital, LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-09 |  |  |  | 2026-09 |  |  |  |  |  |
Investment, Interest Rate, Paid in Cash |  | 14.50% | [7] | 14.50% | [11],[25] | 14.50% | [7] | 14.50% | [11],[25] |  |  |
Principal Amount | [24] | $ 15,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost |  | 14,701,000 | [1],[24] | $ 14,662,000 | [4],[25] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 13,033,000 | [24] | $ 13,818,000 | [25] |  |  |  |  |  |  |
Diversified Financial Services | Unsecured 11.50% | Gibraltar Business Capital, LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-09 |  | 2026-09 |  | 2026-09 |  | 2026-09 |  |  |  |
Investment, Interest Rate, Paid in Cash |  | 11.50% | [7] | 11.50% | [11],[25] | 11.50% | [7] | 11.50% | [11],[25] |  |  |
Principal Amount |  | $ 10,000,000 | [24] | $ 10,000,000 | [25] |  |  |  |  |  |  |
Investment cost |  | 9,844,000 | [1],[24] | 9,823,000 | [4],[25] |  |  |  |  |  |  |
Investments at Fair Value |  | 9,006,000 | [24] | $ 9,394,000 | [25] |  |  |  |  |  |  |
Diversified Financial Services | Unsecured 5.00 % | Hercules Adviser LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2023-05 |  |  |  | 2023-05 |  |  |  |
Investment, Interest Rate, Paid in Cash | [11],[25] |  |  | 5.00% |  |  |  | 5.00% |  |  |  |
Principal Amount | [25] |  |  | $ 8,850,000 |  |  |  |  |  |  |  |
Investment cost | [4],[25] |  |  | 8,850,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [25] |  |  | $ 8,850,000 |  |  |  |  |  |  |  |
Diversified Financial Services | Convertible Debt | Newfront Insurance Holdings, Inc. | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2022-08 |  |  |  | 2022-08 |  |  |  |
Investment, Interest Rate, Floor | [11],[26] |  |  | 0.19% |  |  |  | 0.19% |  |  |  |
Investment, Interest Rate, Paid in Kind | [11],[26] |  |  | 0.19% |  |  |  | 0.19% |  |  |  |
Principal Amount | [26] |  |  | $ 403,000 |  |  |  |  |  |  |  |
Investment cost | [4],[26] |  |  | 403,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [26] |  |  | 403,000 |  |  |  |  |  |  |  |
Investment Funds And Vehicles |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | 2,032,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | 1,814,000 |  |  |  |  |  |  |  |
Investment Funds And Vehicles | Forbion Growth Opportunities Fund I C V |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[15],[27],[28] |  |  | 2,032,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [15],[27],[28] |  |  | $ 1,814,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6],[27],[28] |  |  | Nov. 16, 2020 |  |  |  |  |  |  |  |
Surgical Devices |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 1,536,000 |  | $ 1,029,000 |  |  |  |  |  |  |  |
Surgical Devices | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 1,941,000 | [1] | 1,941,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 0 |  | 543,000 |  |  |  |  |  |  |  |
Surgical Devices | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 152,000 | [1] | 206,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 1,536,000 |  | 486,000 |  |  |  |  |  |  |  |
Surgical Devices | Gynesonics, Inc. | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 1,941,000 | [1] | 1,941,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 543,000 |  |  |  |  |  |  |  |
Shares | shares |  | 9,595,178 |  | 9,595,178 |  | 9,595,178 |  | 9,595,178 |  |  |  |
Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series D |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 712,000 | [1] | $ 712,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 81,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Feb. 08, 2013 | [5] | Feb. 08, 2013 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,991,157 |  | 1,991,157 |  | 1,991,157 |  | 1,991,157 |  |  |  |
Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series B |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 250,000 | [1] | $ 250,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 9,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jan. 18, 2007 | [5] | Jan. 18, 2007 | [6] |  |  |  |  |  |  |
Shares | shares |  | 219,298 |  | 219,298 |  | 219,298 |  | 219,298 |  |  |  |
Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series C |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 282,000 | [1] | $ 282,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 26,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 16, 2010 | [5] | Jun. 16, 2010 | [6] |  |  |  |  |  |  |
Shares | shares |  | 656,538 |  | 656,538 |  | 656,538 |  | 656,538 |  |  |  |
Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series E |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 429,000 | [1] | $ 429,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 131,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jul. 14, 2015 | [5] | Jul. 14, 2015 | [6] |  |  |  |  |  |  |
Shares | shares |  | 2,786,367 |  | 2,786,367 |  | 2,786,367 |  | 2,786,367 |  |  |  |
Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series F |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 118,000 | [1] | $ 118,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 123,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 18, 2018 | [5] | Dec. 18, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,523,693 |  | 1,523,693 |  | 1,523,693 |  | 1,523,693 |  |  |  |
Surgical Devices | Gynesonics, Inc. | Equity | Series F One Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 150,000 | [1] | $ 150,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 173,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 18, 2018 | [5] | Dec. 18, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 2,418,125 |  | 2,418,125 |  | 2,418,125 |  | 2,418,125 |  |  |  |
Surgical Devices | Gynesonics, Inc. | Warrant Investment | Preferred Series C |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 13,000 | [1] | $ 67,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 6,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 05, 2012 | [5] | Feb. 08, 2012 | [6] |  |  |  |  |  |  |
Shares | shares |  | 33,670 |  | 151,123 |  | 33,670 |  | 151,123 |  |  |  |
Surgical Devices | TransMedics Group, Inc. (p.k.a Transmedics, Inc.) | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 139,000 | [1],[5] | $ 139,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,536,000 | [5] | $ 480,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 07, 2012 | [5] | Nov. 07, 2012 |  |  |  |  |  |  |  |
Shares | shares |  | 64,440 | [5] | 64,440 | [6] | 64,440 | [5] | 64,440 | [6] |  |  |
Drug Discovery & Development |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,091,827,000 |  | $ 967,383,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 42,548,000 | [1] | 33,401,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 32,844,000 |  | 24,860,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 7,709,000 | [1] | 7,393,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 4,074,000 |  | 4,745,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Investment Funds & Vehicles [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 2,758,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 2,665,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 16,378,000 | [1] | 20,036,000 | [4] |  |  |  |  |  |  |
Investments at Fair Value |  | 16,093,000 |  | 20,036,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 1,039,957,000 | [1] | 916,421,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 1,036,151,000 |  | 915,928,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Chemocentryx, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 1,000,000 | [1],[5],[29] | 1,000,000 | [2],[6],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 891,000 | [5],[29] | $ 628,000 | [6],[27] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 15, 2020 | [5] | Jun. 15, 2020 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 17,241 | [5],[29] | 17,241 | [6],[27] | 17,241 | [5],[29] | 17,241 | [6],[27] |  |  |
Drug Discovery & Development | Akero Therapeutics, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 1,000,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5],[29] | $ 1,310,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Sep. 19, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5],[29] | 38,461 |  |  |  | 38,461 |  |  |  |  |  |
Drug Discovery & Development | Akero Therapeutics, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5],[29] | $ 56,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5],[29] | $ 398,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jun. 15, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5],[29] | 18,360 |  |  |  | 18,360 |  |  |  |  |  |
Drug Discovery & Development | Albireo Pharma, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,000,000 | [1],[5],[29] | $ 1,000,000 | [2],[6],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 484,000 | [5],[29] | $ 582,000 | [6],[27] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 14, 2020 | [5] | Sep. 14, 2020 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 25,000 | [5],[29] | 25,000 | [6],[27] | 25,000 | [5],[29] | 25,000 | [6],[27] |  |  |
Drug Discovery & Development | Albireo Pharma, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 61,000 | [1],[5],[29] | $ 61,000 | [2],[6],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 26,000 | [5],[29] | $ 42,000 | [6],[27] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 08, 2020 | [5] | Jun. 08, 2020 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 5,311 | [5],[29] | 5,311 | [6],[27] | 5,311 | [5],[29] | 5,311 | [6],[27] |  |  |
Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,715,000 | [1],[5] | $ 1,715,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,565,000 | [5] | $ 892,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jul. 31, 2011 | [5] | Jul. 31, 2011 | [6] |  |  |  |  |  |  |
Shares | shares |  | 190,179 | [5] | 190,179 | [6] | 190,179 | [5] | 190,179 | [6] |  |  |
Drug Discovery & Development | Axsome Therapeutics, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5],[19],[22],[29] | $ 4,165,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5],[19],[22],[29] | $ 5,360,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | May 09, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5],[19],[22],[29] | 127,021 |  |  |  | 127,021 |  |  |  |  |  |
Drug Discovery & Development | Axsome Therapeutics, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 880,000 | [1],[5],[19],[29] | $ 681,000 | [2],[6],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 783,000 | [5],[19],[29] | $ 142,000 | [6],[27] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 25, 2020 | [5] | Sep. 25, 2020 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 40,396 | [5],[19],[22],[29] | 15,541 | [6],[27] | 40,396 | [5],[19],[22],[29] | 15,541 | [6],[27] |  |  |
Drug Discovery & Development | Bicycle Therapeutics PLC | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,871,000 | [1],[5],[29],[30] | $ 1,871,000 | [2],[6],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,282,000 | [5],[29],[30] | $ 5,971,000 | [6],[27],[28] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 05, 2020 | [5] | Oct. 05, 2020 | [6],[27],[28] |  |  |  |  |  |  |
Shares | shares |  | 98,100 | [5],[29],[30] | 98,100 | [6],[27],[28] | 98,100 | [5],[29],[30] | 98,100 | [6],[27],[28] |  |  |
Drug Discovery & Development | BridgeBio Pharma, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 2,255,000 | [1],[5] | $ 2,255,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,299,000 | [5] | $ 3,859,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 21, 2018 | [5] | Jun. 21, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 231,329 | [5] | 231,329 | [6] | 231,329 | [5] | 231,329 | [6] |  |  |
Drug Discovery & Development | Cellarity, Inc. | Warrant Investment | Preferred Series B |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 287,000 | [1],[31] | $ 287,000 | [2],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 370,000 | [31] | $ 287,000 | [32] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 08, 2021 | [5] | Dec. 08, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 100,000 | [31] | 100,000 | [32] | 100,000 | [31] | 100,000 | [32] |  |  |
Drug Discovery & Development | Century Therapeutics, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 37,000 | [1],[5] | $ 37,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 16,000 | [5] | $ 64,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 14, 2020 | [5] | Sep. 14, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 16,112 | [5] | 16,112 | [6] | 16,112 | [5] | 16,112 | [6] |  |  |
Drug Discovery & Development | enGene, Inc. | Warrant Investment | Preferred Series 3 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[29],[30] | $ 72,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [29],[30] | $ 31,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Dec. 30, 2021 |  |  |  |  |  |  |  |  |  |
Shares | shares | [29],[30] | 133,692 |  |  |  | 133,692 |  |  |  |  |  |
Drug Discovery & Development | enGene, Inc. | Warrant Investment | Preferred Series 3 Class C |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[27],[28] |  |  | $ 64,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [27],[28] |  |  | $ 64,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6],[27],[28] |  |  | Dec. 30, 2021 |  |  |  |  |  |  |  |
Shares | shares | [27],[28] |  |  | 84,714 |  |  |  | 84,714 |  |  |  |
Drug Discovery & Development | Hibercell, Inc. | Equity | Preferred Series B |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 4,250,000 | [1],[31] | $ 4,250,000 | [2],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,917,000 | [31] | $ 3,264,000 | [32] |  |  |  |  |  |  |
Investment, Acquisition Date |  | May 07, 2021 | [5] | May 07, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 3,466,840 | [31] | 3,466,840 | [32] | 3,466,840 | [31] | 3,466,840 | [32] |  |  |
Drug Discovery & Development | HilleVax, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5] | $ 4,000,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5] | $ 4,021,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | May 03, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5] | 235,295 |  |  |  | 235,295 |  |  |  |  |  |
Drug Discovery & Development | Humanigen, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 800,000 | [1],[5],[29] | $ 800,000 | [2],[6],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 8,000 | [5],[29] | $ 161,000 | [6],[27] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 31, 2021 | [5] | Mar. 31, 2021 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 43,243 | [5],[29] | 43,243 | [6],[27] | 43,243 | [5],[29] | 43,243 | [6],[27] |  |  |
Drug Discovery & Development | Kaleido Biosciences, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[6] |  |  | $ 1,000,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [6] |  |  | $ 207,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Feb. 10, 2021 |  |  |  |  |  |  |  |
Shares | shares | [6] |  |  | 86,585 |  |  |  | 86,585 |  |  |  |
Drug Discovery & Development | Madrigal Pharmaceutical, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5],[29] | $ 177,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5],[29] | $ 214,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | May 09, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5],[29] | 10,131 |  |  |  | 10,131 |  |  |  |  |  |
Drug Discovery & Development | Phathom Pharmaceuticals, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 848,000 | [1],[5],[19],[29],[31] | $ 848,000 | [2],[6],[27],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 113,000 | [5],[19],[29],[31] | $ 307,000 | [6],[21],[27],[32] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 17, 2021 | [5] | Sep. 17, 2021 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 64,687 | [5],[19],[29],[31] | 64,687 | [6],[21],[27],[32] | 64,687 | [5],[19],[29],[31] | 64,687 | [6],[21],[27],[32] |  |  |
Drug Discovery & Development | Provention Bio, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5] | $ 281,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5] | $ 224,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Sep. 15, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5] | 111,934 |  |  |  | 111,934 |  |  |  |  |  |
Drug Discovery & Development | Redshift Bioanalytics, Inc. | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [31] | $ 18,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Redshift Bioanalytics, Inc. | Warrant Investment | Preferred Series E |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[31] | $ 20,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Mar. 23, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [31] | 475,510 |  |  |  | 475,510 |  |  |  |  |  |
Drug Discovery & Development | Scynexis, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 296,000 | [1],[5] | $ 188,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 47,000 | [5] | $ 142,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | May 14, 2021 | [5] | May 14, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 106,035 | [5] | 90,887 | [6] | 106,035 | [5] | 90,887 | [6] |  |  |
Drug Discovery & Development | Tarsus Pharmaceuticals, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5],[29] | $ 2,100,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5],[29] | $ 2,663,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | May 05, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5],[29] | 155,555 |  |  |  | 155,555 |  |  |  |  |  |
Drug Discovery & Development | TG Therapeutics, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,033,000 | [1],[5],[18],[29] | $ 1,033,000 | [2],[6],[27],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 335,000 | [5],[18],[29] | $ 2,172,000 | [6],[27],[33] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Feb. 28, 2019 | [5] | Feb. 28, 2019 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 231,613 | [5],[18],[29] | 231,613 | [6],[27],[33] | 231,613 | [5],[18],[29] | 231,613 | [6],[27],[33] |  |  |
Drug Discovery & Development | Uni Qure B V | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 332,000 | [1],[5],[19],[29],[30] | $ 332,000 | [2],[6],[21],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 322,000 | [5],[19],[29],[30] | $ 356,000 | [6],[21],[27],[28] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jan. 31, 2019 | [5] | Jan. 31, 2019 | [6],[27],[28] |  |  |  |  |  |  |
Shares | shares |  | 17,175 | [5],[19],[29],[30] | 17,175 | [6],[21],[27],[28] | 17,175 | [5],[19],[29],[30] | 17,175 | [6],[21],[27],[28] |  |  |
Drug Discovery & Development | Valo Health L L C | Equity | Preferred Series B |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 3,000,000 | [1] | $ 3,000,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 3,622,000 |  | $ 4,650,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 11, 2020 | [5] | Dec. 11, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 510,308 |  | 510,308 |  | 510,308 |  | 510,308 |  |  |  |
Drug Discovery & Development | Valo Health L L C | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 242,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jun. 15, 2020 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Valo Health L L C | Warrant Investment | Common Units |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 256,000 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 102,216 |  |  |  | 102,216 |  |  |  |  |  |
Drug Discovery & Development | X Four Pharmaceuticals Inc | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 2,522,000 | [1],[5] | $ 1,641,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,901,000 | [5] | $ 454,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 26, 2019 | [5] | Nov. 26, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,111,519 | [5] | 198,277 | [6] | 1,111,519 | [5] | 198,277 | [6] |  |  |
Drug Discovery & Development | X Four Pharmaceuticals Inc | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 792,000 | [1],[5] | $ 673,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 628,000 | [5] | $ 2,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 18, 2019 | [5] | Mar. 18, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,021,576 | [5] | 108,334 | [6] | 1,021,576 | [5] | 108,334 | [6] |  |  |
Drug Discovery & Development | Applied Molecular Transport | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 42,000 | [1],[5],[29] | $ 42,000 | [2],[6],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,000 | [5],[29] | $ 14,000 | [6],[27] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Apr. 06, 2021 | [5] | Apr. 06, 2021 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 1,000 | [5],[29] | 1,000 | [6],[27] | 1,000 | [5],[29] | 1,000 | [6],[27] |  |  |
Drug Discovery & Development | Avalo Therapeutics, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,000,000 | [1],[5] | $ 1,000,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 33,000 | [5] | $ 202,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 19, 2014 | [5] | Aug. 19, 2014 | [6] |  |  |  |  |  |  |
Shares | shares |  | 9,924 | [5] | 119,087 | [6] | 9,924 | [5] | 119,087 | [6] |  |  |
Drug Discovery & Development | Concert Pharmaceuticals, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,367,000 | [1],[5],[29] | $ 1,367,000 | [2],[6],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 474,000 | [5],[29] | $ 223,000 | [6],[27] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Feb. 13, 2019 | [5] | Feb. 13, 2019 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 70,796 | [5],[29] | 70,796 | [6],[27] | 70,796 | [5],[29] | 70,796 | [6],[27] |  |  |
Drug Discovery & Development | Concert Pharmaceuticals, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[6],[27] |  |  | $ 178,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [6],[27] |  |  | $ 3,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6],[27] |  |  | Jun. 08, 2017 |  |  |  |  |  |  |  |
Shares | shares | [6],[27] |  |  | 61,273 |  |  |  | 61,273 |  |  |  |
Drug Discovery & Development | Dare Biosciences, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,000,000 | [1],[5] | $ 1,000,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 14,000 | [5] | $ 27,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jan. 08, 2015 | [5] | Jan. 08, 2015 | [6] |  |  |  |  |  |  |
Shares | shares |  | 13,550 | [5] | 13,550 | [6] | 13,550 | [5] | 13,550 | [6] |  |  |
Drug Discovery & Development | Dynavax Technologies | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 550,000 | [1],[5],[29] | $ 550,000 | [2],[6],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 209,000 | [5],[29] | $ 281,000 | [6],[27] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jul. 22, 2015 | [5] | Jul. 22, 2015 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 20,000 | [5],[29] | 20,000 | [6],[27] | 20,000 | [5],[29] | 20,000 | [6],[27] |  |  |
Drug Discovery & Development | NorthSea Therapeutics | Equity | Preferred Series C |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 2,000,000 | [1],[29],[30] | $ 2,000,000 | [2],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,515,000 | [29],[30] | $ 2,000,000 | [27],[28] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 15, 2021 | [5] | Dec. 15, 2021 | [6],[27],[28] |  |  |  |  |  |  |
Shares | shares |  | 983 | [29],[30] | 983 | [27],[28] | 983 | [29],[30] | 983 | [27],[28] |  |  |
Drug Discovery & Development | Paratek Pharmaceuticals, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 2,744,000 | [1],[5] | $ 2,744,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 196,000 | [5] | $ 343,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Feb. 26, 2007 | [5] | Feb. 26, 2007 | [6] |  |  |  |  |  |  |
Shares | shares |  | 76,362 | [5] | 76,362 | [6] | 76,362 | [5] | 76,362 | [6] |  |  |
Drug Discovery & Development | Paratek Pharmaceuticals, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 520,000 | [1],[5] | $ 546,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 72,000 | [5] | $ 427,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 01, 2018 | [5] | Jun. 27, 2017 | [6] |  |  |  |  |  |  |
Shares | shares |  | 426,866 | [5] | 432,240 | [6] | 426,866 | [5] | 432,240 | [6] |  |  |
Drug Discovery & Development | Rocket Pharmaceuticals, Ltd. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,500,000 | [1],[5] | $ 1,500,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 15,000 | [5] | $ 21,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 22, 2007 | [5] | Aug. 22, 2007 | [6] |  |  |  |  |  |  |
Shares | shares |  | 944 | [5] | 944 | [6] | 944 | [5] | 944 | [6] |  |  |
Drug Discovery & Development | Savara, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 203,000 | [1],[5] | $ 202,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 17,000 | [5] | $ 14,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 11, 2015 | [5] | Aug. 11, 2015 | [6] |  |  |  |  |  |  |
Shares | shares |  | 11,119 | [5] | 11,119 | [6] | 11,119 | [5] | 11,119 | [6] |  |  |
Drug Discovery & Development | Sio Gene Therapies, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,269,000 | [1],[5] | $ 1,269,000 | [2],[6],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 4,000 | [5] | $ 21,000 | [6],[27] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Feb. 02, 2017 | [5] | Feb. 02, 2017 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 16,228 | [5] | 16,228 | [6],[27] | 16,228 | [5] | 16,228 | [6],[27] |  |  |
Drug Discovery & Development | Tricida, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 863,000 | [1],[5] | $ 863,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 721,000 | [5] | $ 658,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Feb. 28, 2018 | [5] | Feb. 28, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 68,816 | [5] | 68,816 | [6] | 68,816 | [5] | 68,816 | [6] |  |  |
Drug Discovery & Development | Tricida, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 280,000 | [1],[5] | $ 280,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 22,000 | [5] | $ 20,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 27, 2019 | [5] | Mar. 27, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 31,352 | [5] | 31,352 | [6] | 31,352 | [5] | 31,352 | [6] |  |  |
Drug Discovery & Development | ADMA Biologics, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 295,000 | [1],[5] | $ 295,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,000 | [5] | $ 1,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 21, 2012 | [5] | Dec. 21, 2012 | [6] |  |  |  |  |  |  |
Shares | shares |  | 89,750 | [5] | 89,750 | [6] | 89,750 | [5] | 89,750 | [6] |  |  |
Drug Discovery & Development | Brickell Biotech, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[6] |  |  | $ 119,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [6] |  |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Feb. 18, 2016 |  |  |  |  |  |  |  |
Shares | shares | [6] |  |  | 9,005 |  |  |  | 9,005 |  |  |  |
Drug Discovery & Development | Dermavant Sciences Ltd. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 101,000 | [1],[18],[29],[30] | $ 101,000 | [2],[27],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 104,000 | [18],[29],[30] | $ 354,000 | [27],[33] |  |  |  |  |  |  |
Investment, Acquisition Date |  | May 31, 2019 | [5] | May 31, 2019 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 223,642 | [18],[29],[30] | 223,642 | [27],[33] | 223,642 | [18],[29],[30] | 223,642 | [27],[33] |  |  |
Drug Discovery & Development | Evofem Biosciences, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 266,000 | [1],[5] | $ 266,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 | [5] | $ 0 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 11, 2014 | [5] | Jun. 11, 2014 | [6] |  |  |  |  |  |  |
Shares | shares |  | 520 | [5] | 7,806 | [6] | 520 | [5] | 7,806 | [6] |  |  |
Drug Discovery & Development | Myovant Sciences, Ltd. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 460,000 | [1],[5],[29],[30] | $ 460,000 | [2],[6],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 429,000 | [5],[29],[30] | $ 267,000 | [6],[27] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 16, 2017 | [5] | Oct. 16, 2017 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 73,710 | [5],[29],[30] | 73,710 | [6],[27] | 73,710 | [5],[29],[30] | 73,710 | [6],[27] |  |  |
Drug Discovery & Development | Stealth Bio Therapeutics Corp. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 158,000 | [1],[5],[29],[30] | $ 158,000 | [2],[6],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 | [5],[29],[30] | $ 0 | [6],[27] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 30, 2017 | [5] | Jun. 30, 2017 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 500,000 | [5],[29],[30] | 500,000 | [6],[27] | 500,000 | [5],[29],[30] | 500,000 | [6],[27] |  |  |
Drug Discovery & Development | Yumanity Therapeutics, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 110,000 | [1],[5] | $ 110,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 | [5] | $ 3,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 20, 2019 | [5] | Dec. 20, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 15,414 | [5] | 15,414 | [6] | 15,414 | [5] | 15,414 | [6] |  |  |
Drug Discovery & Development | Fresh Tracks Therapeutics, Inc. (p.k.a. Brickell Biotech, Inc.) | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5] | $ 119,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5] | $ 0 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Feb. 18, 2016 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5] | 200 |  |  |  | 200 |  |  |  |  |  |
Drug Discovery & Development | Forbion Growth Opportunities Fund I C V | Investment Funds & Vehicles [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[29],[30] | $ 2,353,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[29],[30] | $ 2,291,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Nov. 16, 2020 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Forbion Growth Opportunities Fund I I C V | Investment Funds & Vehicles [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[29],[30] | $ 405,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[29],[30] | $ 374,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jun. 23, 2022 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Valo Health, LLC (p.k.a. Integral Health Holdings, LLC) | Warrant Investment | Common Units |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 256,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 441,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Jun. 15, 2020 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 102,216 |  |  |  | 102,216 |  |  |  |
Drug Discovery & Development | Acacia Pharma Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 304,000 | [1],[29],[30] | $ 305,000 | [2],[6],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 | [29],[30] | $ 6,000 | [6],[27],[28] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 29, 2018 | [5] | Jun. 29, 2018 | [6],[27],[28] |  |  |  |  |  |  |
Shares | shares |  | 201,330 | [29],[30] | 201,330 | [6],[27],[28] | 201,330 | [29],[30] | 201,330 | [6],[27],[28] |  |  |
Drug Discovery & Development | Genocea Biosciences Inc | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[6] |  |  | $ 2,000,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [6] |  |  | $ 32,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Nov. 20, 2014 |  |  |  |  |  |  |  |
Shares | shares | [6] |  |  | 27,933 |  |  |  | 27,933 |  |  |  |
Drug Discovery & Development | Genocea Biosciences Inc | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[6] |  |  | $ 165,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [6] |  |  | $ 1,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Apr. 24, 2018 |  |  |  |  |  |  |  |
Shares | shares | [6] |  |  | 41,176 |  |  |  | 41,176 |  |  |  |
Drug Discovery & Development | Motif Bio P L C | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[27] |  |  | $ 282,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [27] |  |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6],[27] |  |  | Jan. 27, 2020 |  |  |  |  |  |  |  |
Shares | shares | [27] |  |  | 121,337,041 |  |  |  | 121,337,041 |  |  |  |
Drug Discovery & Development | Senior Secured | Chemocentryx, Inc. | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2022-12 |  | 2022-12 |  | 2022-12 |  | 2022-12 |  |  |  |
Investment Interest Rate | [11],[27] |  |  | 6.25% |  |  |  | 6.25% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 3.30% | [7] | 3.30% | [11],[27] | 3.30% | [7] | 3.30% | [11],[27] |  |  |
Investment, Interest Rate, Floor |  | 8.05% | [7] | 8.05% | [11],[27] | 8.05% | [7] | 8.05% | [11],[27] |  |  |
Interest Rate and Floor | [11],[27] |  |  | 6.25% |  |  |  | 6.25% |  |  |  |
Principal Amount |  | $ 11,451,000 | [17],[29] | $ 18,951,000 | [27] |  |  |  |  |  |  |
Investment cost |  | 12,677,000 | [1],[17],[29] | 20,036,000 | [4],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 12,780,000 | [17],[29] | $ 20,036,000 | [27] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Chemocentryx, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-02 |  | 2025-02 |  | 2025-02 |  | 2025-02 |  |  |  |
Investment Interest Rate | [11],[27] |  |  | 7.15% |  |  |  | 7.15% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 3.25% | [7] | 3.25% | [11],[27] | 3.25% | [7] | 3.25% | [11],[27] |  |  |
Investment, Interest Rate, Floor |  | 8.50% | [7] | 8.50% | [11],[27] | 8.50% | [7] | 8.50% | [11],[27] |  |  |
Interest Rate and Floor | [11],[27] |  |  | 7.15% |  |  |  | 7.15% |  |  |  |
Principal Amount |  | $ 5,000,000 | [17],[29] | $ 5,000,000 | [27] |  |  |  |  |  |  |
Investment cost |  | 5,214,000 | [1],[17],[29] | 5,161,000 | [2],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 5,408,000 | [17],[29] | $ 5,070,000 | [27] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Nabriva Therapeutics | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2023-06 |  |  |  | 2023-06 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.30% |  |  |  | 4.30% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 9.80% |  |  |  | 9.80% |  |  |  |  |  |
Principal Amount | [17],[29],[30] | $ 3,077,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[17],[29],[30] | 3,701,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [17],[29],[30] | $ 3,313,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Nabriva Therapeutics | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2023-06 |  |  |  | 2023-06 |  |  |  |
Investment Interest Rate | [11],[27],[28] |  |  | 6.95% |  |  |  | 6.95% |  |  |  |
Investment, Basis Spread, Variable Rate | [11],[27],[28] |  |  | 4.30% |  |  |  | 4.30% |  |  |  |
Investment, Interest Rate, Floor | [11],[27],[28] |  |  | 9.80% |  |  |  | 9.80% |  |  |  |
Interest Rate and Floor | [11],[27],[28] |  |  | 6.95% |  |  |  | 6.95% |  |  |  |
Principal Amount | [27],[28] |  |  | $ 5,000,000 |  |  |  |  |  |  |  |
Investment cost | [2],[27],[28] |  |  | 5,500,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [27],[28] |  |  | $ 5,459,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Akero Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-01 |  |  |  | 2027-01 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 3.65% |  |  |  | 3.65% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 7.65% |  |  |  | 7.65% |  |  |  |  |  |
Principal Amount | [10],[29] | $ 5,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[29] | 4,966,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[29] | $ 4,983,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Albireo Pharma, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2024-07 |  |  |  | 2024-07 |  |  |  |
Investment Interest Rate | [11],[27] |  |  | 6.95% |  |  |  | 6.95% |  |  |  |
Investment, Basis Spread, Variable Rate | [11],[27] |  |  | 5.90% |  |  |  | 5.90% |  |  |  |
Investment, Interest Rate, Floor | [11],[27] |  |  | 9.15% |  |  |  | 9.15% |  |  |  |
Interest Rate and Floor | [11],[27] |  |  | 6.95% |  |  |  | 6.95% |  |  |  |
Principal Amount | [14],[27] |  |  | $ 10,000,000 |  |  |  |  |  |  |  |
Investment cost | [4],[14],[27] |  |  | 10,229,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [14],[27] |  |  | $ 10,268,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Alladapt Immunotherapeutics Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-09 |  |  |  | 2026-09 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 3.65% |  |  |  | 3.65% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.40% |  |  |  | 8.40% |  |  |  |  |  |
Principal Amount | [10] | $ 15,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10] | 14,858,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10] | $ 14,858,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Aldeyra Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2023-10 |  | 2023-10 |  | 2023-10 |  | 2023-10 |  |  |  |
Investment Interest Rate | [11] |  |  | 6.95% |  |  |  | 6.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 3.10% | [7] | 3.10% | [11] | 3.10% | [7] | 3.10% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.60% | [7] | 8.60% | [11] | 8.60% | [7] | 8.60% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 6.95% |  |  |  | 6.95% |  |  |  |
Principal Amount |  | $ 15,000,000 | [12] | $ 15,000,000 |  |  |  |  |  |  |  |
Investment cost |  | 15,817,000 | [1],[12] | 15,639,000 | [4] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 15,608,000 | [12] | $ 15,653,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Applied Genetic Technologies Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-04 |  | 2024-04 |  | 2024-04 |  | 2024-04 |  |  |  |
Investment Interest Rate | [11] |  |  | 9.75% |  |  |  | 9.75% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 6.50% | [7] | 6.50% | [11] | 6.50% | [7] | 6.50% | [11] |  |  |
Investment, Interest Rate, Floor | [7] | 9.75% |  |  |  | 9.75% |  |  |  |  |  |
Interest Rate and Floor | [11] |  |  | 9.75% |  |  |  | 9.75% |  |  |  |
Principal Amount |  | $ 15,609,000 | [17] | $ 20,000,000 |  |  |  |  |  |  |  |
Investment cost |  | 16,450,000 | [1],[17] | 20,416,000 | [4] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 16,308,000 | [17] | $ 20,339,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | ATAI Life Sciences N.V. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-08 |  |  |  | 2026-08 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.55% |  |  |  | 4.55% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.55% |  |  |  | 8.55% |  |  |  |  |  |
Principal Amount | [10],[29],[30] | $ 10,500,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[29],[30] | 10,467,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[29],[30] | $ 10,467,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Aveo Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-09 |  | 2024-09 |  | 2024-09 |  | 2024-09 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 6.40% | [7] | 6.40% | [11] | 6.40% | [7] | 6.40% | [11] |  |  |
Investment, Interest Rate, Floor |  | 9.65% | [7] | 9.65% | [11] | 9.65% | [7] | 9.65% | [11] |  |  |
Principal Amount |  | $ 40,000,000 | [12],[31] | $ 40,000,000 | [14],[32] |  |  |  |  |  |  |
Investment cost |  | 41,439,000 | [1],[12],[31] | 40,842,000 | [4],[14],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 41,374,000 | [12],[31] | $ 40,776,000 | [14],[32] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Axsome Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-10 |  | 2026-10 |  | 2026-10 |  | 2026-10 |  |  |  |
Investment Interest Rate | [11],[27] |  |  | 5.82% |  |  |  | 5.82% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.70% | [7] | 5.70% | [11],[27] | 5.70% | [7] | 5.70% | [11],[27] |  |  |
Investment, Interest Rate, Floor |  | 8.95% | [7] | 8.95% | [11],[27] | 8.95% | [7] | 8.95% | [11],[27] |  |  |
Interest Rate and Floor | [11],[27] |  |  | 5.82% |  |  |  | 5.82% |  |  |  |
Principal Amount |  | $ 81,725,000 | [10],[12],[18],[19],[29] | $ 50,000,000 | [27],[33] |  |  |  |  |  |  |
Investment cost |  | 81,388,000 | [1],[10],[12],[18],[19],[29] | 49,542,000 | [4],[27],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 79,295,000 | [10],[12],[18],[19],[29] | $ 48,859,000 | [27],[33] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Bicycle Therapeutics PLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-07 |  | 2024-10 |  | 2025-07 |  | 2024-10 |  |  |  |
Investment Interest Rate | [11],[27],[28] |  |  | 5.00% |  |  |  | 5.00% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 4.55% | [7] | 5.60% | [11],[27],[28] | 4.55% | [7] | 5.60% | [11],[27],[28] |  |  |
Investment, Interest Rate, Floor |  | 8.05% | [7] | 8.85% | [11],[27],[28] | 8.05% | [7] | 8.85% | [11],[27],[28] |  |  |
Interest Rate and Floor | [11],[27],[28] |  |  | 5.00% |  |  |  | 5.00% |  |  |  |
Principal Amount |  | $ 11,500,000 | [12],[18],[29],[30] | $ 24,000,000 | [14],[15],[27],[28],[33] |  |  |  |  |  |  |
Investment cost |  | 11,724,000 | [1],[12],[18],[29],[30] | 24,271,000 | [4],[14],[15],[27],[28],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 11,619,000 | [12],[18],[29],[30] | $ 24,454,000 | [14],[15],[27],[28],[33] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | BiomX, INC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-09 |  | 2025-09 |  | 2025-09 |  | 2025-09 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.70% | [7] | 5.70% | [11],[27],[28] | 5.70% | [7] | 5.70% | [11],[27],[28] |  |  |
Investment, Interest Rate, Floor |  | 8.95% | [7] | 8.95% | [11],[27],[28] | 8.95% | [7] | 8.95% | [11],[27],[28] |  |  |
Principal Amount |  | $ 9,000,000 | [12],[29],[30] | $ 9,000,000 | [14],[27],[28] |  |  |  |  |  |  |
Investment cost |  | 9,125,000 | [1],[12],[29],[30] | 8,980,000 | [4],[14],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 9,004,000 | [12],[29],[30] | $ 8,980,000 | [14],[27],[28] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | BridgeBio Pharma, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-11 |  | 2026-11 |  | 2026-11 |  | 2026-11 |  |  |  |
Investment, Interest Rate, Paid in Cash |  | 9.00% | [7] | 9.00% | [11] | 9.00% | [7] | 9.00% | [11] |  |  |
Investment Interest Rate | [11] |  |  | 2.00% |  |  |  | 2.00% |  |  |  |
Interest Rate and Floor | [11] |  |  | 2.00% |  |  |  | 2.00% |  |  |  |
Principal Amount |  | $ 37,022,000 | [9],[17],[18] | $ 38,000,000 |  |  |  |  |  |  |  |
Investment cost |  | 36,694,000 | [1],[9],[17],[18] | 37,462,000 | [4] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 33,561,000 | [9],[17],[18] | $ 37,462,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Cellarity, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-06 |  | 2026-06 |  | 2026-06 |  | 2026-06 |  |  |  |
Investment Interest Rate | [11] |  |  | 3.75% |  |  |  | 3.75% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.70% | [7] | 5.70% | [11] | 5.70% | [7] | 5.70% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.95% | [7] | 8.95% | [11] | 8.95% | [7] | 8.95% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 3.75% |  |  |  | 3.75% |  |  |  |
Principal Amount |  | $ 30,000,000 | [17],[31] | $ 30,000,000 | [32] |  |  |  |  |  |  |
Investment cost |  | 29,734,000 | [1],[17],[31] | 29,422,000 | [4],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 29,943,000 | [17],[31] | $ 29,422,000 | [32] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Century Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-04 |  | 2024-04 |  | 2024-04 |  | 2024-04 |  |  |  |
Investment Interest Rate | [11] |  |  | 3.95% |  |  |  | 3.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 6.30% | [7] | 6.30% | [11] | 6.30% | [7] | 6.30% | [11] |  |  |
Investment, Interest Rate, Floor |  | 9.55% | [7] | 9.55% | [11] | 9.55% | [7] | 9.55% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 3.95% |  |  |  | 3.95% |  |  |  |
Principal Amount |  | $ 10,000,000 | [12] | $ 10,000,000 | [14] |  |  |  |  |  |  |
Investment cost |  | 10,197,000 | [1],[12] | 10,075,000 | [4],[14] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 10,261,000 | [12] | $ 10,361,000 | [14] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Codiak Biosciences, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-10 |  | 2025-10 |  | 2025-10 |  | 2025-10 |  |  |  |
Investment Interest Rate | [11] |  |  | 5.50% |  |  |  | 5.50% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.00% | [7] | 5.00% | [11] | 5.00% | [7] | 5.00% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.25% | [7] | 8.25% | [11] | 8.25% | [7] | 8.25% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 5.50% |  |  |  | 5.50% |  |  |  |
Principal Amount |  | $ 25,000,000 | [12] | $ 25,000,000 | [14] |  |  |  |  |  |  |
Investment cost |  | 25,681,000 | [1],[12] | 25,459,000 | [2],[14] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 25,076,000 | [12] | $ 25,316,000 | [14] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Corium, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-09 |  | 2026-09 |  | 2026-09 |  | 2026-09 |  |  |  |
Investment Interest Rate | [11] |  |  | 7.75% |  |  |  | 7.75% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.70% | [7] | 5.70% | [11] | 5.70% | [7] | 5.70% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.95% | [7] | 8.95% | [11] | 8.95% | [7] | 8.95% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 7.75% |  |  |  | 7.75% |  |  |  |
Principal Amount |  | $ 132,675,000 | [17],[19] | $ 91,500,000 | [21] |  |  |  |  |  |  |
Investment cost |  | 133,069,000 | [1],[17],[19] | 90,997,000 | [2],[21] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 135,828,000 | [17],[19] | $ 90,997,000 | [21] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Eloxx Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-04 |  | 2025-04 |  | 2025-04 |  | 2025-04 |  |  |  |
Investment Interest Rate | [11] |  |  | 6.25% |  |  |  | 6.25% |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 6.25% |  |  |  | 6.25% |  |  |  |  |  |
Investment, Interest Rate, Floor |  | 9.50% | [7] | 9.50% | [11] | 9.50% | [7] | 9.50% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 6.25% |  |  |  | 6.25% |  |  |  |
Principal Amount |  | $ 12,500,000 | [31] | $ 12,500,000 | [32] |  |  |  |  |  |  |
Investment cost |  | 12,673,000 | [1],[31] | 12,443,000 | [2],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 12,408,000 | [31] | $ 12,443,000 | [32] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | enGene, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-07 |  | 2025-07 |  | 2025-07 |  | 2025-07 |  |  |  |
Investment Interest Rate | [11],[27],[28] |  |  | 6.35% |  |  |  | 6.35% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.00% | [7] | 5.00% | [11],[27],[28] | 5.00% | [7] | 5.00% | [11],[27],[28] |  |  |
Investment, Interest Rate, Floor | [11],[27],[28] |  |  | 8.25% |  |  |  | 8.25% |  |  |  |
Interest Rate and Floor | [11],[27],[28] |  |  | 6.35% |  |  |  | 6.35% |  |  |  |
Principal Amount |  | $ 11,000,000 | [17],[29],[30] | $ 7,000,000 | [27],[28] |  |  |  |  |  |  |
Investment cost |  | 10,994,000 | [1],[17],[29],[30] | 6,858,000 | [2],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 10,918,000 | [17],[29],[30] | $ 6,858,000 | [27],[28] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Finch Therapeutics Group, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-11 |  |  |  | 2026-11 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.05% |  |  |  | 4.05% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 7.55% |  |  |  | 7.55% |  |  |  |  |  |
Principal Amount | [10] | $ 15,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10] | 14,958,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10] | $ 14,241,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | G1 Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-11 |  | 2026-11 |  | 2026-11 |  | 2026-11 |  |  |  |
Investment Interest Rate | [11],[27] |  |  | 9.86% |  |  |  | 9.86% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.90% | [7] | 5.90% | [11],[27] | 5.90% | [7] | 5.90% | [11],[27] |  |  |
Investment, Interest Rate, Floor |  | 9.15% | [7] | 9.15% | [11],[27] | 9.15% | [7] | 9.15% | [11],[27] |  |  |
Interest Rate and Floor | [11],[27] |  |  | 9.86% |  |  |  | 9.86% |  |  |  |
Principal Amount |  | $ 58,125,000 | [10],[12],[18],[31] | $ 58,125,000 | [14],[15],[27],[32],[33] |  |  |  |  |  |  |
Investment cost |  | 58,472,000 | [1],[10],[12],[18],[31] | 57,873,000 | [2],[14],[15],[27],[32],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 58,006,000 | [10],[12],[18],[31] | $ 57,874,000 | [14],[15],[27],[32],[33] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Geron Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-10 |  | 2024-10 |  | 2024-10 |  | 2024-10 |  |  |  |
Investment Interest Rate | [11],[27] |  |  | 6.55% |  |  |  | 6.55% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.75% | [7] | 5.75% | [11],[27] | 5.75% | [7] | 5.75% | [11],[27] |  |  |
Investment, Interest Rate, Floor |  | 9.00% | [7] | 9.00% | [11],[27] | 9.00% | [7] | 9.00% | [11],[27] |  |  |
Interest Rate and Floor | [11],[27] |  |  | 6.55% |  |  |  | 6.55% |  |  |  |
Principal Amount |  | $ 18,500,000 | [17],[18],[29] | $ 32,500,000 | [27],[33] |  |  |  |  |  |  |
Investment cost |  | 19,003,000 | [1],[17],[18],[29] | 32,704,000 | [2],[27],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 19,059,000 | [17],[18],[29] | $ 32,744,000 | [27],[33] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Gritstone Bio, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-07 |  |  |  | 2027-07 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 3.15% |  |  |  | 3.15% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 7.15% |  |  |  | 7.15% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 2.00% |  |  |  | 2.00% |  |  |  |  |  |
Principal Amount | [9],[10] | $ 15,037,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[9],[10] | 14,989,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [9],[10] | $ 14,989,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Hibercell, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-05 |  | 2025-05 |  | 2025-05 |  | 2025-05 |  |  |  |
Investment Interest Rate | [11] |  |  | 4.95% |  |  |  | 4.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.40% | [7] | 5.40% | [11] | 5.40% | [7] | 5.40% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.65% | [7] | 8.65% | [11] | 8.65% | [7] | 8.65% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 4.95% |  |  |  | 4.95% |  |  |  |
Principal Amount |  | $ 17,000,000 | [17],[31] | $ 17,000,000 | [32] |  |  |  |  |  |  |
Investment cost |  | 17,244,000 | [1],[17],[31] | 17,041,000 | [2],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 17,225,000 | [17],[31] | $ 17,014,000 | [32] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | HilleVax, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-05 |  |  |  | 2027-05 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 1.05% |  |  |  | 1.05% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 4.55% |  |  |  | 4.55% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 2.85% |  |  |  | 2.85% |  |  |  |  |  |
Principal Amount | [9],[10],[31] | $ 4,043,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[9],[10],[31] | 4,043,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [9],[10],[31] | $ 4,044,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Iveric Bio Gene Therapy LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-08 |  |  |  | 2027-08 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.00% |  |  |  | 4.00% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.75% |  |  |  | 8.75% |  |  |  |  |  |
Principal Amount | [10],[29] | $ 24,750,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[29] | 24,530,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[29] | $ 24,531,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Humanigen, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2025-03 |  |  |  | 2025-03 |  |  |  |
Investment Interest Rate | [11],[26],[27] |  |  | 6.75% |  |  |  | 6.75% |  |  |  |
Investment, Basis Spread, Variable Rate | [11],[26],[27] |  |  | 5.50% |  |  |  | 5.50% |  |  |  |
Investment, Interest Rate, Floor | [11],[26],[27] |  |  | 8.75% |  |  |  | 8.75% |  |  |  |
Interest Rate and Floor | [11],[26],[27] |  |  | 6.75% |  |  |  | 6.75% |  |  |  |
Principal Amount | [26],[27] |  |  | $ 20,000,000 |  |  |  |  |  |  |  |
Investment cost | [2],[26],[27] |  |  | 20,235,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [26],[27] |  |  | $ 19,985,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Kaleido Biosciences, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2024-01 |  |  |  | 2024-01 |  |  |  |
Investment Interest Rate | [11] |  |  | 7.55% |  |  |  | 7.55% |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 6.10% |  |  |  | 6.10% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 9.35% |  |  |  | 9.35% |  |  |  |
Interest Rate and Floor | [11] |  |  | 7.55% |  |  |  | 7.55% |  |  |  |
Principal Amount | [33] |  |  | $ 22,500,000 |  |  |  |  |  |  |  |
Investment cost | [2],[33] |  |  | 23,505,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [33] |  |  | $ 23,384,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Locus Biosciences, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-07 |  | 2025-07 |  | 2025-07 |  | 2025-07 |  |  |  |
Investment Interest Rate | [11] |  |  | 4.95% |  |  |  | 4.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 6.10% | [7] | 6.10% | [11] | 6.10% | [7] | 6.10% | [11] |  |  |
Investment, Interest Rate, Floor |  | 9.35% | [7] | 9.35% | [11] | 9.35% | [7] | 9.35% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 4.95% |  |  |  | 4.95% |  |  |  |
Principal Amount |  | $ 8,000,000 | [31] | $ 8,000,000 | [32] |  |  |  |  |  |  |
Investment cost |  | 8,084,000 | [1],[31] | 7,977,000 | [2],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 8,062,000 | [31] | $ 7,900,000 | [32] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Madrigal Pharmaceutical, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-05 |  |  |  | 2026-05 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 7.45% |  |  |  | 7.45% |  |  |  |  |  |
Principal Amount | [29] | $ 34,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[29] | 33,807,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [29] | $ 33,807,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Phathom Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-10 |  | 2026-10 |  | 2026-10 |  | 2026-10 |  |  |  |
Investment Interest Rate | [11],[27] |  |  | 7.50% |  |  |  | 7.50% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 2.25% | [7] | 2.25% | [11],[27] | 2.25% | [7] | 2.25% | [11],[27] |  |  |
Investment, Interest Rate, Floor |  | 5.50% | [7] | 5.50% | [11],[27] | 5.50% | [7] | 5.50% | [11],[27] |  |  |
Investment, Interest Rate, Paid in Kind |  | 3.35% | [7] | 3.35% | [11],[27] | 3.35% | [7] | 3.35% | [11],[27] |  |  |
Interest Rate and Floor | [11],[27] |  |  | 7.50% |  |  |  | 7.50% |  |  |  |
Principal Amount |  | $ 93,978,000 | [9],[10],[18],[19],[29],[31] | $ 87,116,000 | [15],[20],[21],[27],[32],[33] |  |  |  |  |  |  |
Investment cost |  | 93,948,000 | [1],[9],[10],[18],[19],[29],[31] | 86,075,000 | [2],[15],[20],[21],[27],[32],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 94,006,000 | [9],[10],[18],[19],[29],[31] | $ 86,075,000 | [15],[20],[21],[27],[32],[33] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Provention Bio, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-09 |  |  |  | 2026-09 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 2.70% |  |  |  | 2.70% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.20% |  |  |  | 8.20% |  |  |  |  |  |
Principal Amount |  | $ 25,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 24,552,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 24,552,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Redshift Bioanalytics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-01 |  |  |  | 2026-01 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.25% |  |  |  | 4.25% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 7.50% |  |  |  | 7.50% |  |  |  |  |  |
Principal Amount | [31] | $ 5,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[31] | 4,936,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [31] | $ 4,935,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Scynexis, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-03 |  | 2025-03 |  | 2025-03 |  | 2025-03 |  |  |  |
Investment Interest Rate | [11] |  |  | 3.95% |  |  |  | 3.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.80% | [7] | 5.80% | [11] | 5.80% | [7] | 5.80% | [11] |  |  |
Investment, Interest Rate, Floor |  | 9.05% | [7] | 9.05% | [11] | 9.05% | [7] | 9.05% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 3.95% |  |  |  | 3.95% |  |  |  |
Principal Amount |  | $ 18,667,000 | [17],[18] | $ 16,000,000 |  |  |  |  |  |  |  |
Investment cost |  | 18,592,000 | [1],[17],[18] | 15,826,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 18,524,000 | [17],[18] | $ 15,778,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Seres Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-10 |  | 2023-11 |  | 2024-10 |  | 2023-11 |  |  |  |
Investment Interest Rate | [11] |  |  | 4.85% |  |  |  | 4.85% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 6.40% | [7] | 4.40% | [11] | 6.40% | [7] | 4.40% | [11] |  |  |
Investment, Interest Rate, Floor |  | 9.65% | [7] | 9.65% | [11] | 9.65% | [7] | 9.65% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 4.85% |  |  |  | 4.85% |  |  |  |
Principal Amount |  | $ 37,500,000 | [17],[18] | $ 24,051,000 |  |  |  |  |  |  |  |
Investment cost |  | 38,509,000 | [1],[17],[18] | 24,777,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 38,657,000 | [17],[18] | $ 25,183,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Syndax Pharmaceutics Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2024-04 |  |  |  | 2024-04 |  |  |  |
Investment Interest Rate | [11] |  |  | 4.99% |  |  |  | 4.99% |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 6.00% |  |  |  | 6.00% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 9.25% |  |  |  | 9.25% |  |  |  |
Interest Rate and Floor | [11] |  |  | 4.99% |  |  |  | 4.99% |  |  |  |
Principal Amount | [15],[33] |  |  | $ 20,000,000 |  |  |  |  |  |  |  |
Investment cost | [2],[15],[33] |  |  | 20,646,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [15],[33] |  |  | $ 20,653,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Tarsus Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-02 |  |  |  | 2027-02 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 5.20% |  |  |  | 5.20% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.45% |  |  |  | 8.45% |  |  |  |  |  |
Principal Amount | [10],[17],[29] | $ 8,250,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[17],[29] | 8,255,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[17],[29] | $ 8,388,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | TG Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-01 |  | 2026-01 |  | 2026-01 |  | 2026-01 |  |  |  |
Investment Interest Rate | [11],[27] |  |  | 5.95% |  |  |  | 5.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 2.15% | [7] | 2.15% | [11],[27] | 2.15% | [7] | 2.15% | [11],[27] |  |  |
Investment, Interest Rate, Floor |  | 5.40% | [7] | 5.40% | [11],[27] | 5.40% | [7] | 5.40% | [11],[27] |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 3.45% |  |  |  | 3.45% |  |  |  |  |  |
Interest Rate and Floor | [11],[27] |  |  | 5.95% |  |  |  | 5.95% |  |  |  |
Principal Amount |  | $ 47,567,000 | [9],[12],[18],[29] | $ 51,450,000 | [27] |  |  |  |  |  |  |
Investment cost |  | 47,267,000 | [1],[9],[12],[18],[29] | 50,470,000 | [2],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 47,137,000 | [9],[12],[18],[29] | $ 50,470,000 | [27] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Uni Qure B V | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-12 |  | 2025-12 |  | 2025-12 |  | 2025-12 |  |  |  |
Investment Interest Rate | [11],[27],[28] |  |  | 7.28% |  |  |  | 7.28% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 4.70% | [7] | 4.70% | [11],[27],[28] | 4.70% | [7] | 4.70% | [11],[27],[28] |  |  |
Investment, Interest Rate, Floor |  | 7.95% | [7] | 7.95% | [11],[27],[28] | 7.95% | [7] | 7.95% | [11],[27],[28] |  |  |
Interest Rate and Floor | [11],[27],[28] |  |  | 7.28% |  |  |  | 7.28% |  |  |  |
Principal Amount |  | $ 70,000,000 | [12],[18],[19],[29],[30] | $ 77,500,000 | [14],[21],[27],[28],[33] |  |  |  |  |  |  |
Investment cost |  | 72,015,000 | [1],[12],[18],[19],[29],[30] | 78,755,000 | [2],[14],[21],[27],[28],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 73,205,000 | [12],[18],[19],[29],[30] | $ 78,755,000 | [14],[21],[27],[28],[33] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Unity Biotechnology Inc | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-08 |  | 2024-08 |  | 2024-08 |  | 2024-08 |  |  |  |
Investment Interest Rate | [11],[26] |  |  | 6.25% |  |  |  | 6.25% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 6.10% | [7] | 6.10% | [11],[26] | 6.10% | [7] | 6.10% | [11],[26] |  |  |
Investment, Interest Rate, Floor |  | 9.35% | [7] | 9.35% | [11],[26] | 9.35% | [7] | 9.35% | [11],[26] |  |  |
Interest Rate and Floor | [11],[26] |  |  | 6.25% |  |  |  | 6.25% |  |  |  |
Principal Amount |  | $ 20,000,000 | [17] | $ 22,701,000 | [26] |  |  |  |  |  |  |
Investment cost |  | 20,990,000 | [1],[17] | 23,293,000 | [2],[26] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 20,844,000 | [17] | $ 23,627,000 | [26] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Valo Health L L C | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-05 |  | 2024-05 |  | 2024-05 |  | 2024-05 |  |  |  |
Investment Interest Rate | [11] |  |  | 3.85% |  |  |  | 3.85% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 6.45% | [7] | 6.45% | [11] | 6.45% | [7] | 6.45% | [11] |  |  |
Investment, Interest Rate, Floor |  | 9.70% | [7] | 9.70% | [11] | 9.70% | [7] | 9.70% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 3.85% |  |  |  | 3.85% |  |  |  |
Principal Amount |  | $ 9,583,000 | [12],[17] | $ 11,500,000 | [14] |  |  |  |  |  |  |
Investment cost |  | 9,805,000 | [1],[12],[17] | 11,547,000 | [2],[14] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 9,760,000 | [12],[17] | $ 11,492,000 | [14] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Viridian Therapeutics Inc | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-10 |  |  |  | 2026-10 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.20% |  |  |  | 4.20% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 7.45% |  |  |  | 7.45% |  |  |  |  |  |
Principal Amount | [10],[17],[29] | $ 2,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[17],[29] | 2,004,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[17],[29] | $ 1,969,000 |  |  |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | X Four Pharmaceuticals Inc | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-07 |  | 2024-07 |  | 2024-07 |  | 2024-07 |  |  |  |
Investment Interest Rate | [11] |  |  | 8.80% |  |  |  | 8.80% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 3.75% | [7] | 3.75% | [11] | 3.75% | [7] | 3.75% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.75% | [7] | 8.75% | [11] | 8.75% | [7] | 8.75% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 8.80% |  |  |  | 8.80% |  |  |  |
Principal Amount |  | $ 32,500,000 | [12],[17],[18] | $ 32,500,000 | [14],[33] |  |  |  |  |  |  |
Investment cost |  | 33,464,000 | [1],[12],[17],[18] | 34,140,000 | [2],[14],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 33,291,000 | [12],[17],[18] | $ 34,085,000 | [14],[33] |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Yumanity Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2024-01 |  |  |  | 2024-01 |  |  |  |
Investment Interest Rate | [11] |  |  | 5.92% |  |  |  | 5.92% |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 4.00% |  |  |  | 4.00% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 8.75% |  |  |  | 8.75% |  |  |  |
Interest Rate and Floor | [11] |  |  | 5.92% |  |  |  | 5.92% |  |  |  |
Principal Amount |  |  |  | $ 12,732,000 |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | 13,256,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 13,187,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Center for Breakthrough Medicines Holdings, LLC [Member] | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2023-05 |  |  |  | 2023-05 |  |  |  |
Investment Interest Rate | [11] |  |  | 7.50% |  |  |  | 7.50% |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 5.50% |  |  |  | 5.50% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 8.75% |  |  |  | 8.75% |  |  |  |
Interest Rate and Floor | [11] |  |  | 7.50% |  |  |  | 7.50% |  |  |  |
Principal Amount |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |
Investment cost | [4] |  |  | 5,005,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 5,005,000 |  |  |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Floor Rate | enGene, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.25% |  |  |  | 8.25% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Chemocentryx, Inc. | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 6.25% |  |  |  | 6.25% |  |  |  |  |  |
Interest Rate and Floor | [7] | 6.25% |  |  |  | 6.25% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Chemocentryx, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 7.15% |  |  |  | 7.15% |  |  |  |  |  |
Interest Rate and Floor | [7] | 7.15% |  |  |  | 7.15% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Nabriva Therapeutics | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 9.95% |  |  |  | 9.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 9.95% |  |  |  | 9.95% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Akero Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.85% |  |  |  | 5.85% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.85% |  |  |  | 5.85% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Alladapt Immunotherapeutics Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.30% |  |  |  | 5.30% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.30% |  |  |  | 5.30% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Aldeyra Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 6.95% |  |  |  | 6.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 6.95% |  |  |  | 6.95% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Applied Genetic Technologies Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate |  | 6.95% | [7] | 6.95% | [11] | 6.95% | [7] | 6.95% | [11] |  |  |
Interest Rate and Floor |  | 6.95% | [7] | 6.95% | [11] | 6.95% | [7] | 6.95% | [11] |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | ATAI Life Sciences N.V. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 6.95% |  |  |  | 6.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 6.95% |  |  |  | 6.95% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Aveo Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate |  | 6.95% | [7] | 6.95% | [11] | 6.95% | [7] | 6.95% | [11] |  |  |
Interest Rate and Floor |  | 6.95% | [7] | 6.95% | [11] | 6.95% | [7] | 6.95% | [11] |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Axsome Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.31% |  |  |  | 5.31% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.31% |  |  |  | 5.31% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Bicycle Therapeutics PLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.00% |  |  |  | 5.00% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.00% |  |  |  | 5.00% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | BiomX, INC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate |  | 6.55% | [7] | 6.55% | [11],[27],[28] | 6.55% | [7] | 6.55% | [11],[27],[28] |  |  |
Interest Rate and Floor |  | 6.55% | [7] | 6.55% | [11],[27],[28] | 6.55% | [7] | 6.55% | [11],[27],[28] |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | BridgeBio Pharma, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 2.00% |  |  |  | 2.00% |  |  |  |  |  |
Interest Rate and Floor | [7] | 2.00% |  |  |  | 2.00% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Cellarity, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.75% |  |  |  | 3.75% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.75% |  |  |  | 3.75% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Century Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Codiak Biosciences, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.50% |  |  |  | 5.50% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.50% |  |  |  | 5.50% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Corium, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 7.75% |  |  |  | 7.75% |  |  |  |  |  |
Interest Rate and Floor | [7] | 7.75% |  |  |  | 7.75% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Eloxx Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate |  | 6.55% | [7] | 6.55% | [11] | 6.55% | [7] | 6.55% | [11] |  |  |
Interest Rate and Floor |  | 6.55% | [7] | 6.55% | [11] | 6.55% | [7] | 6.55% | [11] |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | enGene, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 6.35% |  |  |  | 6.35% |  |  |  |  |  |
Interest Rate and Floor | [7] | 6.35% |  |  |  | 6.35% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Finch Therapeutics Group, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.50% |  |  |  | 5.50% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.50% |  |  |  | 5.50% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | G1 Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 9.86% |  |  |  | 9.86% |  |  |  |  |  |
Interest Rate and Floor | [7] | 9.86% |  |  |  | 9.86% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Geron Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 6.55% |  |  |  | 6.55% |  |  |  |  |  |
Interest Rate and Floor | [7] | 6.55% |  |  |  | 6.55% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Gritstone Bio, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.75% |  |  |  | 5.75% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.75% |  |  |  | 5.75% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Hibercell, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.95% |  |  |  | 4.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.95% |  |  |  | 4.95% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | HilleVax, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 7.15% |  |  |  | 7.15% |  |  |  |  |  |
Interest Rate and Floor | [7] | 7.15% |  |  |  | 7.15% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Iveric Bio Gene Therapy LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.25% |  |  |  | 4.25% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.25% |  |  |  | 4.25% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Locus Biosciences, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.95% |  |  |  | 4.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.95% |  |  |  | 4.95% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Madrigal Pharmaceutical, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.35% |  |  |  | 5.35% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.35% |  |  |  | 5.35% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Phathom Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 7.50% |  |  |  | 7.50% |  |  |  |  |  |
Interest Rate and Floor | [7] | 7.50% |  |  |  | 7.50% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Provention Bio, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 6.60% |  |  |  | 6.60% |  |  |  |  |  |
Interest Rate and Floor | [7] | 6.60% |  |  |  | 6.60% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Redshift Bioanalytics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.80% |  |  |  | 3.80% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.80% |  |  |  | 3.80% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Scynexis, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Seres Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.98% |  |  |  | 4.98% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.98% |  |  |  | 4.98% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Tarsus Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.75% |  |  |  | 4.75% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.75% |  |  |  | 4.75% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | TG Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.95% |  |  |  | 5.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.95% |  |  |  | 5.95% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Uni Qure B V | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 7.28% |  |  |  | 7.28% |  |  |  |  |  |
Interest Rate and Floor | [7] | 7.28% |  |  |  | 7.28% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Unity Biotechnology Inc | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 6.25% |  |  |  | 6.25% |  |  |  |  |  |
Interest Rate and Floor | [7] | 6.25% |  |  |  | 6.25% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Valo Health L L C | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.85% |  |  |  | 3.85% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.85% |  |  |  | 3.85% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | Viridian Therapeutics Inc | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.76% |  |  |  | 4.76% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.76% |  |  |  | 4.76% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Exit Fee | X Four Pharmaceuticals Inc | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 8.80% |  |  |  | 8.80% |  |  |  |  |  |
Interest Rate and Floor | [7] | 8.80% |  |  |  | 8.80% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Cap Rate | Alladapt Immunotherapeutics Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 10.90% |  |  |  | 10.90% |  |  |  |  |  |
Interest Rate and Floor | [7] | 10.90% |  |  |  | 10.90% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Cap Rate | Aveo Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 15.00% |  |  |  | 15.00% |  |  |  |  |  |
Interest Rate and Floor | [7] | 15.00% |  |  |  | 15.00% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Cap Rate | Axsome Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 10.70% |  |  |  | 10.70% |  |  |  |  |  |
Interest Rate and Floor | [7] | 10.70% |  |  |  | 10.70% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Cap Rate | Bicycle Therapeutics PLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 9.05% |  |  |  | 9.05% |  |  |  |  |  |
Interest Rate and Floor | [7] | 9.05% |  |  |  | 9.05% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Cap Rate | Finch Therapeutics Group, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 8.80% |  |  |  | 8.80% |  |  |  |  |  |
Interest Rate and Floor | [7] | 8.80% |  |  |  | 8.80% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Cap Rate | Gritstone Bio, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 8.65% |  |  |  | 8.65% |  |  |  |  |  |
Interest Rate and Floor | [7] | 8.65% |  |  |  | 8.65% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Cap Rate | HilleVax, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 6.05% |  |  |  | 6.05% |  |  |  |  |  |
Interest Rate and Floor | [7] | 6.05% |  |  |  | 6.05% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Cap Rate | Iveric Bio Gene Therapy LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 10.25% |  |  |  | 10.25% |  |  |  |  |  |
Interest Rate and Floor | [7] | 10.25% |  |  |  | 10.25% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured | Cap Rate | Viridian Therapeutics Inc | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 8.95% |  |  |  | 8.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 8.95% |  |  |  | 8.95% |  |  |  |  |  |
Drug Discovery & Development | Senior Secured Tranche A [Member] | TG Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [11],[27] |  |  | 3.45% |  |  |  | 3.45% |  |  |  |
Drug Discovery & Development | Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,056,335,000 | [1] | $ 936,457,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 1,052,244,000 |  | 935,964,000 |  |  |  |  |  |  |  |
Drug Delivery |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 90,000 |  | 368,000 |  |  |  |  |  |  |  |
Drug Delivery | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 3,638,000 | [1] | 3,638,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | 305,000 |  |  |  |  |  |  |  |
Drug Delivery | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 465,000 | [1] | 465,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 0 |  | 63,000 |  |  |  |  |  |  |  |
Drug Delivery | AcelRx Pharmaceuticals, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 1,329,000 | [1],[5] | 1,329,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 37,000 | [5] | $ 99,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 10, 2018 | [5] | Dec. 10, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 176,730 | [5] | 176,730 | [6] | 176,730 | [5] | 176,730 | [6] |  |  |
Drug Delivery | Aytu BioScience, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,500,000 | [1],[5] | $ 1,500,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 3,000 | [5] | $ 18,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 28, 2014 | [5] | Mar. 28, 2014 | [6] |  |  |  |  |  |  |
Shares | shares |  | 13,600 | [5] | 13,600 | [6] | 13,600 | [5] | 13,600 | [6] |  |  |
Drug Delivery | BioQ Pharma Incorporated | Equity | Preferred Series D |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 500,000 | [1] | $ 500,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 43,000 |  | $ 168,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 08, 2015 | [5] | Dec. 08, 2015 | [6] |  |  |  |  |  |  |
Shares | shares |  | 165,000 |  | 165,000 |  | 165,000 |  | 165,000 |  |  |  |
Drug Delivery | BioQ Pharma Incorporated | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,000 | [1] | $ 1,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 62,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 27, 2014 | [5] | Oct. 27, 2014 | [6] |  |  |  |  |  |  |
Shares | shares |  | 459,183 |  | 459,183 |  | 459,183 |  | 459,183 |  |  |  |
Drug Delivery | PDS Biotechnology Corporation | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5] | $ 309,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5] | $ 7,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Apr. 06, 2015 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5] | 2,498 |  |  |  | 2,498 |  |  |  |  |  |
Drug Delivery | PDS Biotechnology Corporation | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 390,000 | [1],[5] | $ 390,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 | [5] | $ 1,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 28, 2014 | [5] | Aug. 28, 2014 | [6] |  |  |  |  |  |  |
Shares | shares |  | 3,929 | [5] | 3,929 | [6] | 3,929 | [5] | 3,929 | [6] |  |  |
Drug Delivery | Aerami Therapeutics Holdings, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 74,000 | [1] | $ 74,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 30, 2015 | [5] | Sep. 30, 2015 | [6] |  |  |  |  |  |  |
Shares | shares |  | 110,882 |  | 110,882 |  | 110,882 |  | 110,882 |  |  |  |
Drug Delivery | PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[6] |  |  | $ 309,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [6] |  |  | $ 20,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Apr. 06, 2015 |  |  |  |  |  |  |  |
Shares | shares | [6] |  |  | 2,498 |  |  |  | 2,498 |  |  |  |
Healthcare Services Other |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 203,599,000 |  | $ 121,003,000 |  |  |  |  |  |  |  |
Healthcare Services Other | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 6,782,000 | [1] | 6,781,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 3,198,000 |  | 7,364,000 |  |  |  |  |  |  |  |
Healthcare Services Other | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 697,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 521,000 |  |  |  |  |  |  |  |  |  |
Healthcare Services Other | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 156,619,000 | [1] | 113,724,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 155,925,000 |  | 113,639,000 |  |  |  |  |  |  |  |
Healthcare Services Other | Greater than 5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 43,955,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 43,955,000 |  |  |  |  |  |  |  |  |  |
Healthcare Services Other | Carbon Health Technologies, Inc. | Equity | Preferred Series C |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 1,688,000 | [1] | 1,687,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 836,000 |  | $ 1,864,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 30, 2021 | [5] | Mar. 30, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 217,880 |  | 217,880 |  | 217,880 |  | 217,880 |  |  |  |
Healthcare Services Other | Elation Health, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 583,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 501,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Sep. 12, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 362,837 |  |  |  | 362,837 |  |  |  |  |  |
Healthcare Services Other | 23andMe, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 5,094,000 | [1],[5] | $ 5,094,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,362,000 | [5] | $ 5,500,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 11, 2019 | [5] | Mar. 11, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 825,732 | [5] | 825,732 | [6] | 825,732 | [5] | 825,732 | [6] |  |  |
Healthcare Services Other | Vida Health, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 114,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 20,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Mar. 28, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 100,618 |  |  |  | 100,618 |  |  |  |  |  |
Healthcare Services Other | Senior Secured | Better Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-08 |  | 2025-08 |  | 2025-08 |  | 2025-08 |  |  |  |
Investment Interest Rate |  |  |  | 5.95% |  |  |  | 5.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.70% | [7] | 5.70% |  | 5.70% | [7] | 5.70% |  |  |  |
Investment, Interest Rate, Floor |  | 8.95% | [7] | 8.95% |  | 8.95% | [7] | 8.95% |  |  |  |
Interest Rate and Floor |  |  |  | 5.95% |  |  |  | 5.95% |  |  |  |
Principal Amount |  | $ 12,000,000 | [31] | $ 8,000,000 | [15],[32] |  |  |  |  |  |  |
Investment cost |  | 12,093,000 | [1],[31] | 7,966,000 | [2],[15],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 11,996,000 | [31] | $ 7,966,000 | [15],[32] |  |  |  |  |  |  |
Healthcare Services Other | Senior Secured | Blue Sprig Pediatrics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-11 |  | 2026-11 |  | 2026-11 |  | 2026-11 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.00% | [7] | 5.00% |  | 5.00% | [7] | 5.00% |  |  |  |
Investment, Interest Rate, Floor |  | 6.00% | [7] | 6.00% |  | 6.00% | [7] | 6.00% |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 4.45% |  |  |  | 4.45% |  |  |  |  |  |
Principal Amount |  | $ 40,949,000 | [9],[10],[12],[17] | $ 25,022,000 | [15],[20] |  |  |  |  |  |  |
Investment cost |  | 40,403,000 | [1],[9],[10],[12],[17] | 24,653,000 | [2],[15],[20] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 39,332,000 | [9],[10],[12],[17] | $ 24,653,000 | [15],[20] |  |  |  |  |  |  |
Healthcare Services Other | Senior Secured | Carbon Health Technologies, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-03 |  | 2025-03 |  | 2025-03 |  | 2025-03 |  |  |  |
Investment Interest Rate |  |  |  | 4.61% |  |  |  | 4.61% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.60% | [7] | 5.60% |  | 5.60% | [7] | 5.60% |  |  |  |
Investment, Interest Rate, Floor |  | 8.85% | [7] | 8.85% |  | 8.85% | [7] | 8.85% |  |  |  |
Interest Rate and Floor |  |  |  | 4.61% |  |  |  | 4.61% |  |  |  |
Principal Amount |  | $ 46,125,000 | [8],[10],[12],[17],[18] | $ 46,125,000 | [15],[23] |  |  |  |  |  |  |
Investment cost |  | 46,399,000 | [1],[8],[10],[12],[17],[18] | 45,964,000 | [2],[15],[23] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 46,158,000 | [8],[10],[12],[17],[18] | $ 45,964,000 | [15],[23] |  |  |  |  |  |  |
Healthcare Services Other | Senior Secured | Equality Health, LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-02 |  | 2026-02 |  | 2026-02 |  | 2026-02 |  |  |  |
Investment Interest Rate |  |  |  | 1.55% |  |  |  | 1.55% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 6.25% | [7] | 6.25% |  | 6.25% | [7] | 6.25% |  |  |  |
Investment, Interest Rate, Floor |  | 9.50% | [7] | 9.50% |  | 9.50% | [7] | 9.50% |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 1.55% |  |  |  | 1.55% |  |  |  |  |  |
Interest Rate and Floor |  |  |  | 1.55% |  |  |  | 1.55% |  |  |  |
Principal Amount |  | $ 53,388,000 | [9],[18] | $ 35,444,000 | [15],[20],[33] |  |  |  |  |  |  |
Investment cost |  | 52,928,000 | [1],[9],[18] | 35,141,000 | [2],[15],[20],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 53,644,000 | [9],[18] | 35,056,000 | [15],[20],[33] |  |  |  |  |  |  |
Healthcare Services Other | Senior Secured | Elation Health, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-03 |  |  |  | 2026-03 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.25% |  |  |  | 4.25% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 9.00% |  |  |  | 9.00% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 1.95% |  |  |  | 1.95% |  |  |  |  |  |
Principal Amount | [8],[10] | $ 5,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[8],[10] | 4,796,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [8],[10] | $ 4,795,000 |  |  |  |  |  |  |  |  |  |
Healthcare Services Other | Senior Secured | Oak Street Health, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 2.45% |  |  |  | 2.45% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 7.95% |  |  |  | 7.95% |  |  |  |  |  |
Principal Amount | [10],[29] | $ 44,250,000 |  |  |  |  |  |  |  |  |  |
Healthcare Services Other | Senior Secured | Oak Street Health, Inc. | Greater than 5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-10 |  |  |  | 2027-10 |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 1.00% |  |  |  | 1.00% |  |  |  |  |  |
Investment cost | [1],[10],[29] | $ 43,955,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[29] | $ 43,955,000 |  |  |  |  |  |  |  |  |  |
Healthcare Services Other | Senior Secured | Exit Fee | Better Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.95% |  |  |  | 5.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.95% |  |  |  | 5.95% |  |  |  |  |  |
Healthcare Services Other | Senior Secured | Exit Fee | Carbon Health Technologies, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.61% |  |  |  | 4.61% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.61% |  |  |  | 4.61% |  |  |  |  |  |
Healthcare Services Other | Senior Secured | Exit Fee | Elation Health, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Healthcare Services Other | Senior Secured | Cap Rate | Oak Street Health, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 9.45% |  |  |  | 9.45% |  |  |  |  |  |
Interest Rate and Floor | [7] | 9.45% |  |  |  | 9.45% |  |  |  |  |  |
Healthcare Services Other | Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 200,574,000 | [1] | 113,724,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 199,880,000 |  | 113,639,000 |  |  |  |  |  |  |  |
Information Services |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 59,735,000 |  | 74,417,000 |  |  |  |  |  |  |  |
Information Services | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 4,440,000 | [1] | 4,440,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 7,579,000 |  | 9,414,000 |  |  |  |  |  |  |  |
Information Services | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 680,000 | [1] | 645,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 416,000 |  | 557,000 |  |  |  |  |  |  |  |
Information Services | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 52,386,000 | [1] | 64,773,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 51,740,000 |  | 64,446,000 |  |  |  |  |  |  |  |
Information Services | Capella Space Corp. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 207,000 | [1],[31] | 207,000 | [2],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 50,000 | [31] | $ 139,000 | [32] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 21, 2021 | [5] | Oct. 21, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 176,200 | [31] | 176,200 | [32] | 176,200 | [31] | 176,200 | [32] |  |  |
Information Services | Signal Media Limited | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[29],[30] | $ 35,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [29],[30] | $ 21,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jun. 29, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [29],[30] | 94,857 |  |  |  | 94,857 |  |  |  |  |  |
Information Services | Yipit, LLC | Equity | Preferred Series E |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 3,825,000 | [1] | $ 3,825,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,648,000 |  | $ 3,825,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 30, 2021 | [5] | Dec. 30, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 41,021 |  | 41,021 |  | 41,021 |  | 41,021 |  |  |  |
Information Services | Planet Labs, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 615,000 | [1],[5] | $ 615,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,975,000 | [5] | $ 3,369,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 21, 2019 | [5] | Jun. 21, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 547,880 | [5] | 547,880 |  | 547,880 | [5] | 547,880 |  |  |  |
Information Services | Zeta Global Corp. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 0 | [1],[5] | $ 0 | [2],[6],[34] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,956,000 | [5] | $ 2,220,000 | [6],[34] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 20, 2007 | [5] | Nov. 20, 2007 | [6] |  |  |  |  |  |  |
Shares | shares |  | 295,861 | [5] | 295,861 | [6],[34] | 295,861 | [5] | 295,861 | [6],[34] |  |  |
Information Services | I N M O B I Inc | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 82,000 | [1],[29],[30] | $ 82,000 | [2],[27] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 | [29],[30] | $ 0 | [27] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 19, 2014 | [5] | Nov. 19, 2014 | [6],[27] |  |  |  |  |  |  |
Shares | shares |  | 65,587 | [29],[30] | 65,587 | [27] | 65,587 | [29],[30] | 65,587 | [27] |  |  |
Information Services | NetBase Solutions, Inc. | Warrant Investment | Preferred Series 1 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 356,000 | [1] | $ 356,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 345,000 |  | $ 418,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 22, 2017 | [5] | Aug. 22, 2017 | [6] |  |  |  |  |  |  |
Shares | shares |  | 60,000 |  | 60,000 |  | 60,000 |  | 60,000 |  |  |  |
Information Services | Senior Secured | Capella Space Corp. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-11 |  | 2024-11 |  | 2024-11 |  | 2024-11 |  |  |  |
Investment Interest Rate |  |  |  | 4.00% |  |  |  | 4.00% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.00% | [7] | 5.00% |  | 5.00% | [7] | 5.00% |  |  |  |
Investment, Interest Rate, Floor |  | 8.25% | [7] | 8.25% |  | 8.25% | [7] | 8.25% |  |  |  |
Investment, Interest Rate, Paid in Kind |  | 1.10% | [7] | 1.10% |  | 1.10% | [7] | 1.10% |  |  |  |
Interest Rate and Floor |  |  |  | 4.00% |  |  |  | 4.00% |  |  |  |
Principal Amount |  | $ 20,193,000 | [8],[9],[31] | $ 20,025,000 | [20],[23],[32] |  |  |  |  |  |  |
Investment cost |  | 20,302,000 | [1],[8],[9],[31] | 19,751,000 | [2],[20],[23],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 20,219,000 | [8],[9],[31] | $ 19,424,000 | [20],[23],[32] |  |  |  |  |  |  |
Information Services | Senior Secured | Signal Media Limited | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-06 |  |  |  | 2025-06 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 5.50% |  |  |  | 5.50% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 9.00% |  |  |  | 9.00% |  |  |  |  |  |
Principal Amount | [10],[29],[30] | $ 750,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[29],[30] | 739,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[29],[30] | $ 739,000 |  |  |  |  |  |  |  |  |  |
Information Services | Senior Secured | Yipit, LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-09 |  | 2026-09 |  | 2026-09 |  | 2026-09 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 9.08% | [7] | 9.08% |  | 9.08% | [7] | 9.08% |  |  |  |
Investment, Interest Rate, Floor |  | 10.08% | [7] | 10.08% |  | 10.08% | [7] | 10.08% |  |  |  |
Principal Amount |  | $ 31,875,000 | [10],[13] | $ 45,900,000 | [15],[16] |  |  |  |  |  |  |
Investment cost |  | 31,345,000 | [1],[10],[13] | 45,022,000 | [2],[15],[16] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 30,782,000 | [10],[13] | 45,022,000 | [15],[16] |  |  |  |  |  |  |
Information Services | Senior Secured | Exit Fee | Capella Space Corp. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 7.00% |  |  |  | 7.00% |  |  |  |  |  |
Interest Rate and Floor | [7] | 7.00% |  |  |  | 7.00% |  |  |  |  |  |
Information Services | Senior Secured | Exit Fee | Signal Media Limited | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.45% |  |  |  | 3.45% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.45% |  |  |  | 3.45% |  |  |  |  |  |
Information Services | Senior Secured | Cap Rate | Signal Media Limited | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 12.00% |  |  |  | 12.00% |  |  |  |  |  |
Interest Rate and Floor | [7] | 12.00% |  |  |  | 12.00% |  |  |  |  |  |
Information Services | Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 52,386,000 | [1] | 64,773,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 51,740,000 |  | 64,446,000 |  |  |  |  |  |  |  |
Internet Consumer And Business Services |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 489,968,000 |  | 395,506,000 |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 22,058,000 | [1] | 22,151,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 15,377,000 |  | 35,331,000 |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 6,110,000 | [1] | 4,992,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 5,800,000 |  | 10,212,000 |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 82,481,000 | [1] | 22,164,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 82,481,000 |  | 22,164,000 |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 384,097,000 | [1] | 341,001,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 365,957,000 |  | 327,799,000 |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Greater than 5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 21,252,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 20,354,000 |  |  |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Fulfil Solutions Inc [Member] | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 325,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 199,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jul. 29, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 84,995 |  |  |  | 84,995 |  |  |  |  |  |
Internet Consumer And Business Services | SeatGeek, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 842,000 | [1],[19] | 842,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,692,000 | [19] | $ 1,140,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 12, 2019 | [5] | Jun. 12, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,379,761 | [19] | 1,379,761 |  | 1,379,761 | [19] | 1,379,761 |  |  |  |
Internet Consumer And Business Services | Carwow LTD | Equity | Preferred Series D-4 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,151,000 | [1],[29],[30] | $ 1,151,000 | [2],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 216,000 | [29],[30] | $ 608,000 | [27],[28] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 15, 2021 | [5] | Dec. 15, 2021 | [6],[27],[28] |  |  |  |  |  |  |
Shares | shares |  | 199,742 | [29],[30] | 199,742 | [27],[28] | 199,742 | [29],[30] | 199,742 | [27],[28] |  |  |
Internet Consumer And Business Services | Carwow LTD | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 164,000 | [1],[29],[30] | $ 164,000 | [2],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 33,000 | [29],[30] | $ 160,000 | [27],[28] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 14, 2021 | [5] | Dec. 14, 2021 | [6],[27],[28] |  |  |  |  |  |  |
Shares | shares |  | 174,163 | [29],[30] | 174,163 | [27],[28] | 174,163 | [29],[30] | 174,163 | [27],[28] |  |  |
Internet Consumer And Business Services | Convoy, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[19] | $ 974,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [19] | $ 582,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Mar. 30, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [19] | 165,456 |  |  |  | 165,456 |  |  |  |  |  |
Internet Consumer And Business Services | Rhino Labs Incorporation | Equity | Preferred Series B-2 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 1,000,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 866,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jan. 24, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 7,063 |  |  |  | 7,063 |  |  |  |  |  |
Internet Consumer And Business Services | Rhino Labs Incorporation | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 470,000 | [1],[31] | $ 470,000 | [2],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 344,000 | [31] | $ 77,000 | [32] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 12, 2021 | [5] | Mar. 12, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 13,106 | [31] | 13,106 | [32] | 13,106 | [31] | 13,106 | [32] |  |  |
Internet Consumer And Business Services | Skyword, Inc. | Warrant Investment | Preferred Series B |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 83,000 | [1] | $ 83,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,000 |  | $ 7,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 23, 2019 | [5] | Aug. 23, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 444,444 |  | 444,444 |  | 444,444 |  | 444,444 |  |  |  |
Internet Consumer And Business Services | Tectura Corporation | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 900,000 | [1] | $ 900,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Shares | shares |  | 415,994,863 |  | 415,994,863 |  | 415,994,863 |  | 415,994,863 |  |  |  |
Internet Consumer And Business Services | Tectura Corporation | Equity | Preferred Series BB |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 0 | [1],[24] | $ 0 | [2],[25] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 | [24] | $ 0 | [25] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 06, 2016 | [5] | Jun. 06, 2016 | [6],[25] |  |  |  |  |  |  |
Shares | shares |  | 1,000,000 | [24] | 1,000,000 | [25] | 1,000,000 | [24] | 1,000,000 | [25] |  |  |
Internet Consumer And Business Services | Tectura Corporation | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 900,000 | [1],[24] | $ 900,000 | [2],[25] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 | [24] | $ 0 | [25] |  |  |  |  |  |  |
Investment, Acquisition Date |  | May 23, 2018 | [5] | May 23, 2018 | [6],[25] |  |  |  |  |  |  |
Shares | shares |  | 414,994,863 | [24] | 414,994,863 | [25] | 414,994,863 | [24] | 414,994,863 | [25] |  |  |
Internet Consumer And Business Services | Tectura Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Principal Amount |  | $ 31,953,000 |  | $ 31,953,000 |  |  |  |  |  |  |  |
Investment cost |  | 21,513,000 | [1] | 21,513,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 8,318,000 |  | 8,269,000 |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Thumbtack, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 844,000 | [1] | 552,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 459,000 |  | $ 786,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | May 01, 2018 | [5] | May 01, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 267,225 |  | 190,953 |  | 267,225 |  | 190,953 |  |  |  |
Internet Consumer And Business Services | Veem, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 126,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 48,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Mar. 31, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 98,428 |  |  |  | 98,428 |  |  |  |  |  |
Internet Consumer And Business Services | Veem, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Principal Amount |  | $ 10,041,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 10,022,000 |  |  |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Worldremit Group Limited | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 155,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 405,000 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 79,083 |  |  |  | 79,083 |  |  |  |  |  |
Internet Consumer And Business Services | Worldremit Group Limited | Warrant Investment | Preferred Series D |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[19],[29],[30] | $ 129,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [19],[29],[30] | $ 399,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Feb. 11, 2021 |  |  |  |  |  |  |  |  |  |
Shares | shares | [19],[29],[30] | 77,215 |  |  |  | 77,215 |  |  |  |  |  |
Internet Consumer And Business Services | Worldremit Group Limited | Warrant Investment | Preferred Series E |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[19],[29],[30] | $ 26,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [19],[29],[30] | $ 6,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Aug. 27, 2021 |  |  |  |  |  |  |  |  |  |
Shares | shares | [19],[29],[30] | 1,868 |  |  |  | 1,868 |  |  |  |  |  |
Internet Consumer And Business Services | Houzz, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 20,000 | [1] | $ 20,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,000 |  | $ 116,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 29, 2019 | [5] | Oct. 29, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 529,661 |  | 529,661 |  | 529,661 |  | 529,661 |  |  |  |
Internet Consumer And Business Services | Black Crow AI, Inc. affiliates | Equity | Preferred Series Seed |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[35] |  |  | $ 1,000,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [35] |  |  | $ 1,120,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6],[35] |  |  | Mar. 24, 2021 |  |  |  |  |  |  |  |
Shares | shares | [35] |  |  | 872,797 |  |  |  | 872,797 |  |  |  |
Internet Consumer And Business Services | Black Crow AI, Inc. affiliates | Equity | Preferred Note |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 3,000,000 | [1],[36] | $ 3,000,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 3,000,000 | [36] | $ 3,000,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 24, 2021 | [5] | Mar. 24, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 3 | [36] | 3 |  | 3 | [36] | 3 |  |  |  |
Internet Consumer And Business Services | Contentful Global, Inc. | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 638,000 | [1] | $ 638,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 924,000 |  | $ 1,894,000 |  |  |  |  |  |  |  |
Shares | shares |  | 149,500 |  | 149,500 |  | 149,500 |  | 149,500 |  |  |  |
Internet Consumer And Business Services | Contentful Global, Inc. | Equity | Preferred Series D |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 500,000 | [1],[29],[30] | $ 500,000 | [2],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 685,000 | [29],[30] | $ 1,388,000 | [27],[28] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 20, 2018 | [5] | Nov. 20, 2018 | [6],[27],[28] |  |  |  |  |  |  |
Shares | shares |  | 108,500 | [29],[30] | 108,500 | [27],[28] | 108,500 | [29],[30] | 108,500 | [27],[28] |  |  |
Internet Consumer And Business Services | Contentful Global, Inc. | Equity | Preferred Series C |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 138,000 | [1],[29],[30] | $ 138,000 | [2],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 239,000 | [29],[30] | $ 506,000 | [27],[28] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 22, 2020 | [5] | Dec. 22, 2020 | [6],[27],[28] |  |  |  |  |  |  |
Shares | shares |  | 41,000 | [29],[30] | 41,000 | [27],[28] | 41,000 | [29],[30] | 41,000 | [27],[28] |  |  |
Internet Consumer And Business Services | DoorDash, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 945,000 | [1],[5] | $ 945,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 4,055,000 | [5] | $ 12,209,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 20, 2018 | [5] | Dec. 20, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 81,996 | [5] | 81,996 | [6] | 81,996 | [5] | 81,996 | [6] |  |  |
Internet Consumer And Business Services | Lyft Inc | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 5,263,000 | [1],[5] | $ 5,263,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,327,000 | [5] | $ 4,305,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 26, 2018 | [5] | Dec. 26, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 100,738 | [5] | 100,738 | [6] | 100,738 | [5] | 100,738 | [6] |  |  |
Internet Consumer And Business Services | Nerdy Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,000,000 | [1],[5],[22] | $ 1,000,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 209,000 | [5],[22] | $ 450,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 17, 2021 | [5] | Sep. 17, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 100,000 | [5],[22] | 100,000 | [6] | 100,000 | [5],[22] | 100,000 | [6] |  |  |
Internet Consumer And Business Services | Nextdoor.com, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 4,854,000 | [1],[5] | $ 4,854,000 | [2],[6],[34] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,844,000 | [5] | $ 6,624,000 | [6],[34] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 01, 2018 | [5] | Aug. 01, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,019,255 | [5] | 1,019,255 | [6],[34] | 1,019,255 | [5] | 1,019,255 | [6],[34] |  |  |
Internet Consumer And Business Services | OfferUp, Inc. | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 2,295,000 | [1] | $ 2,295,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 577,000 |  | $ 2,471,000 |  |  |  |  |  |  |  |
Shares | shares |  | 394,790 |  | 394,790 |  | 394,790 |  | 394,790 |  |  |  |
Internet Consumer And Business Services | OfferUp, Inc. | Equity | Preferred Series A |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,663,000 | [1] | $ 1,663,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 418,000 |  | $ 1,791,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 25, 2016 | [5] | Oct. 25, 2016 | [6] |  |  |  |  |  |  |
Shares | shares |  | 286,080 |  | 286,080 |  | 286,080 |  | 286,080 |  |  |  |
Internet Consumer And Business Services | OfferUp, Inc. | Equity | Preferred Series A-1 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 632,000 | [1] | $ 632,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 159,000 |  | $ 680,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 25, 2016 | [5] | Oct. 25, 2016 | [6] |  |  |  |  |  |  |
Shares | shares |  | 108,710 |  | 108,710 |  | 108,710 |  | 108,710 |  |  |  |
Internet Consumer And Business Services | Oportun | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 577,000 | [1],[5] | $ 577,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 211,000 | [5] | $ 980,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 28, 2013 | [5] | Jun. 28, 2013 | [6] |  |  |  |  |  |  |
Shares | shares |  | 48,365 | [5] | 48,365 | [6] | 48,365 | [5] | 48,365 | [6] |  |  |
Internet Consumer And Business Services | Reischling Press, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 15,000 | [1] | $ 15,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jul. 31, 2020 | [5] | Jul. 31, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,163 |  | 1,163 |  | 1,163 |  | 1,163 |  |  |  |
Internet Consumer And Business Services | Savage X Holding, LLC | Equity | Class A Units |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 13,000 | [1] | $ 13,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 179,000 |  | $ 71,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Apr. 30, 2010 | [5] | Apr. 30, 2010 | [6] |  |  |  |  |  |  |
Shares | shares |  | 42,137 |  | 42,137 |  | 42,137 |  | 42,137 |  |  |  |
Internet Consumer And Business Services | Savage X Holding, LLC | Warrant Investment | Class A Units |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 0 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 875,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jun. 27, 2014 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 206,185 |  |  |  | 206,185 |  |  |  |  |  |
Internet Consumer And Business Services | TFG Holding, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 89,000 | [1] | $ 89,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 95,000 |  | $ 216,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Apr. 30, 2010 | [5] | Apr. 30, 2010 | [6] |  |  |  |  |  |  |
Shares | shares |  | 42,989 |  | 42,989 |  | 42,989 |  | 42,989 |  |  |  |
Internet Consumer And Business Services | TFG Holding, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 0 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 17,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jun. 27, 2014 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 206,185 |  |  |  | 206,185 |  |  |  |  |  |
Internet Consumer And Business Services | Uber Technologies, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 318,000 | [1],[5] | $ 318,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 874,000 | [5] | $ 1,383,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 01, 2020 | [5] | Dec. 01, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 32,991 | [5] | 32,991 | [6] | 32,991 | [5] | 32,991 | [6] |  |  |
Internet Consumer And Business Services | Snagajobcom Inc | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 860,000 | [1] | $ 860,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 258,000 |  | $ 382,000 |  |  |  |  |  |  |  |
Shares | shares |  | 3,611,537 |  | 3,611,537 |  | 3,611,537 |  | 3,611,537 |  |  |  |
Internet Consumer And Business Services | Snagajobcom Inc | Warrant Investment | Preferred Series A |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 782,000 | [1],[18] | $ 782,000 | [2],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 120,000 | [18] | $ 171,000 | [33] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 30, 2016 | [5] | Jun. 30, 2016 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,800,000 | [18] | 1,800,000 | [33] | 1,800,000 | [18] | 1,800,000 | [33] |  |  |
Internet Consumer And Business Services | Snagajobcom Inc | Warrant Investment | Preferred Series B |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 62,000 | [1],[18] | $ 62,000 | [2],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 69,000 | [18] | $ 90,000 | [33] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 01, 2018 | [5] | Aug. 01, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,211,537 | [18] | 1,211,537 | [33] | 1,211,537 | [18] | 1,211,537 | [33] |  |  |
Internet Consumer And Business Services | Snagajobcom Inc | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 16,000 | [1],[18] | $ 16,000 | [2],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 69,000 | [18] | $ 121,000 | [33] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Apr. 20, 2020 | [5] | Apr. 20, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 600,000 | [18] | 600,000 | [33] | 600,000 | [18] | 600,000 | [33] |  |  |
Internet Consumer And Business Services | Aria Systems, Inc. | Warrant Investment | Preferred Series G |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 74,000 | [1] | $ 74,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | May 22, 2015 | [5] | May 22, 2015 | [6] |  |  |  |  |  |  |
Shares | shares |  | 231,535 |  | 231,535 |  | 231,535 |  | 231,535 |  |  |  |
Internet Consumer And Business Services | Cloudpay, Inc. | Warrant Investment | Preferred Series B |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 54,000 | [1],[29],[30] | $ 54,000 | [2],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 310,000 | [29],[30] | $ 348,000 | [27],[28] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Apr. 10, 2018 | [5] | Apr. 10, 2018 | [6],[27],[28] |  |  |  |  |  |  |
Shares | shares |  | 6,763 | [29],[30] | 6,763 | [27],[28] | 6,763 | [29],[30] | 6,763 | [27],[28] |  |  |
Internet Consumer And Business Services | First Insight, Inc. | Warrant Investment | Preferred Series B |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 95,000 | [1] | $ 96,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 35,000 |  | $ 105,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | May 10, 2018 | [5] | May 10, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 75,917 |  | 75,917 |  | 75,917 |  | 75,917 |  |  |  |
Internet Consumer And Business Services | Landing Holdings Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 116,000 | [1],[31] | $ 116,000 | [2],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 117,000 | [31] | $ 141,000 | [32] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 12, 2021 | [5] | Mar. 12, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 11,806 | [31] | 11,806 | [32] | 11,806 | [31] | 11,806 | [32] |  |  |
Internet Consumer And Business Services | Lendio, Inc. | Warrant Investment | Preferred Series D |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 39,000 | [1] | $ 39,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 35,000 |  | $ 84,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 29, 2019 | [5] | Mar. 29, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 127,032 |  | 127,032 |  | 127,032 |  | 127,032 |  |  |  |
Internet Consumer And Business Services | RumbleON, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 88,000 | [1],[5] | $ 88,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,000 | [5] | $ 33,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Apr. 30, 2018 | [5] | Apr. 30, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 5,139 | [5] | 5,139 | [6] | 5,139 | [5] | 5,139 | [6] |  |  |
Internet Consumer And Business Services | ShareThis, Inc. | Warrant Investment | Preferred Series C |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 547,000 | [1] | $ 547,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 14, 2012 | [5] | Dec. 14, 2012 | [6] |  |  |  |  |  |  |
Shares | shares |  | 493,502 |  | 493,502 |  | 493,502 |  | 493,502 |  |  |  |
Internet Consumer And Business Services | The Faction Group LLC | Warrant Investment | Preferred Series AA |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 234,000 | [1],[7] | $ 234,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 387,000 |  | $ 650,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 03, 2014 | [5] | Nov. 03, 2014 | [6] |  |  |  |  |  |  |
Shares | shares |  | 8,076 |  | 8,076 |  | 8,076 |  | 8,076 |  |  |  |
Internet Consumer And Business Services | Xometry, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[6] |  |  | $ 47,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [6] |  |  | $ 3,038,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | May 09, 2018 |  |  |  |  |  |  |  |
Shares | shares | [6] |  |  | 87,784 |  |  |  | 87,784 |  |  |  |
Internet Consumer And Business Services | Interactions Corporation | Warrant Investment | Series G Three Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 204,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 505,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Jun. 16, 2015 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 68,187 |  |  |  | 68,187 |  |  |  |
Internet Consumer And Business Services | Brigade Group, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 93,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Mar. 01, 2013 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 9,023 |  |  |  | 9,023 |  |  |  |
Internet Consumer And Business Services | Logic Source | Warrant Investment | Preferred Series C |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 30,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 210,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Mar. 21, 2016 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 79,625 |  |  |  | 79,625 |  |  |  |
Internet Consumer And Business Services | Tapjoy, Inc. | Warrant Investment | Preferred Series D |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 317,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 443,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Jul. 01, 2014 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 748,670 |  |  |  | 748,670 |  |  |  |
Internet Consumer And Business Services | Zepz (p.k.a. Worldremit Group Limited) | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 155,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 1,987,000 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 79,083 |  |  |  | 79,083 |  |  |  |
Internet Consumer And Business Services | Zepz (p.k.a. Worldremit Group Limited) | Warrant Investment | Preferred Series D |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[21],[27],[28] |  |  | $ 129,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [21],[27],[28] |  |  | $ 1,962,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6],[27],[28] |  |  | Feb. 11, 2021 |  |  |  |  |  |  |  |
Shares | shares | [21],[27],[28] |  |  | 77,215 |  |  |  | 77,215 |  |  |  |
Internet Consumer And Business Services | Zepz (p.k.a. Worldremit Group Limited) | Warrant Investment | Preferred Series E |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[21],[27],[28] |  |  | $ 26,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [21],[27],[28] |  |  | $ 25,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6],[27],[28] |  |  | Aug. 27, 2021 |  |  |  |  |  |  |  |
Shares | shares | [21],[27],[28] |  |  | 1,868 |  |  |  | 1,868 |  |  |  |
Internet Consumer And Business Services | Senior Secured | Salary.com, LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-09 |  |  |  | 2027-09 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 8.00% |  |  |  | 8.00% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 9.00% |  |  |  | 9.00% |  |  |  |  |  |
Investment cost | [1],[13] | $ 17,640,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [13] | $ 17,640,000 |  |  |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | SeatGeek, Inc. | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2023-06 |  |  |  | 2023-06 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 5.00% |  |  |  | 5.00% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 10.50% |  |  |  | 10.50% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 0.50% |  |  |  | 0.50% |  |  |  |  |  |
Principal Amount | [9],[12],[17],[18],[19] | $ 60,838,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[9],[12],[17],[18],[19] | 60,529,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [9],[12],[17],[18],[19] | $ 60,529,000 |  |  |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | SeatGeek, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-05 |  | 2023-06 |  | 2026-05 |  | 2023-06 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 7.00% | [7] | 5.00% | [11] | 7.00% | [7] | 5.00% | [11] |  |  |
Investment, Interest Rate, Floor |  | 10.50% | [7] | 10.50% | [11] | 10.50% | [7] | 10.50% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 0.50% | [7] | 0.50% | [11] | 0.50% | [7] | 0.50% | [11] |  |  |
Principal Amount |  | $ 25,040,000 | [9],[12],[17],[18],[19] | $ 60,607,000 | [20] |  |  |  |  |  |  |
Investment cost |  | 24,869,000 | [1],[9],[12],[17],[18],[19] | 59,983,000 | [2],[20] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 25,591,000 | [9],[12],[17],[18],[19] | $ 60,316,000 | [20] |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | App Direct Incorporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-04 |  | 2024-08 |  | 2026-04 |  | 2024-08 |  |  |  |
Investment Interest Rate | [11] |  |  | 7.95% |  |  |  | 7.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.50% | [7] | 5.90% | [11] | 5.50% | [7] | 5.90% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.75% | [7] | 9.15% | [11] | 8.75% | [7] | 9.15% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 7.95% |  |  |  | 7.95% |  |  |  |
Principal Amount |  | $ 30,790,000 | [10],[18] | $ 30,790,000 |  |  |  |  |  |  |  |
Investment cost |  | 31,733,000 | [1],[10],[18] | 31,416,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 31,991,000 | [10],[18] | $ 32,248,000 |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Carwow LTD | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-12 |  | 2024-12 |  | 2024-12 |  | 2024-12 |  |  |  |
Investment Interest Rate | [11],[27],[28] |  |  | 4.95% |  |  |  | 4.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 4.70% | [7] | 4.70% | [11],[27],[28] | 4.70% | [7] | 4.70% | [11],[27],[28] |  |  |
Investment, Interest Rate, Floor |  | 7.95% | [7] | 7.95% | [11],[27],[28] | 7.95% | [7] | 7.95% | [11],[27],[28] |  |  |
Investment, Interest Rate, Paid in Kind |  | 1.45% | [7] | 1.45% | [11],[27],[28] | 1.45% | [7] | 1.45% | [11],[27],[28] |  |  |
Interest Rate and Floor | [11],[27],[28] |  |  | 4.95% |  |  |  | 4.95% |  |  |  |
Principal Amount |  | $ 21,021,000 | [9],[29],[30] |  |  | £ 18,798 | [9],[29],[30] | £ 21,250 | [20],[27],[28] |  |  |
Investment cost |  | $ 25,845,000 | [1],[9],[29],[30] | $ 28,632,000 | [2],[20],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value | [20],[27],[28] |  |  | $ 28,632,000 |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Convoy, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-03 |  |  |  | 2026-03 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 3.20% |  |  |  | 3.20% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 6.45% |  |  |  | 6.45% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 1.95% |  |  |  | 1.95% |  |  |  |  |  |
Principal Amount | [8],[9],[19] | $ 73,623,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[8],[9],[19] | 72,447,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [8],[9],[19] | $ 73,092,000 |  |  |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Jobandtalent USA, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-02 |  |  |  | 2025-02 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 8.86% |  |  |  | 8.86% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 9.75% |  |  |  | 9.75% |  |  |  |  |  |
Principal Amount | [29],[30] | $ 14,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[29],[30] | 13,802,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [29],[30] | $ 13,865,000 |  |  |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Nextroll, Inc. | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2023-07 |  | 2022-06 |  | 2023-07 |  | 2022-06 |  |  |  |
Investment Interest Rate | [11] |  |  | 3.50% |  |  |  | 3.50% |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 3.75% |  |  |  | 3.75% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 7.00% |  |  |  | 7.00% |  |  |  |
Investment, Interest Rate, Paid in Kind | [11] |  |  | 2.95% |  |  |  | 2.95% |  |  |  |
Interest Rate and Floor | [11] |  |  | 3.50% |  |  |  | 3.50% |  |  |  |
Principal Amount |  | $ 22,046,000 | [9],[18] | $ 21,555,000 | [20],[23],[33] |  |  |  |  |  |  |
Investment cost |  | 21,952,000 | [1],[9],[18] | 22,164,000 | [2],[20],[23],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 21,952,000 | [9],[18] | $ 22,164,000 | [20],[23],[33] |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Nextroll, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 7.75% |  |  |  | 7.75% |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 3.75% |  |  |  | 3.75% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 2.95% |  |  |  | 2.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 7.75% |  |  |  | 7.75% |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Rhino Labs Incorporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-03 |  | 2024-03 |  | 2024-03 |  | 2024-03 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.50% | [7] | 5.50% | [11] | 5.50% | [7] | 5.50% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.75% | [7] | 8.75% | [11] | 8.75% | [7] | 8.75% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 2.25% | [7] | 2.25% | [11] | 2.25% | [7] | 2.25% | [11] |  |  |
Principal Amount |  | $ 16,407,000 | [9],[31] | $ 16,136,000 | [20],[32] |  |  |  |  |  |  |
Investment cost |  | 16,180,000 | [1],[9],[31] | 15,765,000 | [2],[20],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 16,331,000 | [9],[31] | $ 15,876,000 | [20],[32] |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | R V Share Limited Liability Company | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-12 |  | 2026-12 |  | 2026-12 |  | 2026-12 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.50% | [7] | 5.50% | [11] | 5.50% | [7] | 5.50% | [11] |  |  |
Investment, Interest Rate, Floor |  | 6.50% | [7] | 6.50% | [11] | 6.50% | [7] | 6.50% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 4.00% | [7] | 4.00% | [11] | 4.00% | [7] | 4.00% | [11] |  |  |
Principal Amount |  | $ 20,489,000 | [9],[10],[17],[31] | $ 15,000,000 | [15],[32] |  |  |  |  |  |  |
Investment cost |  | 20,138,000 | [1],[9],[10],[17],[31] | 14,701,000 | [2],[15],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 20,130,000 | [9],[10],[17],[31] | $ 14,701,000 | [15],[32] |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Skyword, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-09 |  | 2024-09 |  | 2024-09 |  | 2024-09 |  |  |  |
Investment Interest Rate | [11] |  |  | 4.00% |  |  |  | 4.00% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 3.88% | [7] | 3.88% | [11] | 3.88% | [7] | 3.88% | [11] |  |  |
Investment, Interest Rate, Floor |  | 9.38% | [7] | 9.38% | [11] | 9.38% | [7] | 9.38% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 1.90% | [7] | 1.90% | [11] | 1.90% | [7] | 1.90% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 4.00% |  |  |  | 4.00% |  |  |  |
Principal Amount |  | $ 12,607,000 | [9],[17] | $ 12,426,000 | [20] |  |  |  |  |  |  |
Investment cost |  | 12,922,000 | [1],[9],[17] | 12,665,000 | [2],[20] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 12,708,000 | [9],[17] | $ 12,521,000 | [20] |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Thumbtack, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-04 |  | 2023-09 |  | 2026-04 |  | 2023-09 |  |  |  |
Investment Interest Rate | [11] |  |  | 3.95% |  |  |  | 3.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 4.95% | [7] | 3.45% | [11] | 4.95% | [7] | 3.45% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.95% | [7] | 8.95% | [11] | 8.95% | [7] | 8.95% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 1.50% | [7] | 1.50% | [11] | 1.50% | [7] | 1.50% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 3.95% |  |  |  | 3.95% |  |  |  |
Principal Amount |  | $ 10,065,000 | [9],[10],[18] | $ 25,618,000 | [20],[33] |  |  |  |  |  |  |
Investment cost |  | 9,985,000 | [1],[9],[10],[18] | 25,965,000 | [2],[20],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | 9,938,000 | [9],[10],[18] | $ 26,372,000 | [20],[33] |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Veem, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 9,891,000 |  |  |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Worldremit Group Limited | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-02 |  | 2025-02 |  | 2025-02 |  | 2025-02 |  |  |  |
Investment Interest Rate | [11],[27],[28] |  |  | 3.00% |  |  |  | 3.00% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 9.25% | [7] | 9.25% | [11],[27],[28] | 9.25% | [7] | 9.25% | [11],[27],[28] |  |  |
Investment, Interest Rate, Floor |  | 10.25% | [7] | 10.25% | [11],[27],[28] | 10.25% | [7] | 10.25% | [11],[27],[28] |  |  |
Interest Rate and Floor | [11],[27],[28] |  |  | 3.00% |  |  |  | 3.00% |  |  |  |
Principal Amount |  | $ 94,500,000 | [8],[12],[18],[19],[29],[30] | $ 103,000,000 | [21],[23],[27],[28],[33] |  |  |  |  |  |  |
Investment cost |  | 94,115,000 | [1],[8],[12],[18],[19],[29],[30] | 101,674,000 | [2],[21],[23],[27],[28],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 92,293,000 | [8],[12],[18],[19],[29],[30] | $ 100,472,000 | [21],[23],[27],[28],[33] |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | E Pay Policy Holdings L L C | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2024-12 |  |  |  | 2024-12 |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 8.50% |  |  |  | 8.50% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 9.50% |  |  |  | 9.50% |  |  |  |
Principal Amount | [14],[15] |  |  | $ 8,169,000 |  |  |  |  |  |  |  |
Investment cost | [2],[14],[15] |  |  | 8,011,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [14],[15] |  |  | $ 7,967,000 |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Logic Source | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-07 |  |  |  | 2027-07 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 8.93% |  |  |  | 8.93% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 9.93% |  |  |  | 9.93% |  |  |  |  |  |
Principal Amount | [10] | $ 13,300,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10] | 13,017,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10] | $ 13,017,000 |  |  |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Exit Fee | App Direct Incorporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 9.70% |  |  |  | 9.70% |  |  |  |  |  |
Interest Rate and Floor | [7] | 9.70% |  |  |  | 9.70% |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Exit Fee | Carwow LTD | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.95% |  |  |  | 4.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.95% |  |  |  | 4.95% |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Exit Fee | Convoy, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.55% |  |  |  | 4.55% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.55% |  |  |  | 4.55% |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Exit Fee | Jobandtalent USA, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.00% |  |  |  | 3.00% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.00% |  |  |  | 3.00% |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Exit Fee | Nextroll, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 1.95% |  |  |  | 1.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 1.95% |  |  |  | 1.95% |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Exit Fee | Skyword, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.00% |  |  |  | 4.00% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.00% |  |  |  | 4.00% |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Exit Fee | Thumbtack, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured | Exit Fee | Worldremit Group Limited | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.00% |  |  |  | 3.00% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.00% |  |  |  | 3.00% |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured Tranche A [Member] | Tectura Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-07 |  | 2024-07 |  | 2024-07 |  | 2024-07 |  |  |  |
Investment, Interest Rate, Paid in Kind |  | 5.00% | [7] | 5.00% | [11],[25],[37] | 5.00% | [7] | 5.00% | [11],[25],[37] |  |  |
Principal Amount |  | $ 10,680,000 | [9],[24],[38] | $ 10,680,000 | [20],[25],[37] |  |  |  |  |  |  |
Investment cost |  | 240,000 | [1],[9],[24],[38] | 240,000 | [2],[20],[25],[37] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 | [9],[24],[38] | $ 0 | [20],[25],[37] |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured Tranche A [Member] | Veem, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-03 |  |  |  | 2025-03 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.00% |  |  |  | 4.00% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 7.25% |  |  |  | 7.25% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 1.25% |  |  |  | 1.25% |  |  |  |  |  |
Principal Amount | [9],[17] | $ 5,027,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[9],[17] | 4,959,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [9],[17] | $ 4,967,000 |  |  |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured Tranche A [Member] | Exit Fee | Veem, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured Tranche B [Member] | Tectura Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-07 |  | 2024-07 |  | 2024-07 |  | 2024-07 |  |  |  |
Investment, Interest Rate, Paid in Cash |  | 8.25% | [7] | 8.25% | [11],[25],[37] | 8.25% | [7] | 8.25% | [11],[25],[37] |  |  |
Principal Amount |  | $ 8,250,000 | [24] | $ 8,250,000 | [25],[37] |  |  |  |  |  |  |
Investment cost |  | 8,250,000 | [1],[24] | 8,250,000 | [2],[25],[37] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 8,250,000 | [24] | $ 8,250,000 | [25],[37] |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured Tranche B [Member] | Veem, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-03 |  |  |  | 2025-03 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.70% |  |  |  | 4.70% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 7.95% |  |  |  | 7.95% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 1.50% |  |  |  | 1.50% |  |  |  |  |  |
Principal Amount |  | $ 5,014,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 4,932,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 5,055,000 |  |  |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured Tranche B [Member] | Exit Fee | Veem, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Internet Consumer And Business Services | Senior Secured Tranche C [Member] | Tectura Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-07 |  | 2024-07 |  | 2024-07 |  | 2024-07 |  |  |  |
Investment, Interest Rate, Paid in Kind |  | 5.00% | [7] | 5.00% | [11],[25],[37] | 5.00% | [7] | 5.00% | [11],[25],[37] |  |  |
Principal Amount |  | $ 13,023,000 | [9],[24],[38] | $ 13,023,000 | [20],[25],[37] |  |  |  |  |  |  |
Investment cost |  | 13,023,000 | [1],[9],[24],[38] | 13,023,000 | [2],[20],[25],[37] |  |  |  |  |  |  |
Investments at Fair Value |  | 68,000 | [9],[24],[38] | 19,000 | [20],[25],[37] |  |  |  |  |  |  |
Internet Consumer And Business Services | Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 487,830,000 | [1] | 363,165,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 468,792,000 |  | $ 349,963,000 |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Convertible Debt | Salary.com, LLC | Greater than 5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [13] | $ 18,000 |  |  |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Convertible Debt | Houzz, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2028-05 |  |  |  | 2028-05 |  |  |  |
Investment, Interest Rate, Paid in Kind | [11],[26] |  |  | 5.50% |  |  |  | 5.50% |  |  |  |
Principal Amount | [20],[26] |  |  | $ 20,676,000 |  |  |  |  |  |  |  |
Investment cost | [2],[20],[26] |  |  | 20,676,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [20],[26] |  |  | 20,425,000 |  |  |  |  |  |  |  |
Internet Consumer And Business Services | Convertible Debt | Houzz, Inc. | Greater than 5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2028-05 |  |  |  | 2028-05 |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 5.50% |  |  |  | 5.50% |  |  |  |  |  |
Principal Amount | [9],[39] | $ 21,252,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[9],[39] | 21,252,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [9],[39] | 20,354,000 |  |  |  |  |  |  |  |  |  |
Manufacturing Technology | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 726,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 4,338,000 |  |  |  |  |  |  |  |  |  |
Manufacturing Technology | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 15,902,000 | [1] | 14,995,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 16,045,000 |  | $ 14,995,000 |  |  |  |  |  |  |  |
Manufacturing Technology | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 23,597,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 23,509,000 |  |  |  |  |  |  |  |  |  |
Manufacturing Technology | Bright Machines, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 151,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 320,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Mar. 31, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 196,335 |  |  |  | 196,335 |  |  |  |  |  |
Manufacturing Technology | MacroFab, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 528,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 603,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Mar. 23, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 1,111,111 |  |  |  | 1,111,111 |  |  |  |  |  |
Manufacturing Technology | Xometry, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5] | $ 47,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5] | $ 3,415,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | May 09, 2018 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5] | 87,784 |  |  |  | 87,784 |  |  |  |  |  |
Manufacturing Technology | Senior Secured | Bright Machines, Inc. | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2022-11 |  | 2022-11 |  | 2022-11 |  | 2022-11 |  |  |  |
Investment Interest Rate | [11] |  |  | 6.95% |  |  |  | 6.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.70% | [7] | 5.70% | [11] | 5.70% | [7] | 5.70% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.95% | [7] | 8.95% | [11] | 8.95% | [7] | 8.95% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 6.95% |  |  |  | 6.95% |  |  |  |
Principal Amount |  | $ 15,000,000 | [8],[12] | $ 15,000,000 | [23] |  |  |  |  |  |  |
Investment cost |  | 15,902,000 | [1],[8],[12] | 14,995,000 | [2],[23] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 16,045,000 | [8],[12] | 14,995,000 | [23] |  |  |  |  |  |  |
Manufacturing Technology | Senior Secured | MacroFab, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-03 |  |  |  | 2026-03 |  |  |  |  |  |
Investment Interest Rate | [7] | 7.60% |  |  |  | 7.60% |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.35% |  |  |  | 4.35% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 1.25% |  |  |  | 1.25% |  |  |  |  |  |
Interest Rate and Floor | [7] | 7.60% |  |  |  | 7.60% |  |  |  |  |  |
Principal Amount | [9],[18] | $ 17,083,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[9],[18] | 16,616,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [9],[18] | $ 16,469,000 |  |  |  |  |  |  |  |  |  |
Manufacturing Technology | Senior Secured | Ouster, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-05 |  |  |  | 2026-05 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 6.15% |  |  |  | 6.15% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 9.40% |  |  |  | 9.40% |  |  |  |  |  |
Principal Amount | [10],[17],[29] | $ 7,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[17],[29] | 6,981,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[17],[29] | $ 7,040,000 |  |  |  |  |  |  |  |  |  |
Manufacturing Technology | Senior Secured | Exit Fee | Bright Machines, Inc. | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 6.95% |  |  |  | 6.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 6.95% |  |  |  | 6.95% |  |  |  |  |  |
Manufacturing Technology | Senior Secured | Exit Fee | MacroFab, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Manufacturing Technology | Senior Secured | Exit Fee | Ouster, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 7.45% |  |  |  | 7.45% |  |  |  |  |  |
Interest Rate and Floor | [7] | 7.45% |  |  |  | 7.45% |  |  |  |  |  |
Manufacturing Technology | Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 39,499,000 | [1] | 14,995,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 39,554,000 |  | 14,995,000 |  |  |  |  |  |  |  |
Medical Devices & Equipment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 17,421,000 |  | 12,612,000 |  |  |  |  |  |  |  |
Medical Devices & Equipment | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 2,953,000 | [1] | 3,991,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 2,143,000 |  | 10,538,000 |  |  |  |  |  |  |  |
Medical Devices & Equipment | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 2,035,000 | [1] | 2,483,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 443,000 |  | 2,074,000 |  |  |  |  |  |  |  |
Medical Devices & Equipment | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 14,927,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 14,835,000 |  |  |  |  |  |  |  |  |  |
Medical Devices & Equipment | Lucira Health, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5] | 110,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5] | $ 0 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Feb. 04, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5] | 59,642 |  |  |  | 59,642 |  |  |  |  |  |
Medical Devices & Equipment | Coronado Aesthetics, LLC | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 250,000 | [1] | 250,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 400,000 |  | $ 565,000 |  |  |  |  |  |  |  |
Shares | shares |  | 5,180,000 |  | 5,180,000 |  | 5,180,000 |  | 5,180,000 |  |  |  |
Medical Devices & Equipment | Coronado Aesthetics, LLC | Equity | Preferred Series A-2 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 250,000 | [1],[24] | $ 250,000 | [2],[25] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 391,000 | [24] | $ 500,000 | [25] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 15, 2021 | [5] | Oct. 15, 2021 | [6],[25] |  |  |  |  |  |  |
Shares | shares |  | 5,000,000 | [24] | 5,000,000 | [25] | 5,000,000 | [24] | 5,000,000 | [25] |  |  |
Medical Devices & Equipment | Coronado Aesthetics, LLC | Equity | Common Units |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 0 | [1],[24] | $ 0 | [2],[25] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 9,000 | [24] | $ 65,000 | [25] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 15, 2021 | [5] | Oct. 15, 2021 | [6],[25] |  |  |  |  |  |  |
Shares | shares |  | 180,000 | [24] | 180,000 | [25] | 180,000 | [24] | 180,000 | [25] |  |  |
Medical Devices & Equipment | Flowonix Medical Incorporated | Equity | Preferred Series AA |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,500,000 | [1] | $ 1,500,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 03, 2014 | [5] | Nov. 03, 2014 | [6] |  |  |  |  |  |  |
Shares | shares |  | 221,893 |  | 221,893 |  | 221,893 |  | 221,893 |  |  |  |
Medical Devices & Equipment | Flowonix Medical Incorporated | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 714,000 | [1] | $ 714,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Shares | shares |  | 836,752 |  | 881,131 |  | 836,752 |  | 881,131 |  |  |  |
Medical Devices & Equipment | Flowonix Medical Incorporated | Warrant Investment | Preferred Series BB |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 352,000 | [1] | $ 351,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 21, 2018 | [5] | Sep. 21, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 725,806 |  | 725,806 |  | 725,806 |  | 725,806 |  |  |  |
Medical Devices & Equipment | Flowonix Medical Incorporated | Warrant Investment | Preferred Series AA |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 362,000 | [1],[18] | $ 363,000 | [2],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 | [18] | $ 0 | [33] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 03, 2014 | [5] | Nov. 03, 2014 | [6] |  |  |  |  |  |  |
Shares | shares |  | 110,946 | [18] | 155,325 | [33] | 110,946 | [18] | 155,325 | [33] |  |  |
Medical Devices & Equipment | Gelesis, Inc. | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 1,003,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 9,772,000 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 662,071 |  |  |  | 662,071 |  |  |  |
Medical Devices & Equipment | Gelesis, Inc. | Equity | Preferred Series A-1 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 503,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 3,593,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Dec. 30, 2011 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 243,432 |  |  |  | 243,432 |  |  |  |
Medical Devices & Equipment | Gelesis, Inc. | Equity | Preferred Series A-2 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 500,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 2,828,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Dec. 31, 2011 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 191,626 |  |  |  | 191,626 |  |  |  |
Medical Devices & Equipment | Gelesis, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 871,000 | [1],[5] | $ 0 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,611,000 | [5] | $ 3,351,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 30, 2009 | [5] | Nov. 30, 2009 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,490,700 | [5] | 227,013 |  | 1,490,700 | [5] | 227,013 |  |  |  |
Medical Devices & Equipment | ViewRay, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 332,000 | [1],[5] | $ 333,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 132,000 | [5] | $ 201,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 16, 2013 | [5] | Dec. 16, 2013 | [6] |  |  |  |  |  |  |
Shares | shares |  | 36,457 | [5] | 36,457 | [6] | 36,457 | [5] | 36,457 | [6] |  |  |
Medical Devices & Equipment | Aspire Bariatrics, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 455,000 | [1] | $ 455,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jan. 28, 2015 | [5] | Jan. 28, 2015 | [6] |  |  |  |  |  |  |
Shares | shares |  | 22,572 |  | 22,572 |  | 22,572 |  | 22,572 |  |  |  |
Medical Devices & Equipment | Intuity Medical, Inc. | Warrant Investment | Preferred Series B-1 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 294,000 | [1] | $ 294,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 30,000 |  | $ 264,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 29, 2017 | [5] | Dec. 29, 2017 | [6] |  |  |  |  |  |  |
Shares | shares |  | 3,076,323 |  | 3,076,323 |  | 3,076,323 |  | 3,076,323 |  |  |  |
Medical Devices & Equipment | Outset Medical, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 401,000 | [1],[5] | $ 401,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 413,000 | [5] | $ 1,797,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 27, 2013 | [5] | Sep. 27, 2013 | [6] |  |  |  |  |  |  |
Shares | shares |  | 62,794 | [5] | 62,794 | [6] | 62,794 | [5] | 62,794 | [6] |  |  |
Medical Devices & Equipment | Tela Bio, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 61,000 | [1],[5] | $ 61,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 | [5] | $ 13,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 31, 2017 | [5] | Mar. 31, 2017 | [6] |  |  |  |  |  |  |
Shares | shares |  | 15,712 | [5] | 15,712 | [6] | 15,712 | [5] | 15,712 | [6] |  |  |
Medical Devices & Equipment | Medrobotics Corporation | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 905,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 0 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 374,703 |  |  |  | 374,703 |  |  |  |
Medical Devices & Equipment | Medrobotics Corporation | Equity | Preferred Series E |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 250,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Sep. 12, 2013 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 136,798 |  |  |  | 136,798 |  |  |  |
Medical Devices & Equipment | Medrobotics Corporation | Equity | Preferred Series F |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 155,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Oct. 22, 2014 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 73,971 |  |  |  | 73,971 |  |  |  |
Medical Devices & Equipment | Medrobotics Corporation | Equity | Preferred Series G |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 500,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Oct. 16, 2015 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 163,934 |  |  |  | 163,934 |  |  |  |
Medical Devices & Equipment | Medrobotics Corporation | Warrant Investment | Preferred Series E |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 370,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Mar. 13, 2013 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 455,539 |  |  |  | 455,539 |  |  |  |
Medical Devices & Equipment | SonaCare Medical, LLC | Warrant Investment | Preferred Series A |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 188,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Sep. 28, 2012 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 6,464 |  |  |  | 6,464 |  |  |  |
Medical Devices & Equipment | Senior Secured | Lucira Health, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-02 |  |  |  | 2026-02 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 5.50% |  |  |  | 5.50% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.75% |  |  |  | 8.75% |  |  |  |  |  |
Principal Amount | [17] | $ 15,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[17] | 14,927,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [17] | $ 14,835,000 |  |  |  |  |  |  |  |  |  |
Medical Devices & Equipment | Senior Secured | Exit Fee | Lucira Health, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.25% |  |  |  | 5.25% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.25% |  |  |  | 5.25% |  |  |  |  |  |
Medical Devices & Equipment | Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 14,927,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 14,835,000 |  |  |  |  |  |  |  |  |  |
Semiconductors |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 20,621,000 |  | $ 22,498,000 |  |  |  |  |  |  |  |
Semiconductors | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 160,000 | [1] | 160,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 259,000 |  | 725,000 |  |  |  |  |  |  |  |
Semiconductors | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 850,000 | [1] | 850,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 715,000 |  | 2,701,000 |  |  |  |  |  |  |  |
Semiconductors | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 19,492,000 | [1] | 19,072,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 19,647,000 |  | 19,072,000 |  |  |  |  |  |  |  |
Semiconductors | Fungible, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 751,000 | [1],[31] | 751,000 | [2],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 77,000 | [31] | $ 751,000 | [32] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 16, 2021 | [5] | Dec. 16, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 800,000 | [31] | 800,000 | [32] | 800,000 | [31] | 800,000 | [32] |  |  |
Semiconductors | Achronix Semiconductor Corporation | Equity | Preferred Series C |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 160,000 | [1] | $ 160,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 259,000 |  | $ 725,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jul. 01, 2011 | [5] | Jul. 01, 2011 | [6] |  |  |  |  |  |  |
Shares | shares |  | 277,995 |  | 277,995 |  | 277,995 |  | 277,995 |  |  |  |
Semiconductors | Achronix Semiconductor Corporation | Warrant Investment | Preferred Series D-2 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 99,000 | [1] | $ 99,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 638,000 |  | $ 1,950,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 26, 2015 | [5] | Jun. 26, 2015 | [6] |  |  |  |  |  |  |
Shares | shares |  | 750,000 |  | 750,000 |  | 750,000 |  | 750,000 |  |  |  |
Semiconductors | Senior Secured | Fungible, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-12 |  | 2024-12 |  | 2024-12 |  | 2024-12 |  |  |  |
Investment Interest Rate | [11] |  |  | 4.95% |  |  |  | 4.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.00% | [7] | 5.00% | [11] | 5.00% | [7] | 5.00% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.25% | [7] | 8.25% | [11] | 8.25% | [7] | 8.25% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 4.95% |  |  |  | 4.95% |  |  |  |
Principal Amount |  | $ 20,000,000 | [8],[31] | $ 20,000,000 | [23],[32] |  |  |  |  |  |  |
Investment cost |  | 19,492,000 | [1],[8],[31] | 19,072,000 | [2],[23],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 19,647,000 | [8],[31] | 19,072,000 | [23],[32] |  |  |  |  |  |  |
Semiconductors | Senior Secured | Exit Fee | Fungible, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.95% |  |  |  | 4.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.95% |  |  |  | 4.95% |  |  |  |  |  |
Semiconductors | Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | 19,072,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 19,647,000 |  | 19,072,000 |  |  |  |  |  |  |  |
Software |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 680,216,000 |  | 585,622,000 |  |  |  |  |  |  |  |
Software | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 24,006,000 | [1] | 23,905,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 24,997,000 |  | 45,087,000 |  |  |  |  |  |  |  |
Software | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 7,639,000 | [1] | 5,594,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 6,217,000 |  | 11,133,000 |  |  |  |  |  |  |  |
Software | Investment Funds & Vehicles [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 381,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 381,000 |  |  |  |  |  |  |  |  |  |
Software | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 10,691,000 | [1] | 68,743,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 10,691,000 |  | 68,287,000 |  |  |  |  |  |  |  |
Software | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 614,819,000 | [1] | 437,659,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 615,863,000 |  | 441,115,000 |  |  |  |  |  |  |  |
Software | Greater than 5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 22,066,000 | [1] | 19,851,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 22,066,000 |  | 20,000,000 |  |  |  |  |  |  |  |
Software | Automation Anywhere, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 448,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 437,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Sep. 23, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 254,778 |  |  |  | 254,778 |  |  |  |  |  |
Software | Cutover, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[29],[30] | $ 26,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [29],[30] | $ 25,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Sep. 21, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [29],[30] | 102,898 |  |  |  | 102,898 |  |  |  |  |  |
Software | Liberty Zim Co-Invest L.P. | Investment Funds & Vehicles [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[29],[30] | $ 381,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [29],[30] | $ 381,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jul. 21, 2022 |  |  |  |  |  |  |  |  |  |
Software | Delphix Corp. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,594,000 | [1] | 1,594,000 | [2],[21] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,306,000 |  | $ 3,275,000 | [21] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 08, 2019 | [5] | Oct. 08, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 718,898 |  | 718,898 | [21] | 718,898 |  | 718,898 | [21] |  |  |
Software | Pymetrics, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 77,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 218,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Sep. 15, 2020 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 150,943 |  |  |  | 150,943 |  |  |  |
Software | 3GTMS, LLC | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,000,000 | [1] | $ 1,000,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 675,000 |  | $ 985,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 09, 2021 | [5] | Aug. 09, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,000,000 |  | 1,000,000 |  | 1,000,000 |  | 1,000,000 |  |  |  |
Software | Brain Corporation | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 165,000 | [1],[31] | $ 165,000 | [2],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 61,000 | [31] | $ 132,000 | [32] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 04, 2021 | [5] | Oct. 04, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 194,629 | [31] | 194,629 | [32] | 194,629 | [31] | 194,629 | [32] |  |  |
Software | CloudBolt Software, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 117,000 | [1] | $ 117,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,000 |  | $ 85,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 30, 2020 | [5] | Sep. 30, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 211,342 |  | 211,342 |  | 211,342 |  | 211,342 |  |  |  |
Software | Dashlane, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 353,000 | [1] | $ 404,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 120,000 |  | $ 415,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 11, 2019 | [5] | Mar. 11, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 453,641 |  | 560,536 |  | 453,641 |  | 560,536 |  |  |  |
Software | Demandbase, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 545,000 | [1] | $ 404,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 140,000 |  | $ 443,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 02, 2021 | [5] | Aug. 02, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 727,047 |  | 483,248 |  | 727,047 |  | 483,248 |  |  |  |
Software | Eigen Technologies Ltd. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[29],[30] | $ 8,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [29],[30] | $ 8,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Apr. 13, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [29],[30] | 522 |  |  |  | 522 |  |  |  |  |  |
Software | Esme Learning Solutions, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 198,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jan. 27, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 56,765 |  |  |  | 56,765 |  |  |  |  |  |
Software | Mixpanel, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 252,000 | [1] | $ 252,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 233,000 |  | $ 906,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 30, 2020 | [5] | Sep. 30, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 82,362 |  | 82,362 |  | 82,362 |  | 82,362 |  |  |  |
Software | Nuvolo Technologies Corporation | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 172,000 | [1] | $ 88,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 190,000 |  | $ 283,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 29, 2019 | [5] | Mar. 29, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 70,000 |  | 50,000 |  | 70,000 |  | 50,000 |  |  |  |
Software | Pollen, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Principal Amount |  |  |  | $ 20,498,000 |  |  |  |  |  |  |  |
Investment cost |  | $ 21,030,000 | [1] | 20,533,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 22,014,000 |  | 20,406,000 |  |  |  |  |  |  |  |
Software | Tact.ai Technologies, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 206,000 | [1] | 206,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 90,000 |  | $ 162,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Feb. 13, 2020 | [5] | Feb. 13, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,041,667 |  | 1,041,667 |  | 1,041,667 |  | 1,041,667 |  |  |  |
Software | Udacity, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 218,000 | [1] | $ 218,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 21,000 |  | $ 345,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 25, 2020 | [5] | Sep. 25, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 486,359 |  | 486,359 |  | 486,359 |  | 486,359 |  |  |  |
Software | VideoAmp, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[31] | $ 1,275,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [31] | $ 416,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jan. 21, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares | [31] | 152,048 |  |  |  | 152,048 |  |  |  |  |  |
Software | Zimperium, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 72,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 56,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Jul. 02, 2021 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 20,563 |  |  |  | 20,563 |  |  |  |
Software | SingleStore, Inc. | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 2,280,000 | [1] | $ 2,279,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,428,000 |  | $ 2,479,000 |  |  |  |  |  |  |  |
Shares | shares |  | 633,939 |  | 633,939 |  | 633,939 |  | 633,939 |  |  |  |
Software | SingleStore, Inc. | Equity | Preferred Series E |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 2,000,000 | [1] | $ 2,000,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,278,000 |  | $ 2,239,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 25, 2020 | [5] | Nov. 25, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 580,983 |  | 580,983 |  | 580,983 |  | 580,983 |  |  |  |
Software | SingleStore, Inc. | Equity | Preferred Series F |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 280,000 | [1] | $ 279,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 150,000 |  | $ 240,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 12, 2021 | [5] | Aug. 12, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 52,956 |  | 52,956 |  | 52,956 |  | 52,956 |  |  |  |
Software | SingleStore, Inc. | Warrant Investment | Preferred Series D |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 103,000 | [1] | $ 103,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 258,000 |  | $ 704,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Apr. 28, 2020 | [5] | Apr. 28, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 312,596 |  | 312,596 |  | 312,596 |  | 312,596 |  |  |  |
Software | CapLinked, Inc. | Equity | Preferred Series A-3 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 51,000 | [1] | $ 51,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 5,000 |  | $ 65,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 26, 2012 | [5] | Oct. 26, 2012 | [6] |  |  |  |  |  |  |
Shares | shares |  | 53,614 |  | 53,614 |  | 53,614 |  | 53,614 |  |  |  |
Software | Docker, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 4,284,000 | [1] | $ 4,284,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 494,000 |  | $ 3,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 29, 2018 | [5] | Nov. 29, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 20,000 |  | 20,000 |  | 20,000 |  | 20,000 |  |  |  |
Software | Druva Holdings, Inc. | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,300,000 | [1] | $ 1,300,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,758,000 |  | $ 2,916,000 |  |  |  |  |  |  |  |
Shares | shares |  | 552,461 |  | 552,461 |  | 552,461 |  | 552,461 |  |  |  |
Software | Druva Holdings, Inc. | Equity | Preferred Series 3 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 300,000 | [1] | $ 300,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 330,000 |  | $ 529,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 24, 2017 | [5] | Aug. 24, 2017 | [6] |  |  |  |  |  |  |
Shares | shares |  | 93,620 |  | 93,620 |  | 93,620 |  | 93,620 |  |  |  |
Software | Druva Holdings, Inc. | Equity | Preferred Series 2 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 1,000,000 | [1] | $ 1,000,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,428,000 |  | $ 2,387,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Oct. 22, 2015 | [5] | Oct. 22, 2015 | [6] |  |  |  |  |  |  |
Shares | shares |  | 458,841 |  | 458,841 |  | 458,841 |  | 458,841 |  |  |  |
Software | HighRoads, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 307,000 | [1] | $ 307,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jan. 18, 2013 | [5] | Jan. 18, 2013 | [6] |  |  |  |  |  |  |
Shares | shares |  | 190 |  | 190 |  | 190 |  | 190 |  |  |  |
Software | Lightbend, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 265,000 | [1] | $ 265,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 14,000 |  | $ 5,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 04, 2020 | [5] | Dec. 04, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 38,461 |  | 38,461 |  | 38,461 |  | 38,461 |  |  |  |
Software | Lightbend, Inc. | Warrant Investment | Preferred Series D |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 131,000 | [1] | $ 131,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,000 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Feb. 14, 2018 | [5] | Feb. 14, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 89,685 |  | 89,685 |  | 89,685 |  | 89,685 |  |  |  |
Software | Palantir Technologies | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 8,670,000 | [1],[5] | $ 8,670,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 11,531,000 | [5] | $ 25,828,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 23, 2020 | [5] | Sep. 23, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,418,337 | [5] | 1,418,337 | [6] | 1,418,337 | [5] | 1,418,337 | [6] |  |  |
Software | Sprinklr, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 3,748,000 | [1],[5] | $ 3,749,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 6,454,000 | [5] | $ 11,109,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 22, 2017 | [5] | Mar. 22, 2017 | [6] |  |  |  |  |  |  |
Shares | shares |  | 700,000 | [5] | 700,000 | [6] | 700,000 | [5] | 700,000 | [6] |  |  |
Software | Verana Health, Inc. | Equity | Preferred Series E |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 2,000,000 | [1] | $ 2,000,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,171,000 |  | $ 1,697,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jul. 08, 2021 | [5] | Jul. 08, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 952,562 |  | 952,562 |  | 952,562 |  | 952,562 |  |  |  |
Software | Bitsight Technologies Inc | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 284,000 | [1] | $ 284,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 597,000 |  | $ 1,272,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 18, 2020 | [5] | Nov. 18, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 29,691 |  | 29,691 |  | 29,691 |  | 29,691 |  |  |  |
Software | Cloudian Inc | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 71,000 | [1] | $ 71,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 17,000 |  | $ 33,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 06, 2018 | [5] | Nov. 06, 2018 | [6] |  |  |  |  |  |  |
Shares | shares |  | 477,454 |  | 477,454 |  | 477,454 |  | 477,454 |  |  |  |
Software | Dronedeploy Incorporation | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 278,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 307,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jun. 30, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 95,911 |  |  |  | 95,911 |  |  |  |  |  |
Software | Evernote Corporation | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 107,000 | [1] | $ 106,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 15,000 |  | $ 65,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Sep. 30, 2016 | [5] | Sep. 30, 2016 | [6] |  |  |  |  |  |  |
Shares | shares |  | 62,500 |  | 62,500 |  | 62,500 |  | 62,500 |  |  |  |
Software | Poplicus Inc | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 0 | [1] | $ 0 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | May 28, 2014 | [5] | May 28, 2014 | [6] |  |  |  |  |  |  |
Shares | shares |  | 132,168 |  | 132,168 |  | 132,168 |  | 132,168 |  |  |  |
Software | Reltio Inc | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 215,000 | [1] | $ 215,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 296,000 |  | $ 637,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 30, 2020 | [5] | Jun. 30, 2020 | [6] |  |  |  |  |  |  |
Shares | shares |  | 69,120 |  | 69,120 |  | 69,120 |  | 69,120 |  |  |  |
Software | Sign Post Inc | Warrant Investment | Series Junior 1 Preferred |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 314,000 | [1] | $ 314,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jan. 13, 2016 | [5] | Jan. 13, 2016 | [6] |  |  |  |  |  |  |
Shares | shares |  | 474,019 |  | 474,019 |  | 474,019 |  | 474,019 |  |  |  |
Software | Zero Fox Inc | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5],[22] | $ 101,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5],[22] | $ 1,467,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | May 07, 2020 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5],[22] | 289,992 |  |  |  | 289,992 |  |  |  |  |  |
Software | Zero Fox Inc | Warrant Investment | Preferred Series C-1 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 101,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 603,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | May 07, 2020 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 648,350 |  |  |  | 648,350 |  |  |  |
Software | Couchbase Inc | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 462,000 | [1],[5] | $ 462,000 | [2],[6],[34] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 563,000 | [5] | $ 1,343,000 | [6],[34] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Apr. 25, 2019 | [5] | Apr. 25, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 105,350 | [5] | 105,350 | [6],[34] | 105,350 | [5] | 105,350 | [6],[34] |  |  |
Software | D N Anexus Inc | Warrant Investment | Preferred Series C |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 97,000 | [1] | $ 97,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 114,000 |  | $ 102,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 21, 2014 | [5] | Mar. 21, 2014 | [6] |  |  |  |  |  |  |
Shares | shares |  | 909,091 |  | 909,091 |  | 909,091 |  | 909,091 |  |  |  |
Software | Fuze, Inc. | Warrant Investment | Preferred Series F |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 89,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Jun. 30, 2017 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 256,158 |  |  |  | 256,158 |  |  |  |
Software | Rapid Miner Inc | Warrant Investment | Preferred Series C-1 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 24,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 54,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Nov. 28, 2017 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 4,982 |  |  |  | 4,982 |  |  |  |
Software | Senior Secured | Automation Anywhere, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-09 |  |  |  | 2027-09 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.25% |  |  |  | 4.25% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 9.00% |  |  |  | 9.00% |  |  |  |  |  |
Principal Amount | [8],[10] | $ 19,600,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[8],[10] | 19,008,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [8],[10] | $ 19,008,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Constructor.io Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-07 |  |  |  | 2027-07 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 8.44% |  |  |  | 8.44% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 9.44% |  |  |  | 9.44% |  |  |  |  |  |
Principal Amount | [10],[13] | $ 4,688,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[13] | 4,569,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[13] | $ 4,569,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Omeda Holdings, LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-07 |  |  |  | 2027-07 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 8.05% |  |  |  | 8.05% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 9.05% |  |  |  | 9.05% |  |  |  |  |  |
Principal Amount | [10],[13] | $ 7,500,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[13] | 7,251,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[13] | $ 7,251,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Cutover, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-10 |  |  |  | 2025-10 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 5.20% |  |  |  | 5.20% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 9.95% |  |  |  | 9.95% |  |  |  |  |  |
Principal Amount | [29],[30] | $ 5,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[29],[30] | 4,927,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [29],[30] | $ 4,927,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Delphix Corp. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2023-02 |  |  |  | 2023-02 |  |  |  |
Investment Interest Rate | [11] |  |  | 5.00% |  |  |  | 5.00% |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 5.50% |  |  |  | 5.50% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 10.25% |  |  |  | 10.25% |  |  |  |
Interest Rate and Floor | [11] |  |  | 5.00% |  |  |  | 5.00% |  |  |  |
Principal Amount | [21],[23],[33] |  |  | $ 60,000,000 |  |  |  |  |  |  |  |
Investment cost | [2],[21],[23],[33] |  |  | 61,736,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [21],[23],[33] |  |  | $ 62,345,000 |  |  |  |  |  |  |  |
Software | Senior Secured | Khoros (p.k.a Lithium Technologies) | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2022-10 |  |  |  | 2022-10 |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 8.00% |  |  |  | 8.00% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 9.00% |  |  |  | 9.00% |  |  |  |
Principal Amount | [15] |  |  | $ 56,208,000 |  |  |  |  |  |  |  |
Investment cost | [2],[15] |  |  | 55,834,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [15] |  |  | $ 55,834,000 |  |  |  |  |  |  |  |
Software | Senior Secured | Khoros (p.k.a Lithium Technologies) | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-01 |  |  |  | 2024-01 |  |  |  |  |  |
Principal Amount | [10] | $ 56,208,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10] | 56,028,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10] | $ 55,958,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Pymetrics, Inc. | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2022-10 |  |  |  | 2022-10 |  |  |  |
Investment Interest Rate | [11] |  |  | 4.00% |  |  |  | 4.00% |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 5.50% |  |  |  | 5.50% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 8.75% |  |  |  | 8.75% |  |  |  |
Investment, Interest Rate, Paid in Kind | [11] |  |  | 1.75% |  |  |  | 1.75% |  |  |  |
Interest Rate and Floor | [11] |  |  | 4.00% |  |  |  | 4.00% |  |  |  |
Principal Amount | [20] |  |  | $ 9,667,000 |  |  |  |  |  |  |  |
Investment cost | [2],[20] |  |  | 9,845,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [20] |  |  | $ 9,845,000 |  |  |  |  |  |  |  |
Software | Senior Secured | 3GTMS, LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-02 |  | 2025-02 |  | 2025-02 |  | 2025-02 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 9.28% | [7] | 9.28% | [11] | 9.28% | [7] | 9.28% | [11] |  |  |
Investment, Interest Rate, Floor |  | 10.28% | [7] | 10.28% | [11] | 10.28% | [7] | 10.28% | [11] |  |  |
Principal Amount |  | $ 10,808,000 | [10],[12],[13] | $ 10,000,000 | [15],[16] |  |  |  |  |  |  |
Investment cost |  | 10,660,000 | [1],[10],[12],[13] | 9,812,000 | [2],[15],[16] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 10,496,000 | [10],[12],[13] | $ 9,656,000 | [15],[16] |  |  |  |  |  |  |
Software | Senior Secured | Agilence, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-10 |  | 2026-10 |  | 2026-10 |  | 2026-10 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 9.00% | [7] | 9.00% | [11] | 9.00% | [7] | 9.00% | [11] |  |  |
Investment, Interest Rate, Floor |  | 10.00% | [7] | 10.00% | [11] | 10.00% | [7] | 10.00% | [11] |  |  |
Principal Amount |  | $ 9,330,000 | [10],[13],[18] | $ 9,400,000 | [15] |  |  |  |  |  |  |
Investment cost |  | 9,100,000 | [1],[10],[13],[18] | 9,138,000 | [2],[15] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 8,880,000 | [10],[13],[18] | $ 9,138,000 | [15] |  |  |  |  |  |  |
Software | Senior Secured | Annex Cloud | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-02 |  |  |  | 2027-02 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 9.00% |  |  |  | 9.00% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 10.00% |  |  |  | 10.00% |  |  |  |  |  |
Principal Amount | [10],[17] | $ 8,500,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[17] | 8,282,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[17] | $ 8,148,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Brain Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-04 |  | 2025-04 |  | 2025-04 |  | 2025-04 |  |  |  |
Investment Interest Rate | [11] |  |  | 3.95% |  |  |  | 3.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 3.70% | [7] | 3.70% | [11] | 3.70% | [7] | 3.70% | [11] |  |  |
Investment, Interest Rate, Floor |  | 6.95% | [7] | 6.95% | [11] | 6.95% | [7] | 6.95% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 1.00% | [7] | 1.00% | [11] | 1.00% | [7] | 1.00% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 3.95% |  |  |  | 3.95% |  |  |  |
Principal Amount |  | $ 20,116,000 | [9],[10],[17],[31] | $ 10,016,000 | [15],[20],[32] |  |  |  |  |  |  |
Investment cost |  | 20,101,000 | [1],[9],[10],[17],[31] | 9,943,000 | [2],[15],[20],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 20,196,000 | [9],[10],[17],[31] | $ 9,943,000 | [15],[20],[32] |  |  |  |  |  |  |
Software | Senior Secured | Campaign Monitor Limited | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-11 |  | 2025-11 |  | 2025-11 |  | 2025-11 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 8.90% | [7] | 7.90% | [11] | 8.90% | [7] | 7.90% | [11] |  |  |
Investment, Interest Rate, Floor |  | 9.90% | [7] | 11.15% | [11] | 9.90% | [7] | 11.15% | [11] |  |  |
Principal Amount |  | $ 33,000,000 | [8],[17] | $ 33,000,000 | [23] |  |  |  |  |  |  |
Investment cost |  | 32,546,000 | [1],[8],[17] | 32,459,000 | [2],[23] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 32,944,000 | [8],[17] | $ 33,000,000 | [23] |  |  |  |  |  |  |
Software | Senior Secured | Catchpoint Systems, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-06 |  |  |  | 2026-06 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 8.76% |  |  |  | 8.76% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7],[10],[13] | 9.76% |  |  |  | 9.76% |  |  |  |  |  |
Principal Amount | [13] | $ 10,200,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[13] | 10,034,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [13] | $ 10,043,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Ceros, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-09 |  | 2026-09 |  | 2026-09 |  | 2026-09 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 8.89% | [7] | 8.89% | [11] | 8.89% | [7] | 8.89% | [11] |  |  |
Investment, Interest Rate, Floor |  | 9.89% | [7],[10],[13] | 9.89% | [11] | 9.89% | [7],[10],[13] | 9.89% | [11] |  |  |
Principal Amount |  | $ 19,855,000 | [10],[13] | $ 17,978,000 | [15],[16] |  |  |  |  |  |  |
Investment cost |  | 19,420,000 | [1],[10],[13] | 17,474,000 | [2],[15],[16] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 19,482,000 | [10],[13] | $ 17,474,000 | [15],[16] |  |  |  |  |  |  |
Software | Senior Secured | CloudBolt Software, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-10 |  | 2024-10 |  | 2024-10 |  | 2024-10 |  |  |  |
Investment Interest Rate | [11] |  |  | 2.95% |  |  |  | 2.95% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 6.70% | [7] | 6.70% | [11] | 6.70% | [7] | 6.70% | [11] |  |  |
Investment, Interest Rate, Floor |  | 9.95% | [7] | 9.95% | [11] | 9.95% | [7] | 9.95% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 2.95% |  |  |  | 2.95% |  |  |  |
Principal Amount |  | $ 10,000,000 | [8],[12],[18] | $ 10,000,000 | [14],[23],[33] |  |  |  |  |  |  |
Investment cost |  | 10,021,000 | [1],[8],[12],[18] | 9,923,000 | [2],[14],[23],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 10,014,000 | [8],[12],[18] | $ 10,035,000 | [14],[23],[33] |  |  |  |  |  |  |
Software | Senior Secured | Copper CRM, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-03 |  |  |  | 2025-03 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.25% |  |  |  | 8.25% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 1.95% |  |  |  | 1.95% |  |  |  |  |  |
Principal Amount | [9],[12] | $ 10,095,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[9],[12] | 10,058,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [9],[12] | $ 9,882,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Cybermaxx Intermediate Holdings, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-08 |  | 2026-08 |  | 2026-08 |  | 2026-08 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 9.28% | [7] | 9.28% | [11] | 9.28% | [7] | 9.28% | [11] |  |  |
Investment, Interest Rate, Floor |  | 10.28% | [7] | 10.28% | [11] | 10.28% | [7] | 10.28% | [11] |  |  |
Principal Amount |  | $ 7,980,000 | [10],[17] | $ 8,000,000 | [15] |  |  |  |  |  |  |
Investment cost |  | 7,808,000 | [1],[10],[17] | 7,801,000 | [2],[15] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 7,732,000 | [10],[17] | $ 7,801,000 | [15] |  |  |  |  |  |  |
Software | Senior Secured | Dashlane, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-07 |  | 2025-07 |  | 2025-07 |  | 2025-07 |  |  |  |
Investment Interest Rate | [11] |  |  | 7.10% |  |  |  | 7.10% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 3.05% | [7] | 3.05% | [11] | 3.05% | [7] | 3.05% | [11] |  |  |
Investment, Interest Rate, Floor |  | 7.55% | [7] | 7.55% | [11] | 7.55% | [7] | 7.55% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 1.10% | [7] | 1.10% | [11] | 1.10% | [7] | 1.10% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 7.10% |  |  |  | 7.10% |  |  |  |
Principal Amount |  | $ 31,841,000 | [8],[9],[10],[12],[17] | $ 20,719,000 | [14],[15],[20],[23] |  |  |  |  |  |  |
Investment cost |  | 32,186,000 | [1],[8],[9],[10],[12],[17] | 21,807,000 | [2],[14],[15],[20],[23] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 31,580,000 | [8],[9],[10],[12],[17] | $ 21,734,000 | [14],[15],[20],[23] |  |  |  |  |  |  |
Software | Senior Secured | Demandbase, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-08 |  | 2025-08 |  | 2025-08 |  | 2025-08 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 2.25% | [7] | 5.25% | [11] | 2.25% | [7] | 5.25% | [11] |  |  |
Investment, Interest Rate, Floor |  | 5.50% | [7] | 8.50% | [11] | 5.50% | [7] | 8.50% | [11] |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 3.00% |  |  |  | 3.00% |  |  |  |  |  |
Principal Amount |  | $ 28,288,000 | [8],[9],[10],[17] | $ 16,875,000 | [15],[23] |  |  |  |  |  |  |
Investment cost |  | 28,010,000 | [1],[8],[9],[10],[17] | 16,463,000 | [2],[15],[23] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 28,187,000 | [8],[9],[10],[17] | $ 16,463,000 | [15],[23] |  |  |  |  |  |  |
Software | Senior Secured | Eigen Technologies Ltd. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-04 |  |  |  | 2025-04 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 5.10% |  |  |  | 5.10% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.35% |  |  |  | 8.35% |  |  |  |  |  |
Principal Amount | [29],[30] | $ 3,750,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[29],[30] | 3,730,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [29],[30] | $ 3,726,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Enmark Systems, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-09 |  | 2026-09 |  | 2026-09 |  | 2026-09 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 6.83% | [7] | 6.83% | [11] | 6.83% | [7] | 6.83% | [11] |  |  |
Investment, Interest Rate, Floor |  | 7.83% | [7] | 7.83% | [11] | 7.83% | [7] | 7.83% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 2.19% | [7] | 2.19% | [11] | 2.19% | [7] | 2.19% | [11] |  |  |
Principal Amount |  | $ 8,178,000 | [9],[10],[12],[13] | $ 8,000,000 | [14],[15],[16] |  |  |  |  |  |  |
Investment cost |  | 8,001,000 | [1],[9],[10],[12],[13] | 7,798,000 | [2],[14],[15],[16] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 7,948,000 | [9],[10],[12],[13] | $ 7,798,000 | [14],[15],[16] |  |  |  |  |  |  |
Software | Senior Secured | Esentire, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-05 |  | 2024-05 |  | 2024-05 |  | 2024-05 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 9.96% | [7] | 9.96% | [11],[27],[28] | 9.96% | [7] | 9.96% | [11],[27],[28] |  |  |
Investment, Interest Rate, Floor |  | 10.96% | [7] | 10.96% | [11],[27],[28] | 10.96% | [7] | 10.96% | [11],[27],[28] |  |  |
Principal Amount |  | $ 8,468,000 | [12],[13],[29],[30] | $ 21,000,000 | [14],[16],[27],[28] |  |  |  |  |  |  |
Investment cost |  | 8,380,000 | [1],[12],[13],[29],[30] | 20,699,000 | [2],[14],[16],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 8,425,000 | [12],[13],[29],[30] | $ 20,750,000 | [14],[16],[27],[28] |  |  |  |  |  |  |
Software | Senior Secured | Esme Learning Solutions, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-02 |  |  |  | 2025-02 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 5.50% |  |  |  | 5.50% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.75% |  |  |  | 8.75% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 1.50% |  |  |  | 1.50% |  |  |  |  |  |
Principal Amount | [9] | $ 5,045,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[9] | 4,890,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [9] | $ 4,270,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Gryphon Networks Corp. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-01 |  | 2026-01 |  | 2026-01 |  | 2026-01 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 9.69% | [7] | 9.69% | [11] | 9.69% | [7] | 9.69% | [11] |  |  |
Investment, Interest Rate, Floor |  | 10.69% | [7] | 10.69% | [11] | 10.69% | [7] | 10.69% | [11] |  |  |
Principal Amount |  | $ 5,232,000 | [10],[12] | $ 5,232,000 | [14],[15] |  |  |  |  |  |  |
Investment cost |  | 5,125,000 | [1],[10],[12] | 5,106,000 | [2],[14],[15] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 5,258,000 | [10],[12] | $ 5,088,000 | [14],[15] |  |  |  |  |  |  |
Software | Senior Secured | Ikon Science Limited | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-10 |  | 2024-10 |  | 2024-10 |  | 2024-10 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 9.00% | [7] | 9.00% | [11],[27],[28] | 9.00% | [7] | 9.00% | [11],[27],[28] |  |  |
Investment, Interest Rate, Floor | [7] | 10.00% |  |  |  | 10.00% |  |  |  |  |  |
Principal Amount |  | $ 6,650,000 | [10],[13],[29],[30] | $ 6,913,000 | [15],[16],[27],[28] |  |  |  |  |  |  |
Investment cost |  | 6,510,000 | [1],[10],[13],[29],[30] | 6,719,000 | [2],[15],[16],[27],[28] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 6,572,000 | [10],[13],[29],[30] | $ 6,767,000 | [15],[16],[27],[28] |  |  |  |  |  |  |
Software | Senior Secured | Imperva, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-01 |  |  |  | 2027-01 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 8.75% |  |  |  | 8.75% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 7.75% |  |  |  | 7.75% |  |  |  |  |  |
Principal Amount | [8] | $ 20,000,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[8] | 19,869,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [8] | $ 20,000,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Imperva, Inc. | Greater than 5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2027-01 |  |  |  | 2027-01 |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 7.75% |  |  |  | 7.75% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 8.75% |  |  |  | 8.75% |  |  |  |
Principal Amount | [23] |  |  | $ 20,000,000 |  |  |  |  |  |  |  |
Investment cost | [2],[23] |  |  | 19,851,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [23] |  |  | $ 20,000,000 |  |  |  |  |  |  |  |
Software | Senior Secured | Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.) | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2023-07 |  |  |  | 2023-07 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 10.15% |  |  |  | 10.15% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 11.15% |  |  |  | 11.15% |  |  |  |  |  |
Principal Amount | [13] | $ 10,819,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[13] | 10,691,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [13] | $ 10,691,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.) | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2023-07 |  |  |  | 2023-07 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 8.00% | [7] | 10.14% | [11] | 8.00% | [7] | 10.14% | [11] |  |  |
Investment, Interest Rate, Floor |  | 9.00% | [7] | 11.14% | [11] | 9.00% | [7] | 11.14% | [11] |  |  |
Principal Amount | [16] |  |  | $ 8,571,000 |  |  |  |  |  |  |  |
Investment cost | [2],[16] |  |  | 8,403,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [16] |  |  | $ 8,375,000 |  |  |  |  |  |  |  |
Software | Senior Secured | Logicworks | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-01 |  | 2024-01 |  | 2024-01 |  | 2024-01 |  |  |  |
Investment Interest Rate | [7] | 0.75% |  |  |  | 0.75% |  |  |  |  |  |
Investment, Basis Spread, Variable Rate |  | 7.50% | [7] | 7.50% | [11] | 7.50% | [7] | 7.50% | [11] |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 10.75% |  |  |  | 10.75% |  |  |  |
Interest Rate and Floor | [7] | 0.75% |  |  |  | 0.75% |  |  |  |  |  |
Principal Amount |  | $ 14,500,000 | [18] | $ 10,000,000 | [15],[33] |  |  |  |  |  |  |
Investment cost |  | 14,373,000 | [1],[18] | 9,862,000 | [2],[15],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 14,356,000 | [18] | $ 9,965,000 | [15],[33] |  |  |  |  |  |  |
Software | Senior Secured | Mixpanel, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-08 |  | 2024-08 |  | 2024-08 |  | 2024-08 |  |  |  |
Investment Interest Rate | [11] |  |  | 3.00% |  |  |  | 3.00% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 4.70% | [7] | 4.70% | [11] | 4.70% | [7] | 4.70% | [11] |  |  |
Investment, Interest Rate, Floor |  | 7.95% | [7] | 7.95% | [11] | 7.95% | [7] | 7.95% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 1.80% | [7] | 1.80% | [11] | 1.80% | [7] | 1.80% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 3.00% |  |  |  | 3.00% |  |  |  |
Principal Amount |  | $ 20,713,000 | [8],[9] | $ 20,431,000 | [20],[23],[33] |  |  |  |  |  |  |
Investment cost |  | 20,755,000 | [1],[8],[9] | 20,292,000 | [2],[20],[23],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 21,554,000 | [8],[9] | $ 21,030,000 | [20],[23],[33] |  |  |  |  |  |  |
Software | Senior Secured | Mobile Solutions Services | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-12 |  | 2025-12 |  | 2025-12 |  | 2025-12 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 9.06% | [7] | 9.87% | [11] | 9.06% | [7] | 9.87% | [11] |  |  |
Investment, Interest Rate, Floor |  | 10.06% | [7] | 10.87% | [11] | 10.06% | [7] | 10.87% | [11] |  |  |
Principal Amount |  | $ 17,668,000 | [10],[13] | $ 19,074,000 | [15],[16] |  |  |  |  |  |  |
Investment cost |  | 17,283,000 | [1],[10],[13] | 18,575,000 | [2],[15],[16] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 16,984,000 | [10],[13] | $ 18,834,000 | [15],[16] |  |  |  |  |  |  |
Software | Senior Secured | Nuvolo Technologies Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-07 |  | 2025-07 |  | 2025-07 |  | 2025-07 |  |  |  |
Investment Interest Rate | [11] |  |  | 1.75% |  |  |  | 1.75% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.25% | [7] | 7.70% | [11] | 5.25% | [7] | 7.70% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.50% | [7] | 10.95% | [11] | 8.50% | [7] | 10.95% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 1.75% |  |  |  | 1.75% |  |  |  |
Principal Amount |  | $ 17,500,000 | [8],[10],[17],[18] | $ 15,000,000 | [23],[33] |  |  |  |  |  |  |
Investment cost |  | 17,525,000 | [1],[8],[10],[17],[18] | 14,967,000 | [2],[23],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | 17,586,000 | [8],[10],[17],[18] | $ 15,017,000 | [23],[33] |  |  |  |  |  |  |
Software | Senior Secured | Pollen, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Principal Amount |  | $ 20,662,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Riviera Partners LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-04 |  |  |  | 2027-04 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 7.53% |  |  |  | 7.53% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.53% |  |  |  | 8.53% |  |  |  |  |  |
Principal Amount | [10],[13] | $ 26,184,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[13] | 25,595,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[13] | $ 25,595,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | ShadowDragon, LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-12 |  | 2026-12 |  | 2026-12 |  | 2026-12 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 9.00% | [7] | 9.00% | [11] | 9.00% | [7] | 9.00% | [11] |  |  |
Investment, Interest Rate, Floor |  | 10.00% | [7] | 10.00% | [11] | 10.00% | [7] | 10.00% | [11] |  |  |
Principal Amount |  | $ 6,000,000 | [13] | $ 6,000,000 | [15],[16] |  |  |  |  |  |  |
Investment cost |  | 5,849,000 | [1],[13] | 5,828,000 | [2],[15],[16] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 5,780,000 | [13] | $ 5,828,000 | [15],[16] |  |  |  |  |  |  |
Software | Senior Secured | Tact.ai Technologies, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-02 |  | 2024-02 |  | 2024-02 |  | 2024-02 |  |  |  |
Investment Interest Rate | [11] |  |  | 5.50% |  |  |  | 5.50% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 4.00% | [7] | 4.00% | [11] | 4.00% | [7] | 4.00% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.75% | [7] | 8.75% | [11] | 8.75% | [7] | 8.75% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 2.00% | [7] | 2.00% | [11] | 2.00% | [7] | 2.00% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 5.50% |  |  |  | 5.50% |  |  |  |
Principal Amount |  | $ 5,009,000 | [9] | $ 5,185,000 | [20] |  |  |  |  |  |  |
Investment cost |  | 5,213,000 | [1],[9] | 5,305,000 | [2],[20] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 4,885,000 | [9] | $ 5,245,000 | [33] |  |  |  |  |  |  |
Software | Senior Secured | ThreatConnect, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2026-05 |  | 2026-05 |  | 2026-05 |  | 2026-05 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 9.00% | [7] | 9.00% | [11] | 9.00% | [7] | 9.00% | [11] |  |  |
Investment, Interest Rate, Floor |  | 10.00% | [7] | 10.00% | [11] | 10.00% | [7] | 10.00% | [11] |  |  |
Principal Amount |  | $ 11,060,000 | [10],[13],[18] | $ 11,144,000 | [15],[16],[33] |  |  |  |  |  |  |
Investment cost |  | 10,791,000 | [1],[10],[13],[18] | 10,831,000 | [2],[15],[16],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 10,832,000 | [10],[13],[18] | $ 10,859,000 | [15],[16],[33] |  |  |  |  |  |  |
Software | Senior Secured | Udacity, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-09 |  | 2024-09 |  | 2024-09 |  | 2024-09 |  |  |  |
Investment Interest Rate | [11] |  |  | 3.00% |  |  |  | 3.00% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 4.50% | [7] | 4.50% | [11] | 4.50% | [7] | 4.50% | [11] |  |  |
Investment, Interest Rate, Floor |  | 7.75% | [7] | 7.75% | [11] | 7.75% | [7] | 7.75% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 2.00% | [7] | 2.00% | [11] | 2.00% | [7] | 2.00% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 3.00% |  |  |  | 3.00% |  |  |  |
Principal Amount |  | $ 51,675,000 | [9],[18] | $ 50,895,000 | [20],[33] |  |  |  |  |  |  |
Investment cost |  | 51,851,000 | [1],[9],[18] | 50,646,000 | [2],[20],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 52,330,000 | [9],[18] | $ 51,722,000 | [20],[33] |  |  |  |  |  |  |
Software | Senior Secured | VideoAmp, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-02 |  |  |  | 2025-02 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 3.70% |  |  |  | 3.70% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 6.95% |  |  |  | 6.95% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 1.25% |  |  |  | 1.25% |  |  |  |  |  |
Principal Amount | [8],[9],[31] | $ 62,987,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[8],[9],[31] | 62,056,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [8],[9],[31] | $ 62,467,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Zimperium, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2027-05 |  | 2024-07 |  | 2027-05 |  | 2024-07 |  |  |  |
Investment, Basis Spread, Variable Rate |  | 8.31% | [7] | 8.95% | [11] | 8.31% | [7] | 8.95% | [11] |  |  |
Investment, Interest Rate, Floor |  | 9.31% | [7] | 9.95% | [11] | 9.31% | [7] | 9.95% | [11] |  |  |
Principal Amount |  | $ 16,313,000 | [10],[13] | $ 15,633,000 | [16],[33] |  |  |  |  |  |  |
Investment cost |  | 15,984,000 | [1],[10],[13] | 15,347,000 | [2],[16],[33] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 15,984,000 | [10],[13] | $ 15,347,000 | [16],[33] |  |  |  |  |  |  |
Software | Senior Secured | Alchemer LLC | Greater than 5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2028-05 |  |  |  | 2028-05 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 7.89% |  |  |  | 7.89% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.89% |  |  |  | 8.89% |  |  |  |  |  |
Principal Amount | [10],[13] | $ 15,125,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[13] | 14,778,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[13] | $ 14,778,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Dispatch Technologies, Inc. | Greater than 5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2028-04 |  |  |  | 2028-04 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 8.01% |  |  |  | 8.01% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 8.76% |  |  |  | 8.76% |  |  |  |  |  |
Principal Amount | [10],[13] | $ 7,500,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[10],[13] | 7,288,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [10],[13] | $ 7,288,000 |  |  |  |  |  |  |  |  |  |
Software | Senior Secured | Reltio Inc | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2023-07 |  |  |  | 2023-07 |  |  |  |
Investment Interest Rate | [11] |  |  | 4.95% |  |  |  | 4.95% |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 5.70% |  |  |  | 5.70% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 8.95% |  |  |  | 8.95% |  |  |  |
Investment, Interest Rate, Paid in Kind | [11] |  |  | 1.70% |  |  |  | 1.70% |  |  |  |
Interest Rate and Floor | [11] |  |  | 4.95% |  |  |  | 4.95% |  |  |  |
Principal Amount | [20],[23] |  |  | $ 10,248,000 |  |  |  |  |  |  |  |
Investment cost | [2],[20],[23] |  |  | 10,336,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [20],[23] |  |  | $ 10,542,000 |  |  |  |  |  |  |  |
Software | Senior Secured | Regent Education | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2022-01 |  |  |  | 2022-01 |  |  |  |
Investment, Interest Rate, Paid in Cash | [11],[37] |  |  | 10.00% |  |  |  | 10.00% |  |  |  |
Investment Interest Rate | [11],[37] |  |  | 7.94% |  |  |  | 7.94% |  |  |  |
Investment, Interest Rate, Paid in Kind | [11],[37] |  |  | 2.00% |  |  |  | 2.00% |  |  |  |
Interest Rate and Floor | [11],[37] |  |  | 7.94% |  |  |  | 7.94% |  |  |  |
Principal Amount | [20],[37] |  |  | $ 2,951,000 |  |  |  |  |  |  |  |
Investment cost | [2],[20],[37] |  |  | 3,064,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [20],[37] |  |  | $ 2,608,000 |  |  |  |  |  |  |  |
Software | Senior Secured | Cloud 9 Software | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2024-04 |  |  |  | 2024-04 |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 8.20% |  |  |  | 8.20% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 9.20% |  |  |  | 9.20% |  |  |  |
Principal Amount | [33] |  |  | $ 9,953,000 |  |  |  |  |  |  |  |
Investment cost | [2],[33] |  |  | 9,856,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [33] |  |  | $ 9,953,000 |  |  |  |  |  |  |  |
Software | Senior Secured | Floor Rate | Ikon Science Limited | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment, Interest Rate, Floor | [11],[27],[28] |  |  | 10.00% |  |  |  | 10.00% |  |  |  |
Software | Senior Secured | Exit Fee | Automation Anywhere, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 2.50% |  |  |  | 2.50% |  |  |  |  |  |
Interest Rate and Floor | [7] | 2.50% |  |  |  | 2.50% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | Cutover, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.95% |  |  |  | 4.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.95% |  |  |  | 4.95% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | Brain Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | CloudBolt Software, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.45% |  |  |  | 3.45% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.45% |  |  |  | 3.45% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | Copper CRM, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | Dashlane, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.95% |  |  |  | 4.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.95% |  |  |  | 4.95% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | Demandbase, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.00% |  |  |  | 5.00% |  |  |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 2.00% |  |  |  | 2.00% |  |  |  |
Interest Rate and Floor | [7] | 5.00% |  |  |  | 5.00% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | Eigen Technologies Ltd. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 2.95% |  |  |  | 2.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 2.95% |  |  |  | 2.95% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | Esme Learning Solutions, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.00% |  |  |  | 3.00% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.00% |  |  |  | 3.00% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | Mixpanel, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.00% |  |  |  | 3.00% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.00% |  |  |  | 3.00% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | Nuvolo Technologies Corporation | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 2.04% |  |  |  | 2.04% |  |  |  |  |  |
Interest Rate and Floor | [7] | 2.04% |  |  |  | 2.04% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | Tact.ai Technologies, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.50% |  |  |  | 5.50% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.50% |  |  |  | 5.50% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | Udacity, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.00% |  |  |  | 3.00% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.00% |  |  |  | 3.00% |  |  |  |  |  |
Software | Senior Secured | Exit Fee | VideoAmp, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 5.25% |  |  |  | 5.25% |  |  |  |  |  |
Interest Rate and Floor | [7] | 5.25% |  |  |  | 5.25% |  |  |  |  |  |
Software | Senior Secured | Cap Rate | Copper CRM, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 10.25% |  |  |  | 10.25% |  |  |  |  |  |
Interest Rate and Floor | [7] | 10.25% |  |  |  | 10.25% |  |  |  |  |  |
Software | Senior Secured Tranche A [Member] | Pollen, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2023-11 |  | 2023-11 |  | 2023-11 |  | 2023-11 |  |  |  |
Investment Interest Rate | [11] |  |  | 4.50% |  |  |  | 4.50% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 4.75% | [7] | 4.75% | [11] | 4.75% | [7] | 4.75% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.00% | [7] | 8.00% | [11] | 8.00% | [7] | 8.00% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 0.50% | [7] | 0.50% | [11] | 0.50% | [7] | 0.50% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 4.50% |  |  |  | 4.50% |  |  |  |
Principal Amount |  | $ 7,486,000 | [9] | $ 7,457,000 | [20] |  |  |  |  |  |  |
Investment cost |  | 7,657,000 | [1],[9] | 7,528,000 | [2],[20] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 7,975,000 | [9] | $ 7,314,000 | [20] |  |  |  |  |  |  |
Software | Senior Secured Tranche A [Member] | Exit Fee | Pollen, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Software | Senior Secured Tranche B [Member] | Pollen, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2023-11 |  | 2023-11 |  | 2023-11 |  | 2023-11 |  |  |  |
Investment Interest Rate | [11] |  |  | 4.50% |  |  |  | 4.50% |  |  |  |
Investment, Basis Spread, Variable Rate |  | 5.25% | [7] | 5.25% | [11] | 5.25% | [7] | 5.25% | [11] |  |  |
Investment, Interest Rate, Floor |  | 8.50% | [7] | 8.50% | [11] | 8.50% | [7] | 8.50% | [11] |  |  |
Investment, Interest Rate, Paid in Kind |  | 1.35% | [7] | 1.35% | [11] | 1.35% | [7] | 1.35% | [11] |  |  |
Interest Rate and Floor | [11] |  |  | 4.50% |  |  |  | 4.50% |  |  |  |
Principal Amount |  | $ 13,176,000 | [9],[31] | $ 13,041,000 | [20],[32] |  |  |  |  |  |  |
Investment cost |  | 13,373,000 | [1],[9],[31] | 13,005,000 | [2],[20],[32] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 14,039,000 | [9],[31] | 13,092,000 | [20],[32] |  |  |  |  |  |  |
Software | Senior Secured Tranche B [Member] | Exit Fee | Pollen, Inc. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Interest Rate and Floor | [7] | 4.50% |  |  |  | 4.50% |  |  |  |  |  |
Software | Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 647,576,000 | [1] | 526,253,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 648,620,000 |  | 529,402,000 |  |  |  |  |  |  |  |
Sustainable And Renewable Technology |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 15,683,000 |  | 39,387,000 |  |  |  |  |  |  |  |
Sustainable And Renewable Technology | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 11,508,000 | [1] | 12,412,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 8,406,000 |  | 11,228,000 |  |  |  |  |  |  |  |
Sustainable And Renewable Technology | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 792,000 | [1] | 950,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 373,000 |  | 1,034,000 |  |  |  |  |  |  |  |
Sustainable And Renewable Technology | Warrant Investment | Preferred Series D |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | 120,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Jun. 20, 2013 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 471,327 |  |  |  | 471,327 |  |  |  |
Sustainable And Renewable Technology | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 19,659,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  | 6,904,000 |  | 19,625,000 |  |  |  |  |  |  |  |
Sustainable And Renewable Technology | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 7,109,000 | [1] | 7,500,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | 7,500,000 |  |  |  |  |  |  |  |
Sustainable And Renewable Technology | Impossible Foods, Inc. | Equity | Series E One Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 2,000,000 | [1] | 2,000,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,438,000 |  | $ 3,430,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | May 10, 2019 | [5] | May 10, 2019 | [6] |  |  |  |  |  |  |
Shares | shares |  | 188,611 |  | 188,611 |  | 188,611 |  | 188,611 |  |  |  |
Sustainable And Renewable Technology | Impossible Foods, Inc. | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [11] |  |  | 9.00% |  |  |  | 9.00% |  |  |  |
Investment, Basis Spread, Variable Rate | [11] |  |  | 3.95% |  |  |  | 3.95% |  |  |  |
Investment, Interest Rate, Floor | [11] |  |  | 8.95% |  |  |  | 8.95% |  |  |  |
Interest Rate and Floor | [11] |  |  | 9.00% |  |  |  | 9.00% |  |  |  |
Sustainable And Renewable Technology | Ampion, PBC. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 53,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 42,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Apr. 15, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 18,472 |  |  |  | 18,472 |  |  |  |  |  |
Sustainable And Renewable Technology | Pineapple Energy LLC | Equity | Class A Units |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2],[35] |  |  | $ 4,767,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [35] |  |  | $ 591,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6],[35] |  |  | Dec. 10, 2020 |  |  |  |  |  |  |  |
Shares | shares | [35] |  |  | 3,000,000 |  |  |  | 3,000,000 |  |  |  |
Sustainable And Renewable Technology | Pineapple Energy LLC | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[5],[22] | $ 3,153,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [5],[22] | $ 243,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Dec. 10, 2020 |  |  |  |  |  |  |  |  |  |
Shares | shares | [5],[22] | 304,486 |  |  |  | 304,486 |  |  |  |  |  |
Sustainable And Renewable Technology | Pineapple Energy LLC | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment, Interest Rate, Paid in Cash | [11],[26],[35] |  |  | 10.00% |  |  |  | 10.00% |  |  |  |
Sustainable And Renewable Technology | Pineapple Energy LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [11],[35],[37] |  |  | 10.00% |  |  |  | 10.00% |  |  |  |
Sustainable And Renewable Technology | Modumetal, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 500,000 | [1] | $ 500,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 01, 2015 | [5] | Jun. 01, 2015 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,035 |  | 1,035 |  | 1,035 |  | 1,035 |  |  |  |
Sustainable And Renewable Technology | NantEnergy, LLC | Equity | Common Units |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 102,000 | [1] | $ 102,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Aug. 31, 2013 | [5] | Aug. 31, 2013 | [6] |  |  |  |  |  |  |
Shares | shares |  | 59,665 |  | 59,665 |  | 59,665 |  | 59,665 |  |  |  |
Sustainable And Renewable Technology | Pivot Bio, Inc. | Equity | Preferred Series D |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 4,500,000 | [1] | $ 4,500,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,571,000 |  | $ 3,164,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Jun. 28, 2021 | [5] | Jun. 28, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 593,080 |  | 593,080 |  | 593,080 |  | 593,080 |  |  |  |
Sustainable And Renewable Technology | Proterra, Inc. | Equity | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 542,000 | [1],[5] | $ 543,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,280,000 | [5] | $ 4,043,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | May 28, 2015 | [5] | May 28, 2015 | [6] |  |  |  |  |  |  |
Shares | shares |  | 457,841 | [5] | 457,841 | [6] | 457,841 | [5] | 457,841 | [6] |  |  |
Sustainable And Renewable Technology | Halio Inc |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 111,000 |  |  |  |  |  |  |  |  |  |
Sustainable And Renewable Technology | Halio Inc | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 218,000 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 456,883 |  |  |  | 456,883 |  |  |  |  |  |
Sustainable And Renewable Technology | Halio Inc | Warrant Investment | Preferred Series A |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 155,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 83,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Apr. 22, 2014 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 325,000 |  |  |  | 325,000 |  |  |  |  |  |
Sustainable And Renewable Technology | Halio Inc | Warrant Investment | Preferred Series B |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 63,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 28,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Apr. 07, 2015 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 131,883 |  |  |  | 131,883 |  |  |  |  |  |
Sustainable And Renewable Technology | Agrivida Inc | Warrant Investment | Preferred Series D |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 120,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jun. 20, 2013 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 471,327 |  |  |  | 471,327 |  |  |  |  |  |
Sustainable And Renewable Technology | Fulcrum Bioenergy Inc | Equity | Preferred Series C-1 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 711,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 874,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Sep. 13, 2012 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 187,265 |  |  |  | 187,265 |  |  |  |  |  |
Sustainable And Renewable Technology | Fulcrum Bioenergy Inc | Warrant Investment | Preferred Series C-1 |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 64,000 | [1] | $ 274,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 220,000 |  | $ 699,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Apr. 30, 2013 | [5] | Sep. 13, 2012 | [6] |  |  |  |  |  |  |
Shares | shares |  | 93,632 |  | 280,897 |  | 93,632 |  | 280,897 |  |  |  |
Sustainable And Renewable Technology | Polyera Corporation | Warrant Investment | Preferred Series C |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 337,000 | [1] | $ 338,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 11, 2012 | [5] | Dec. 11, 2012 | [6] |  |  |  |  |  |  |
Shares | shares |  | 311,612 |  | 311,609 |  | 311,612 |  | 311,609 |  |  |  |
Sustainable And Renewable Technology | Halio Inc P K Kinestral Technologies Inc | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 218,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 335,000 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 456,883 |  |  |  | 456,883 |  |  |  |
Sustainable And Renewable Technology | Halio Inc P K Kinestral Technologies Inc | Warrant Investment | Preferred Series A |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 155,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 249,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Apr. 22, 2014 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 325,000 |  |  |  | 325,000 |  |  |  |
Sustainable And Renewable Technology | Halio Inc P K Kinestral Technologies Inc | Warrant Investment | Preferred Series B |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [2] |  |  | $ 63,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  |  |  | $ 86,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date | [6] |  |  | Apr. 07, 2015 |  |  |  |  |  |  |  |
Shares | shares |  |  |  | 131,883 |  |  |  | 131,883 |  |  |  |
Sustainable And Renewable Technology | Senior Secured | Impossible Foods, Inc. | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2022-07 |  |  |  | 2022-07 |  |  |  |
Principal Amount | [33] |  |  | $ 15,022,000 |  |  |  |  |  |  |  |
Investment cost | [2],[33] |  |  | 19,379,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [33] |  |  | $ 19,378,000 |  |  |  |  |  |  |  |
Sustainable And Renewable Technology | Senior Secured | Ampion, PBC. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2025-05 |  |  |  | 2025-05 |  |  |  |  |  |
Investment, Basis Spread, Variable Rate | [7] | 4.70% |  |  |  | 4.70% |  |  |  |  |  |
Investment, Interest Rate, Floor | [7] | 7.95% |  |  |  | 7.95% |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 1.45% |  |  |  | 1.45% |  |  |  |  |  |
Principal Amount | [9],[17] | $ 4,022,000 |  |  |  |  |  |  |  |  |  |
Investment cost | [1],[9],[17] | 3,953,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [9],[17] | $ 3,943,000 |  |  |  |  |  |  |  |  |  |
Sustainable And Renewable Technology | Senior Secured | Pineapple Energy LLC | Debt Investments Under 1 Year Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  |  |  | 2022-01 |  |  |  | 2022-01 |  |  |  |
Principal Amount | [15],[26],[35] |  |  | $ 280,000 |  |  |  |  |  |  |  |
Investment cost | [2],[15],[26],[35] |  |  | 280,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [15],[26],[35] |  |  | $ 247,000 |  |  |  |  |  |  |  |
Sustainable And Renewable Technology | Senior Secured | Pineapple Energy LLC | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maturity Date |  | 2024-12 |  | 2023-12 |  | 2024-12 |  | 2023-12 |  |  |  |
Investment, Interest Rate, Paid in Kind | [7] | 10.00% |  |  |  | 10.00% |  |  |  |  |  |
Principal Amount |  | $ 3,156,000 | [9] | $ 7,500,000 | [15],[20],[35],[37] |  |  |  |  |  |  |
Investment cost |  | 3,156,000 | [1],[9] | 7,500,000 | [2],[15],[20],[35],[37] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,961,000 | [9] | 7,500,000 | [15],[20],[35],[37] |  |  |  |  |  |  |
Sustainable And Renewable Technology | Senior Secured | Exit Fee | Ampion, PBC. | Debt Investments 1-5 Years Maturity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment Interest Rate | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Interest Rate and Floor | [7] | 3.95% |  |  |  | 3.95% |  |  |  |  |  |
Sustainable And Renewable Technology | Debt Investments |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 7,109,000 | [1] | 27,159,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 6,904,000 |  | 27,125,000 |  |  |  |  |  |  |  |
Media/Content/Info | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 348,000 | [1] | 348,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 0 |  | 0 |  |  |  |  |  |  |  |
Media/Content/Info | Zoom Media Group, Inc. | Warrant Investment | Preferred Series A |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 348,000 | [1] | 348,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 0 |  | $ 0 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Dec. 21, 2012 | [5] | Dec. 21, 2012 | [6] |  |  |  |  |  |  |
Shares | shares |  | 1,204 |  | 1,204 |  | 1,204 |  | 1,204 |  |  |  |
Electronics & Computer Hardware |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 2,498,000 |  | $ 1,040,000 |  |  |  |  |  |  |  |
Electronics & Computer Hardware | Equity |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 1,500,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | 1,034,000 |  |  |  |  |  |  |  |  |  |
Electronics & Computer Hardware | Warrant Investment |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 692,000 | [1] | 658,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | 1,464,000 |  | 1,040,000 |  |  |  |  |  |  |  |
Electronics & Computer Hardware | Locus Robotics Corporation | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | 34,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 27,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Jun. 21, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 8,511 |  |  |  | 8,511 |  |  |  |  |  |
Electronics & Computer Hardware | Skydio, Inc. | Equity | Preferred Series E |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost | [1] | $ 1,500,000 |  |  |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,034,000 |  |  |  |  |  |  |  |  |  |
Investment, Acquisition Date | [5] | Mar. 08, 2022 |  |  |  |  |  |  |  |  |  |
Shares | shares |  | 248,900 |  |  |  | 248,900 |  |  |  |  |  |
Electronics & Computer Hardware | Skydio, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 557,000 | [1] | 557,000 | [2] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 1,153,000 |  | $ 422,000 |  |  |  |  |  |  |  |
Investment, Acquisition Date |  | Nov. 08, 2021 | [5] | Nov. 08, 2021 | [6] |  |  |  |  |  |  |
Shares | shares |  | 622,255 |  | 124,451 |  | 622,255 |  | 124,451 |  |  |  |
Electronics & Computer Hardware | 908 Devices, Inc. | Warrant Investment | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 101,000 | [1],[5] | $ 101,000 | [2],[6] |  |  |  |  |  |  |
Investments at Fair Value |  | $ 284,000 | [5] | $ 618,000 | [6] |  |  |  |  |  |  |
Investment, Acquisition Date |  | Mar. 15, 2017 | [5] | Mar. 15, 2017 | [6] |  |  |  |  |  |  |
Shares | shares |  | 49,078 | [5] | 49,078 | [6] | 49,078 | [5] | 49,078 | [6] |  |  |
Investment, Affiliated Issuer, Controlled [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | $ 87,249,000 |  | $ 84,039,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  | 80,325,000 | [40] | $ 73,504,000 | [41] |  |  |  |  | $ 65,835,000 |  | $ 57,400,000
Investment, Affiliated Issuer, Controlled [Member] | Gibraltar Business Capital, LLC |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [42] | 37,662,000 |  |  |  |  |  |  |  | 40,737,000 |  |
Investment, Affiliated Issuer, Controlled [Member] | Hercules Adviser LLC |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [42] | 33,945,000 |  |  |  |  |  |  |  | 16,804,000 |  |
Investment, Affiliated Issuer, Controlled [Member] | Tectura Corporation |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [42] | 8,318,000 |  |  |  |  |  |  |  | 8,294,000 |  |
Investment, Affiliated Issuer, Controlled [Member] | Coronado Aesthetics, LLC |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [42] | 400,000 |  |  |  |  |  |  |  |  |  |
Investment, Affiliated Issuer, Controlled [Member] | Sustainable And Renewable Technology | Senior Secured Tranche A [Member] | Pineapple Energy LLC |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment, Interest Rate, Paid in Kind |  |  |  | 10.00% |  |  |  | 10.00% |  |  |  |
Investment, Affiliated Issuer, Controlled [Member] | Sustainable And Renewable Technology | Senior Secured Tranche B [Member] | Pineapple Energy LLC |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment, Interest Rate, Paid in Cash |  |  |  | 10.00% |  |  |  | 10.00% |  |  |  |
Principal Amount |  |  |  | $ 280,000 |  |  |  |  |  |  |  |
Investment, Affiliated Issuer, Noncontrolled [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 0 |  | 13,547,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  | 0 |  | 9,458,000 | [41] |  |  |  |  | 9,712,000 |  | 8,340,000
Investment, Affiliated Issuer, Noncontrolled [Member] | Pineapple Energy LLC |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  |  |  | 12,547,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  | 0 | [42],[43] | 8,338,000 | [41] |  |  |  |  | 8,469,000 | [42] |
Investment, Affiliated Issuer, Noncontrolled [Member] | Black Crow AI, Inc. affiliates |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investments at Fair Value | [42] | 0 | [43] |  |  |  |  |  |  | 1,243,000 |  |
Investment, Affiliated Issuer, Noncontrolled [Member] | Sustainable And Renewable Technology | Senior Secured Tranche A [Member] | Pineapple Energy LLC |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Principal Amount |  |  |  | 7,500,000 |  |  |  |  |  |  |  |
Investment cost |  |  |  | 7,500,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [41] |  |  | 7,500,000 |  |  |  |  |  |  |  |
Investment, Affiliated Issuer, Noncontrolled [Member] | Sustainable And Renewable Technology | Senior Secured Tranche B [Member] | Pineapple Energy LLC |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  |  |  | 280,000 |  |  |  |  |  |  |  |
Investments at Fair Value | [41] |  |  | 247,000 |  |  |  |  |  |  |  |
Investment, Affiliated Issuer [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Holdings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Investment cost |  | 87,249,000 |  | 97,586,000 |  |  |  |  |  |  |  |
Investments at Fair Value |  | $ 80,325,000 | [40] | $ 82,962,000 | [41] |  |  |  |  | $ 75,547,000 |  | $ 65,740,000
[1] | Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $68.4 million, $110.0 million and $41.6 million, respectively. The tax cost of investments is $2.9 billion.
[2] | Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $121.0 million, $75.7 million, and $45.3 million, respectively. The tax cost of investments is $2.4 billion.
[3] | Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies
[4] | Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
[5] | Except for warrants in 27 publicly traded companies and common stock in 42 publicly traded companies, all investments are restricted as of September 30, 2022 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s valuation committee (the “Valuation Committee”) and approved by the board of directors (the “Board”).
[6] | Except for warrants in 26 publicly traded companies and common stock in 36 publicly traded companies, all investments are restricted as of December 31, 2021 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s Board.
[7] | Interest rate PRIME represents 6.25% as of September 30, 2022. 1-month LIBOR, 3-month LIBOR and 6-month LIBOR represent 3.1427%, 3.7547%, and 4.2320%, respectively, as of September 30, 2022.
[8] | Denotes second lien senior secured debt.
[9] | Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.
[10] | Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of September 30, 2022 (Refer to “Note 11 - Commitments and Contingencies”).
[11] | Interest rate PRIME represents 3.25% as of December 31, 2021. 1-month LIBOR, 3-month LIBOR, and 6-month LIBOR represent, 0.14%, 0.24%, and 0.26%, respectively, as of December 31, 2021.
[12] | Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”).
[13] | Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition.
[14] | Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”).
[15] | Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of December 31, 2021. Refer to “Note 11 — Commitments and Contingencies”.
[16] | Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition.
[17] | Denotes that all or a portion of the debt investment secures the 2031 Asset-Backed Notes (as defined in “Note 5 — Debt”).
[18] | Denotes that all or a portion of the investment is pledged as collateral under the MUFG Bank Facility (as defined in “Note 5 — Debt”).
[19] | Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of September 30, 2022.
[20] | Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.
[21] | Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of December 31, 2021.
[22] | Denotes all or a portion of the public equity or warrant investment was acquired in a transaction exempt from registration under the Securities Act of 1933 (“Securities Act”) and may be deemed to be “restricted securities” under the Securities Act.
[23] | Denotes second lien senior secured debt.
[24] | Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board.
[25] | Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board.
[26] | Denotes that all or a portion of the debt investment is convertible debt.
[27] | Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.
[28] | Non-U.S. company or the company’s principal place of business is outside the United States.
[29] | Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.
[30] | Non-U.S. company or the company’s principal place of business is outside the United States.
[31] | Denotes that all or a portion of the investment in this portfolio company is held by Hercules Capital IV, L.P., the Company’s wholly owned small business investment company.
[32] | Denotes that all or a portion of the investment in this portfolio company is held by HC IV, the Company’s wholly owned SBIC subsidiary.
[33] | Denotes that all or a portion of the investment is pledged as collateral under the Union Bank Facility (as defined in “Note 5 — Debt”).
[34] | Denotes all or a portion of the public equity or warrant investment was acquired in a transaction exempt from registration under the Securities Act of 1933 (“Securities Act”) and may be deemed to be “restricted securities” under the Securities Act.
[35] | Affiliate investment as defined under the 1940 Act in which Hercules owns at least 5% but generally less than 25% of the company’s voting securities.
[36] | Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of Common Stock for Black Crow AI, Inc., subject to release upon repayment of the outstanding balance of the notes. As of September 30, 2022, the Black Crow AI, Inc. affiliates promissory notes had an outstanding balance of $3.0 million.
[37] | Debt is on non-accrual status as of December 31, 2021, and is therefore considered non-income producing. Note that only the PIK portion is on non-accrual for the Company’s debt investment in Tectura Corporation and Pineapple Energy LLC.
[38] | Debt is on non-accrual status as of September 30, 2022, and is therefore considered non-income producing. Note that as of September 30, 2022, only the PIK, or payment-in-kind, portion is on non-accrual for the Company’s debt investment in Tectura Corporation.
[39] | Denotes that all or a portion of the debt investment is convertible debt.
[40] | All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.
[41] | All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.
[42] | In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of September 30, 2022 and September 30, 2021, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”.
[43] | As of September 30, 2022, Black Crow AI, Inc. and Pineapple Energy LLC are no longer affiliates as defined under the 1940 Act.

X
- Definition Investments Maturity Month and Year. + References No definition available. + Details
Name: | htgc_InvestmentsMaturityMonthAndYear
Namespace Prefix: | htgc_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap-supplement_InvestmentAcquisitionDate
Namespace Prefix: | us-gaap-supplement_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap-supplement_InvestmentBasisSpreadVariableRate
Namespace Prefix: | us-gaap-supplement_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap-supplement_InvestmentInterestRateFloor
Namespace Prefix: | us-gaap-supplement_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap-supplement_InvestmentInterestRatePaidInCash
Namespace Prefix: | us-gaap-supplement_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap-supplement_InvestmentInterestRatePaidInKind
Namespace Prefix: | us-gaap-supplement_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_InvestmentHoldingsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Rate of interest on investment. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563 + Details
Name: | us-gaap_InvestmentInterestRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Cost of the investment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 + Details
Name: | us-gaap_InvestmentOwnedAtCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 5D -Subparagraph (SX 210.12-13D(Column C)) -URI https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)) -URI https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedAtFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition For investments which are quantified by principal amount, the principle balance held at close of period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -URI https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedBalancePrincipalAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -URI https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_InvestmentSecondaryCategorizationAxis=htgc_EquityInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentSecondaryCategorizationAxis=htgc_WarrantInvestmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentSecondaryCategorizationAxis=htgc_InvestmentsInSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentSecondaryCategorizationAxis=htgc_InvestmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentSecondaryCategorizationAxis=htgc_InvestmentFundsVehiclesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=htgc_SeniorSecuredDebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BlueSprigPediatricsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentSecondaryCategorizationAxis=htgc_DebtInvestmentsOneToFiveYearsMaturityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=htgc_TotalInvestmentsBeforeCashAndCashEquivalentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=htgc_TotalInvestmentsWithCashAndCashEquivalentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=htgc_TotalInvestmentInSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_GSFinancialSquareGovernmentFundMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=htgc_DebtInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_UnsecuredDebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_CommunicationsAndNetworkingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AryakaNetworksIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PeerlessNetworkHoldingsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SpringMobileSolutionsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CytracomHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_RocketLabGlobalServicesLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=htgc_ExitFeeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_ConsumerAndBusinessProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_GroveCollaborativeIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PenumbraBrandsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TechStyleIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_GadgetGuardLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TheNeatCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_WhoopIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TechStyleIncPKJustFabulousIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_DiversifiedFinancialServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentSecondaryCategorizationAxis=htgc_DebtInvestmentsUnderOneYearMaturityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_GibraltarBusinessCapitalLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_HerculesAdviserLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_MemberUnitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_NewfrontInsuranceHoldingsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesDTwoPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=htgc_UnsecuredDebtFourteenPointFiveZeroPercentageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=htgc_UnsecuredDebtElevenPointFiveZeroPercentageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=htgc_UnsecuredDebtFivePercentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_ConvertibleDebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_InvestmentFundsAndVehiclesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ForbionGrowthOpportunitiesFundICVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_SurgicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_GynesonicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesFOnePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TransMedicsGroupIncPKTransmedicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_DrugDiscoveryAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ChemocentryxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AkeroTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AlbireoPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AveoPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AxsomeTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BicycleTherapeuticsPLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BridgeBioPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CellarityIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CenturyTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_EnGeneIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesThreePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesThreeClassCPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_HibercellIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_HilleVaxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_HumanigenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_KaleidoBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_MadrigalPharmaceuticalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PhathomPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ProventionBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_RedshiftBioanalyticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ScynexisIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TarsusPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TGTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_UniQureBVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ValoHealthLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=htgc_CommonUnitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_XFourPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AppliedMolecularTransportMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AvaloTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ConcertPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DareBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DynavaxTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_NorthSeaTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ParatekPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_RocketPharmaceuticalsLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SavaraIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SioGeneTherapiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TricidaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ADMABiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BrickellBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DermavantSciencesLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_EvofemBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_MyovantSciencesLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_StealthBioTherapeuticsCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_YumanityTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_FreshTracksTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ForbionGrowthOpportunitiesFundIICVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ValoHealthLLCPKIntegralHealthHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AcaciaPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_GenoceaBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_MotifBioPLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_NabrivaTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AlladaptImmunotherapeuticsincMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AldeyraTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AppliedGeneticTechnologiesCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AtaiLifeSciencesNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BiomXINCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CodiakBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CoriumIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_EloxxPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_FinchTherapeuticsGroupIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_G1TherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_GeronCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_GritstoneBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_IvericBioGeneTherapyLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LocusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SeresTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SyndaxPharmaceuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_UnityBiotechnologyIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ViridianTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CenterForBreakthroughMedicinesHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateFloorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=htgc_CapRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=htgc_SeniorsecuredtrancheaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_DrugDeliveryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AcelRxPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AytuBioScienceIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BioQPharmaIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PDSBiotechnologyCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AeramiTherapeuticsHoldingsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PDSBiotechnologyCorporationPKEdgeTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_HealthcareServicesOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentSecondaryCategorizationAxis=htgc_DebtInvestmentsGreaterThanFiveYearsMaturityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CarbonHealthTechnologiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ElationHealthIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TwentyThreeAndMeIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_VidaHealthIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BetterTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_EqualityHealthLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_OakStreetHealthIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_InformationServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CapellaSpaceCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SignalMediaLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_YipitLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PlanetLabsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ZetaGlobalCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_INMOBIIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_NetBaseSolutionsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesOnePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_InternetConsumerAndBusinessServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_FulfilSolutionsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SeatGeekIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CarwowLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesDFourPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ConvoyIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_RhinoLabsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesBTwoPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SkywordIncorporatinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TecturaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_PreferredSeriesBBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ThumbtackIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_VeemIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_WorldremitGroupLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_HouzzIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BlackCrowAIIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesSeedPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ContentfulGlobalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DoorDashIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LyftIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_NerdyIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_NextdoorComIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_OfferUpIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesAOnePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_OportunMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ReischlingPressIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SavageXHoldingLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TFGHoldingIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_UberTechnologiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SnagajobcomIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AriaSystemsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CloudpayIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_FirstInsightIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LandingHoldingsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LendioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_RumbleONIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ShareThisIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TheFactionGroupLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesAAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_XometryIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_InteractionsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesGThreePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BrigadeGroupIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LogicSourceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TapjoyIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ZepzPKAWorldremitGroupLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SalaryComLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AppDirectIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_JobandtalentUSAIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_NextrollIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_RVShareLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_EPayPolicyHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=htgc_SeniorsecuredtranchebMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=htgc_SeniorsecuredtranchecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_ManufacturingTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BrightMachinesIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_MacroFabIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_OusterIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_MedicalDevicesAndEquipmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LuciraHealthIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CoronadoAestheticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesATwoPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_FlowonixMedicalIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_GelesisIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ViewRayIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AspireBariatricsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_IntuityMedicalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesBOnePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_OutsetMedicalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TelaBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_MedroboticsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SonaCareMedicalLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_SemiconductorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_FungibleIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AchronixSemiconductorCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_SoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AutomationAnyWhereIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CutoverIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LibertyZimCoInvestLPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DelphixCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PymetricsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ThreeGTMSLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BrainCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CloudBoltSoftwareIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DashlaneIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DemandbaseIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_EigenTechnologiesLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_EsmeLearningSolutionsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_MixpanelIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_NuvoloTechnologiesCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PollenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TactAiTechnologiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_UdacityIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_VideoAmpIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ZimperiumIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SingleStoreIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CapLinkedIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesAThreePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DockerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DruvaHoldingsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesTwoPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_HighRoadsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LightbendIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PalantirTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SprinklrIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_VeranaHealthIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BitsightTechnologiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CloudianIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DronedeployIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_EvernoteCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PoplicusIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ReltioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SignPostIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesJuniorOnePreferredMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ZeroFoxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesCOnePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CouchbaseIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DNAnexusIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_FuzeIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_RapidMinerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ConstructorIoCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_OmedaHoldingsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_KhorosMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AgilenceIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AnnexCloudMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CampaignMonitorLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CatchpointSystemsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CerosIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CopperCRMIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CybermaxxIntermediateHoldingsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_EnmarkSystemsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_EsentireIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_GryphonNetworksCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_IkonScienceLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ImpervaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_KazooIncPKYouEarnedItIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LogicworksMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_MobileSolutionsServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_RivieraPartnersLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ShadowDragonLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ThreatConnectIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AlchemerLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DispatchTechnologiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_RegentEducationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CloudNineSoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_SustainableAndRenewableTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ImpossibleFoodsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=htgc_SeriesEOnePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AmpionPBCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PineappleEnergyLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ModumetalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_NantEnergyLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PivotBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ProterraIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_HalioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AgrividaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_FulcrumBioenergyIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PolyeraCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_HalioIncPKKinestralTechnologiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_MediaContentInfoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ZoomMediaGroupIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_ElectronicsComputerHardwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LocusRoboticsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SkydioIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_NineZeroEightDevicesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap-supplement_InvestmentIssuerAffiliationAxis=us-gaap-supplement_InvestmentAffiliatedIssuerControlledMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap-supplement_InvestmentIssuerAffiliationAxis=us-gaap-supplement_InvestmentAffiliatedIssuerNoncontrolledMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap-supplement_InvestmentIssuerAffiliationAxis=us-gaap-supplement_InvestmentAffiliatedIssuerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |